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DISSERTATION ABSTRACT 
 
Kory John Iverson Plakos 
 
Doctor of Philosophy 
 
Department of Chemistry and Biochemistry 
 
December 2016 
 
Title: Platinum-Seq: High-Throughput Mapping of Small-Molecule Platinum Adducts on 
Cellular RNA 
 
 
Methods to map small-molecule interactions with cellular RNAs are important for 
understanding endogenous activation, such as in riboswitches, as well as the potential for 
exogenous compounds to target RNA. Cisplatin is one of the most widely used of the 
platinum anticancer drugs that are prescribed in approximately 40-50% of all 
chemotherapy treatments (Dyson and Sava, 2006; Harper et al., 2010). Despite nearly 40 
years of experience with this class of drugs, we still lack a comprehensive understanding 
of the targets of Pt compounds and their effects on cells. Pt(II) compounds are well-
known DNA and RNA crosslinking agents, but the latter area is under-studied. In order to 
better understand the impacts of cisplatin and other platinum(II)-derived small molecules 
on cellular RNA, we have developed a technique we call “Platinum-seq,” which couples 
reverse transcription mapping of platinated RNAs to high-throughput sequencing. 
Chapter 1 is a study of cisplatin and a novel click-functionalized platinum compound (2-
ADAP Pt) binding to the HDV ribozyme, a small catalytic RNA. Chapter 2 moves our 
platinum mapping approaches from low-throughput, sequencing gel based methods into 
next-generation sequencing for high-throughput analysis of all platinum sites in cellular 
RNA, a method we have named “Platinum-seq.” Chapter 3 is a study of differential gene 
 v 
 
expression of Saccharomyces cerevisiae treated with cisplatin and a second novel 
platinum(II) compound (azaplatin), using data acquired from the work in Chapter 2. 
Chapter 4 describes recent efforts to implement pre-enrichment of sequencing targets 
using click chemistry followed by DNA hybridization, in order to enrich for platinated 
fragments before sequencing library construction. Together, this work represents a 
significant step forward in advancing analysis of Pt(II) binding to cellular RNA, a 
potentially important target for this widely used class of anticancer compounds. Methods 
developed here are broadly applicable to genome-wide identification of platinum 
accumulation on DNA as well, which has not been pursued despite the extensive use of 
these compounds. 
This dissertation contains unpublished, co-authored material. 
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CHAPTER I 
INTRODUCTION 
 
In the early 1960’s, Barnett Rosenberg and colleagues were exploring the effect 
of electric current on E. coli cells when they noticed cells grown in the presence of 
platinum electrodes ceased dividing (Rosenberg et al. 1965). Originally suspecting that 
the electric field was somehow causing the phenotypic response, they soon discovered it 
was a platinum compound itself being released from the electrodes that was responsible 
for this effect. Careful work narrowed the causative agent down to salts of Pt(II) and 
Pt(IV) (Rosenberg et al. 1969). Rosenberg and colleagues had serendipitously discovered 
cisplatin (cis-Pt[NH3]2Cl2), arguably the most important anticancer compound to date 
(Alderden et al., 2006; Dyson et al., 2006). 
Cisplatin (Figure 1.1 A) is comprised of a Pt(II) core with two exchange-inert 
NH3 ligands and two labile chloride ligands. In its di-chloro form it is a water soluble, 
neutral compound. Administration into the high-chloride environment (approximately 
100 mM) of a patient’s bloodstream favors the uncharged di-chloro state, but upon 
entering the low chloride environment of a cell, either through passive diffusion (Basu 
and Krishnamurthy, 2005) or active transport (Safaei and Howell, 2005), one or more of 
the chloride ligands are exchanged for water, conferring a positive charge upon the 
compound (Figure 1.1D). Aquated cisplatin is highly reactive and binds to a wide variety 
of biomolecules, including protein, RNA, DNA, membrane phospholipids, and 
cytoskeleton components (Jamieson and Lippard, 1999). Phenotypic similarities to DNA 
damage suggested cisplatin’s anticancer activity is attributed to coordination with nuclear 
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DNA (Jamieson and Lippard, 1999), where it forms covalent bonds with the N7 position 
of purine nucleobases, most often guanine (Fichtinger-Schepman et al., 1985). A 
prevailing theory suggests cisplatin-induced DNA lesions induce apoptosis in sensitive 
cells (Basu and Krishnamurthy, 2005). However that theory is challenged by several 
observations: cisplatin accumulates more on protein and RNA than DNA (Akaboshi et 
al., 1992), more cisplatin accumulates on total RNA than total DNA (Hostetter et al., 
2012), and cisplatin can induce apoptotic signaling in a nucleus-independent manner 
(Mandic et al., 2003). These observations indicate a need for a more thorough 
understanding of cisplatin’s effect on biomolecules, particularly RNA. 
 
 
Figure 1.1 – Cisplatin and currently approved derivatives. A) Cisplatin. B) Carboplatin. 
C) Oxaliplatin. D) Cisplatin cell distribution. Upon entering the cell through passive 
diffusion (not shown) or active transport (shown), cisplatin becomes aquated and gains a 
positive charge. It is then attracted to numerous biomolecules, including DNA, RNA, and 
proteins. 
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The emerging role of RNA 
One of the most unexpected results of the Human Genome Project was that the 
human genome consists of less than 20,000 protein coding regions, representing less than 
3% of our genetic information (International Human Genome Sequencing Consortium, 
2001). This remaining material, at least part of which was once termed “junk DNA,” 
(Ohno, 1972), was quickly found to contain regions that in fact are transcribed into 
noncoding RNA (Maddick, 2004; Ulitsky and Bartel, 2013), constituting some 98% of 
human genetic output (Mattick, 2001). Long thought to be a passive information carrier 
shuttling genetic information from DNA in the nucleus to ribosomes in the cytoplasm for 
protein synthesis, RNA is now recognized to have important roles in peptide bond 
formation itself, regulating gene expression, and catalyzing chemical reactions, among 
many other things (Morris and Mattick, 2014). 
Recognition of these key roles of cellular RNA has elucidated a whole new 
category of drug targets. Proteins are still considered the predominant class of drug 
targets, but estimates of the number of druggable proteins is surprisingly small – just over 
200 by one estimate (Overington et al., 2006), most of which are G-protein coupled 
receptors, ion channels, or other enzymes (Thomas and Hergenrother, 2007; Makley and 
Gestwicki, 2013). Given the vast output of RNA in a cell, there is a crucial need for tools 
to better understand the diverse landscape of RNA binding sites and RNA binding events 
for small molecule compounds such as cisplatin. 
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Cisplatin accumulation on cellular RNA 
Soon after cisplatin was approved for use in cancer therapy, research results 
began to indicate that RNA played a role in cytotoxicity. Aside from broadly 
demonstrating platinum accumulation in cells (reviewed in Chapman et al., 2011), studies 
have suggested that cisplatin interferes with translation (Rosenberg and Sato, 1988) and 
the RNA-dependent telomere maintenance enzyme telomerase (Burger et al., 1997). 
Recent studies have shown Pt accumulation on ribosomal RNA (Hostetter et al., 2012; 
Melnikov et al., 2016). A comprehensive molecular understanding of platinum 
accumulation on cellular RNA is lacking, however, due to inherent difficulties in 
identifying platinum adducts (Chapman et al., 2011). Numerous methods have been 
employed in attempts to infer platinum accumulation on RNA. 
 
Methods of mapping cisplatin RNA binding sites 
Covalently modify platinum compounds appended with fluorophores have 
enabled colocalization studies to interrogate the compartmentalization of cisplatin in 
treated cells. Fluorophores based on fluorescein (Molenaar et al., 2010), NBD (Benedetti 
et al., 2011), BODIPY (Jagodinsky et al., 2015), and acridine (Ding et al., 2013), have 
been appended to cisplatin-like scaffolds and studied for their localization in cells. 
Accumulation of these various groups was mostly diffuse; cytoplasmic, vesicular, golgi, 
lysosomal, and nucleolar accumulation were all seen, supporting no specific sites of 
platinum accumulation. Given the bulky, lipophilic nature of many of these fluorophores, 
the question remains whether the appended fluorescent moieties or the platinum core 
itself was directing localization. 
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Figure 1.2 – Click-functionalized platinum compounds. A) 2-ADAP Pt (Moghaddam et 
al., 2015). B) Azaplatin (Wirth et al., 2015). Both compounds were synthesized in our 
lab, and feature in work presented later. 
 
To overcome these concerns, the DeRose group (Moghaddam et al., 2015; Wirth 
et al., 2015), and the Bierbach (Ding et al., 2013) group have synthesized several click-
ready platinum compounds for post-treatment fluorescent tagging, two of which are 
featured later in this work (Figure 1.2). As compared with the above Pt-fluorophore 
conjugates, click-ready compounds are minimally modified before reacting with cellular 
components. Cells are treated with a one of these click-ready compounds, fixed, 
permeabilized, and post-treatment modified using the azide-alkyne cycloaddition reaction 
with their fluorescent partner, avoiding unwanted interactions of fluorophores with 
cellular components (White et al., 2016). While post-platination click chemistry is not the 
focus of this work, RNA binding sites of the compounds in Figure 1.2 are mapped to 
single-nucleotide resolution and compared with those from cisplatin. 
Though techniques are maturing rapidly, RNA crystallography is still a 
challenging area. To date, there are only two molecules crystallized with cisplatin on 
RNA: phenylalanine tRNA (Rhodes et al., 1974; Sundaralingam et al., 1985) and, most 
recently, the T. thermophilus ribosome, in vitro (Melnikov et al., 2016). In the ribosome 
crystallography experiment, the authors found that treatment with cisplatin in vitro 
resulted in nine major mainly monofunctional Pt adducts; only one adduct bonded to 
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adjacent guanines. The authors also noted a correlation between cisplatin-modified 
guanine bases and Mg2+ coordination at that site (Melnikov et al., 2016). 
Analytical and spectroscopic techniques have also been applied to the study of 
cisplatin accumulation on RNA. Atomic absorption spectroscopy was used in a study by 
Roberts and colleagues to quantify platinum accumulation on biomolecules in HeLa cells. 
Their results suggest that more cisplatin is bound to RNA than DNA or proteins (Pascoe 
and Roberts, 1974). Likewise, Hostetter et al. used inductively coupled plasma mass 
spectrometry (ICP-MS) to quantify cisplatin accumulation in mRNA, rRNA, total RNA 
and DNA in S. cerevisiae (2012). They found greater accumulation of platinum on DNA 
than RNA on a per-nucleotide basis, but when the ratio of DNA to RNA is considered, 
platinum is approximately 4-20-fold more populated on total RNA than DNA (Hostetter 
et al., 2012). Matrix-assisted laser desorption ionization (MALDI) mass spectrometry has 
also been used to study inhibition of RNA enzymes in vitro by platinum adducts on RNA 
(Chapman and DeRose, 2010), and cisplatin accumulation on model ribosomal RNA 
hairpins (Dedduwa-Mudalige and Chow, 2015). In this work, highly conserved hairpins 
from E. coli (helix 69 from 23S rRNA and helix 24 from 16S rRNA) were modeled, 
platinated, and probed using a combination of RNAse T1, MALDI mass spectrometry, 
and dimethyl sulfate mapping to explore sites of platinum accumulation. The authors 
found platination at several GpG sites and noted similarities to antibiotic binding sites 
(Dedduwa-Mudalige and Chow, 2015). Nuclear magnetic resonance (NMR) spectroscopy 
has been applied to platinated DNA duplexes (Gelasco and Lippard 1998) but to the best 
of our knowledge, has not been applied to the question of cisplatin-derived adducts on 
RNA.  
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Mass spectrometry and crystallography-based techniques are well-suited for 
mapping RNA modification sites to single nucleotide resolution but these techniques are 
labor intensive, cost prohibitive, and require homogenous purified RNA, often in large 
amounts. Cisplatin adducts on DNA or RNA interfere with processive enzymes such as 
RNA polymerase II (Damsma et al., 2007) and reverse transcriptase (Rijal and Chow, 
2009; Chapman and DeRose, 2010), allowing researchers to use reverse transcription 
(RT) primer extension analysis techniques to map cisplatin RNA binding (Stern et al., 
1988; Chapman and DeRose, 2010). RT primer extension analysis creates cDNA copies 
of RNA templates, truncated 3’ to the site of RNA modification (Stern et al., 1988). Gel-
based readouts correlate fragment length with sequencing reference lanes in order to 
identify the modified nucleotide. RT primer extension experiments do not require as 
much RNA, work well in heterogenous RNA samples, and are inherently less labor-
intensive than other analytical methods. Numerous RNA-platinum adducts have been 
studied using RT primer extension, both in synthetic constructs modified in vitro 
(Chapman and DeRose, 2010; Osborn et al., 2014), purified E. coli ribosomal RNA 
treated in vitro with cisplatin (Rijal and Chow, 2009), and ribosomal RNA isolated from 
S. cerevisiae treated with cisplatin (Hostetter et al., 2012; Osborn et al., 2014). The 
ribosome has been the focus of most of these mapping studies, discussed in detail below. 
The ribosome is the large ribonucleoprotein complex responsible for protein 
synthesis. Peptide bond formation is catalyzed by the RNA components of the ribosome, 
making the ribosome a ribozyme (Moore and Steitz, 2003). Proper ribosomal function is 
absolutely crucial to cell survival. Single point mutations to ribosomal RNA can cripple 
the complex entirely, leading to inviable phenotypes (Rakauskaite and Dinman 2008). 
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Numerous antibiotics are known to disrupt protein synthesis by targeting both bacterial 
(Wilson 2014) and eukaryotic (Garreau de Loubresse et al., 2014) ribosomes, especially 
at the peptidyl transferase center (PTC). The toxins sarcin and ricin each act at the PTC 
as well, both damaging the sarcin ricin loop (SRL, 25S helix 95), the longest universally 
conserved sequence in the ribosome. Ricin depurinates A4324 in the rat 23S rRNA and 
sarcin cleaves the phosphodiester bond between G4325 and A4326. Both alterations halt 
protein synthesis, further demonstrating the ribosome’s sensitivity to single nucleotide 
modifications (Tumer and Li, 2011).  
The ribosome is a particularly attractive target for cisplatin, as it is located 
primarily in the cytoplasm and highly abundant (some 80% of yeast RNA is ribosomal 
RNA (Warner, 1999)). The Chow group explored cisplatin binding to bacterial ribosomal 
RNA hairpins using targeted RT primer extension analysis (2009). E. coli ribosomes 
were extracted and purified, then treated with cisplatin and analyzed using RT primer 
extension with a primer designed to anneal upstream of 16S helix 24. They found 
context-dependent platinum adducts on purine-rich regions, showing that helix 24 is 
clearly accessible to cisplatin (Rijal and Chow, 2009). Expanding upon this work, the 
DeRose group has mapped several platinum binding sites in ribosomal RNA isolated 
from cisplatin-treated yeast. Yeast cells were treated with cisplatin, the RNA extracted 
and purified, and primer extension performed across helix 18. This experiment showed 
five main dose-dependent stops along yeast helix 18, as compared with two reported by 
Rijal and Chow (2009). 
The DeRose group also performed RT primer extension across the sarcin ricin 
loop on RNA extracted from yeast treated with cisplatin. Primer extension analysis 
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reveals platinum accumulation to the purine-rich terminal loop, near the substrates for 
sarcin and ricin (Osborn et al., 2014). Helix 90, another component of the PCT, was also 
explored and revealed several concentration-dependent cisplatin binding sites. Primer 
extension analysis suggests that cisplatin adducts are surprisingly frequent in ribosomal 
RNA. 
Traditional RT primer extension approaches use targeted primers to analyze 
specific RNA strands, and due to limitations in sequencing gel resolution have a cleanly 
resolvable window of approximately 30-60 nucleotides. Combined, the ribosome 
mapping efforts described above for S. cerevisiae represent approximately 130 mapped 
nucleotides out of a total of 5196 nucleotides across the large and small ribosomal 
subunits (3396 nt in yeast 25S plus 1800 nt in yeast 18S), or just 2.5% of the yeast 
ribosome (Engel et al., 2013). Considering the myriad of other RNAs in the cell, using 
the techniques outlined above to gain a comprehensive picture of RNA binding is 
impractical. There is a strong need for more high-throughput methods of identifying 
cisplatin adduct sites. 
 
High throughput sequencing of modified RNAs 
 High-throughput sequencing is well-suited for shotgun-style approaches to large-
scale sequencing problems (Reuter et al., 2015). Techniques such as Mod-seq (Talkish et 
al., 2014) and StructureFold (Tang et al., 2015) couple DMS probing, a well-established 
technique for analyzing RNA structure, to high-throughput sequencing for secondary 
structure analysis of large RNAs. DMS is a nucleobase-modifying reagent that 
methylates the N1 of adenosine and N3 of cytosine (Lawley et al., 1963). As with 
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cisplatin adducts, DMS can be mapped in a targeted manner by RT primer extension 
analysis, because these modifications cause reverse transcriptase to stall as described 
above (Tijerina et al., 2007). Mod-seq and StructureFold each take shotgun-styled 
approaches to sequencing rRNA modifications by fragmenting treated RNA, reverse 
transcribing the resulting fragments, and sequencing cDNAs. Sequenced libraries are 
aligned to a source genome and modification sites in treated samples are reconstructed by 
identifying 3’ ends enriched over background, since these represent RT products 
truncated by DMS (Talkish et al., 2014; Tang et al., 2015). Mod-seq differs from 
StructureFold in that the technique employs an enrichment step to preferentially sequence 
cDNA’s resulting from DMS-modification stops (Talkish et al., 2014; Tang et al., 2015). 
Modifications to the ribose backbone have also been mapped using RT-based 
approaches coupled to high-throughput sequencing. SHAPE chemistry uses alkylating 
agents to covalently modify accessible 2’ hydroxyls on the RNA ribose backbone. 
Coupled to high-throughput sequencing, methods have been developed to map SHAPE 
modifications by both primer termination, similar to ModSeq and StructureFold 
(SHAPE-seq, Waters et al., 2015) and through the detection of mutations conferred by 
RT improperly processing modified nucleotides (SHAPE-MaP, Siegfried et al., 2014). 
Using SHAPE-MaP, the authors were able to develop secondary structure models for the 
entire HIV genome (Siegfried et al., 2014). Endogenous RNA 2’O-methylation can also 
be detected using RiboMethSeq, which uses small amounts of starting material (1 ng of 
total RNA) to detect all methylation sites in rRNA (Marchand et al., 2016).  
Target enrichment is an important consideration when sequencing nucleotide 
modifications, as low-frequency modifications might be lost to background noise or 
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require numerous PCR cycles during library preparation, artificially enhancing signal 
(Mamanova et al., 2016). ModSeq accomplishes this through subtractive hybridization of 
fully extended cDNA's, preferentially enriching for truncations at modified nucleotides 
(Talkish et al., 2014). Another approach uses antibodies specific for the modification of 
interest. A recent work by Dominissini and coworkers used methylated RNA andibodies 
to selectively enrich and sequence the location of N1 methyladenosine modifications, 
which had up to this time only been observed on tRNA and rRNA, on mRNA 
(Dominissini et al., 2016). This technique is reminiscent of Chem-seq, a sequencing 
technique that aims to sequence genomic binding sites of DNA-binding small molecules 
(Kapoor et al., 2016). 
 
Chem-Seq 
 Understanding the genomic targets of small molecules is of critical importance for 
drug design and discovery. Dozens of FDA approved and clinical drug candidates 
interact directly with DNA and with DNA binding proteins (Rodriguez and Miller, 2014). 
A method for unbiased genome-wide identification of DNA-binding small molecules and 
proteins has its roots in ChIP-seq (Chromatin Immuno Precipitation followed by high-
throughput sequencing), which broadly describes techniques of profiling the location of 
chromosome-binding proteins through affinity pulldown of fragmented DNA followed by 
high-throughput sequencing (Johnson et al., 2007). This technique has enhanced, among 
others, understanding of transcription factors (Valouev et al., 2008) and histone 
modifications (Barski et al., 2007). Recently, ChIP-seq principles have been applied to 
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studying the genomic binding sites of small molecules in a technique called Chem-seq 
(Anders et al., 2014; Rodriguez and Miller, 2014). 
 In one of the first examples of Chem-seq, a collaborative effort between the 
Bradner and Young groups (Anders et al. 2014), a small-molecule inhibitor (JQ1) of 
BRD-family transcription factor proteins was covalently modified with a biotin 
functional group (bio-JQ1). MM1.S cells were treated with bio-JQ1, DNA was harvested 
and fragmented, and fragments were enriched using streptavidin pulldown and 
sequenced. These data were compared with ChIP-seq on BRD2, BRD3, and BRD4, four 
proteins known to be inhibited by JQ1. ChIP-seq and Chem-Seq profiles correlated well 
and followed a pattern predicted by known affinities of JQ1 for these three proteins in 
vitro. Expanding upon this Chem-Seq technique, the authors performed Chem-Seq on 
biotinylated psoralen, a DNA intercalator recently shown to preferentially intercalate at 
transcription start sites. Chem-Seq confirmed this finding by comparison with ChIP-seq 
identification of RNA Pol II, establishing Chem-Seq as a method for directly mapping 
small molecule binding regions on genomic DNA (Anders et al., 2014). Chem-Seq shows 
promise for greatly enhancing our understanding of how small molecules interact with 
DNA.  
Recent work has made great contributions toward better understanding the extent 
to which cisplatin interacts with cellular components, and this body of work represents a 
significant step toward comprehensive, high-throughput analysis of cisplatin binding sites 
in cellular RNA. 
This dissertation includes unpublished co-authored material. Chapter II will be 
published with co-authors Barbara Golden (Purdue University) and Victoria DeRose. 
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Chapter III will be published with Victoria DeRose as a co-author. Chapter IV was co-
authored with Emily Reister and Victoria DeRose. Chapter V was co-authored with Anna 
Hickey and Victoria DeRose. 
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CHAPTER II 
RNA CROSSLINKING USING PT(II) COMPLEXES TO PROBE THE 
TERTIARY STRUCTURE OF THE HDV RIBOZYME 
 
 This chapter has contributions from Professor Barbara Golden (Purdue 
University) and Professor Victoria DeRose. I performed and analyzed the experiments 
and wrote the text. Professor Golden provided several of the RNA strands used. Professor 
DeRose provided direction and advice for the project and edited the manuscript. 
Additionally, small but valuable contributions were made by Adam Unger, for assisting 
with control experiments, and Amanda Brenner for her work on crosslinking kinetics. 
 
Introduction  
Understanding the tertiary structure of complex RNA is critical to understanding 
its function. Structured RNA plays roles in diseases, such as in subgenomic flaviviral 
RNA which adopts a particular tertiary structure that prevents XRN1 degradation by the 
host cell (Chapman et al., 2014). Additionally, it has been postulated that some single 
nucleotide polymorphisms lead to a disease state by altering the structure of certain 
regulatory RNAs (Halvorsen et al., 2010). Beyond disease states, higher-order RNA 
structure is important for protein recognition (Li et al., 2014) and the proper function of 
autocatalytic RNA sequences such as the hammerhead ribozyme, hepatitis delta virus 
(HDV) ribozyme, and group II intron (Butcher and Pyle, 2011; Ward et al., 2014).  
Numerous methods are used to analyze RNA structure. X-ray crystallography, 
when possible, is an extremely important technique (Holbrook and Kim, 1997). X-ray 
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structures reflect a single crystallized population, however, and the relationship between 
these models and RNAs in solution require verification by other means (Golden and 
Kundrot, 2003). There are numerous chemical approaches used to predict RNA tertiary 
structure in solution conditions. SHAPE (selective 2’ hydroxyl acylation analyzed by 
primer extension, Deigan et al., 2009), hydroxyl radical cleavage (Hampel and Burke, 
2001), lead probing (Lindell et al., 2002), and in-line cleavage (Beaudoin et al., 2013) all 
report on conformationally flexible regions and backbone solvent accessibility and can be 
used to predict globally folded structures. They do not, however, report directly on 
tertiary contacts within a folded RNA.  
  Tertiary contacts in a complex RNA can be identified through the use of chemical 
crosslinking techniques that promote the formation of covalent bonds between 
nucleotides brought into close proximity (Harris and Christian, 2009). Extensive work 
has been done using UV crosslinking of native and UV-active modified nucleobases such 
as 4-thiouridine (Favre et al., 1998; Graifer and Karpova, 2013). The modified bases 
must be incorporated into the RNA being studied, either randomly in vivo or specifically 
through synthetic methods in vitro (Favre et al., 1998). UV-independent crosslinking 
reagents include formaldehyde (McGhee and von Hippel, 1975), a very short-range 
crosslinker. Other organic small molecule crosslinking reagents have been developed 
(reviewed in Harris and Christian, 2009).  
  While they have been effective, chemical crosslinking methods often suffer from 
poor yields (for example, 1-3% for UV-induced crosslinking, Zhirnov and Wollenzien, 
2003) and require enrichment and purification steps (Harris and Christian, 2009). There is 
a need for reagents that can both crosslink with high yield and also affinity tag the RNA 
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for enrichment and structural analysis. We are developing a new method of RNA 
crosslinking using the coordination properties of Pt(II) compounds and based on the well-
studied anticancer drug cisplatin and cisplatin-derived small molecules (Figure 2.1). 
These compounds exhibit interstrand RNA crosslinking yields as high as 40%, are 
specific for certain canonical nucleobases, and can be kinetically recruited to the 
backbone through addition of synthetically derived phosphorothioate substituted RNA, 
allowing us to examine interactions between specific backbone locations and nearby 
nucleophiles (Chapman and DeRose, 2012). 
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Figure 2.1. Platinum complexes and model of phosphorothioate-directed crosslinking. A) 
Cisplatin. B) 2-ADAP Pt (2-azido 1,3 diaminopropane Pt(II). C) Mechanism of 
phosphorothioatedirected cisplatin crosslinking (Chapman and DeRose 2012). 
 
Cisplatin (Figure 2.1A) is a well-studied molecule and widely used as an 
anticancer compound (Jamieson and Lippard, 1999). Substitution at the Pt(II) metal 
center is known to form coordinate covalent bonds with nucleophilic nitrogen donor 
ligands in both DNA and RNA (Chapman et al., 2011). Additionally, Pt(II) adducts 
exhibit 3-4 fold kinetic preference with thiol residues (Elmroth and Lippard, 1994). 
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Incorporation of phosphorothioate-substituted RNA into folded complexes results in a 
kinetically-preferred binding site. Pt(II) complexes recruited to this site then sample 
nearby nucleophiles, creating crosslinks based on distance and orientation (Figure 2.1C, 
Chapman and DeRose, 2012). This phosphorothioate-directed crosslinking approach 
provides the ability to recruit cisplatin to specific sites along an RNA backbone to study 
interactions between the backbone and nucleobases. Such interactions are sometimes 
mediated by metal ions, as in the active sites of ribozymes including the hammerhead and 
the hepatitis delta virus (HDV) ribozyme (Golden, 2011). We have previously 
demonstrated the use of cisplatin crosslinking in probing the active site of the 
hammerhead ribozyme, where cisplatin crosslinks were specific to certain nucleophiles 
within the active site and dependent on proper ribozyme folding (Chapman and DeRose, 
2012). Here we use this technique to explore the in-solution tertiary structure of the HDV 
ribozyme (Figure 2).  
The Hepatitis Delta Virus (HDV) ribozyme (Figure 2.2A and B) was originally 
found in the RNA genome of the Hepatitis D virus, where it catalyzes self-cleavage as 
part of processing genomic units during rolling circle replication (Lai, 1995; Golden, 
2011). Numerous HDV-like ribozymes have recently been discovered, including the 
HDV-like CPEB3 ribozyme, highly conserved in mammals (Salehi-Ashtiani et al., 2006), 
and the R2 retrotransposon, found in most arthropods (Eickbush et al., 2013). 
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Figure 2.2. HDV ribozyme secondary and tertiary structure, based on the crystal structure 
by Chen et al. (2011). A) The HDV secondary structure, annealed to a cleavable substrate 
strand. White arrows represent observed platination sites (see text). Two substrate strands 
(11 and 13 nt) used in these experiments are shown, containing both 2’-deoxy and 
phosphorothioate substitutions at the cleavage site. Sulfur substitutions at the substrate 
cleavage site are indicated by * (phosphorothioate substitution). B) Model of the HDV 
ribozyme active site constructed as in Chen et al. (2010). Shown are key nucleotides 
implicated in catalysis from the enzyme strand (G25, U20, C75, green, from PDB ID 
3NBK) and the modeled-in substrate strand (blue, from PDB ID 2OEU, Martick et al., 
2008). C) Mechanistic model for the HDV, reviewed in (Golden, 2011). The active-site 
metal is in grey with predicted aqua ligands (white circles). 
 
The HDV ribozyme utilizes a divalent metal ion for catalysis that is competitively 
inhibited by exchange inert cobalt hexamine, a hydrated magnesium ion mimic, 
indicating a requirement for inner-sphere coordination (Nakano et al., 2000). The latest 
crystal structure of the pre-cleavage HDV ribozyme shows a partially hydrated 
magnesium ion located in the active site near the scissile phosphate (Figure 2.2B), 
interacting through outer sphere coordination with two water molecules with a G25•U20 
reverse wobble and a single inner-sphere coordination to the pro-Sp oxygen on U23 
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(Chen et al., 2010) (Figure 2.2C). On the inhibitor substrate strand, the authors were able 
to resolve G(1); however, due to poor electron density upstream of G(1), a clear picture 
of the scissile phosphate and U(-1) was not possible with this crystal. Given that cleavage 
of the HDV ribozyme requires that the 2’ hydroxyl of U(-1) be aligned for in-line attack, 
the authors superimposed the structure of the nucleotide downstream of the hammerhead 
ribozyme cleavage site (PDB 2OEU (Martick et al., 2008)) with G1 from their crystal 
structure and found that the resulting structure is consistent with the crystallographic data 
(Figure 2.2B) (Chen et al., 2010).  
Based on this model, Chen and colleagues hypothesized that the catalytic 
magnesium ion interacts through inner-sphere coordination with the 2’-OH of U(-1), 
lowering its pKa and activating it for nucleophilic attack on the scissile phosphate (Figure 
2.2C) (Chen et al., 2010). This metal ion is also hypothesized to interact with the pro-Rp 
oxygen at the scissile phosphate, in agreement with phosphorothioate substitution studies 
(Fauzi et al., 1997; Wrzesinski et al., 2010). The contacts that orient the metal ion in the 
active site include an outer-sphere coordination with the N7 position on G25 of the 
enzyme strand (Figure 2.2C). This presents a good candidate for our technique of 
phosphorothioate-directed cisplatin crosslinking, and we hypothesize that a thiol 
substitution to a nonbridging oxygen at the scissile phosphate will attract our crosslinking 
platinum complexes, which should then crosslink with G25. 
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Figure 2.3. Cisplatin induces interstrand crosslinks between the HDV ribozyme enzyme 
strand (ES) and a phosphorothioate substituted substrate (SS). A) ES and SS (13-
mer,PS,dU1) crosslinks observed after three hours using either 32P 5’ end-labeled 
enzyme (lanes 1 and 2) or substrate strand (lanes 3 and 4). Odd numbered lanes are 
quenched at T=0, even numbered lanes at T=3 hours. B) Crosslinks are dependent on 
phosphorothioate substitution (11-mer,PS,dU1), and increase with increasing cisplatin 
concentration. In odd-numbered lanes, substrate strand is phosphorothioate-substituted 
11-mer,PS,dU1. In even-numbered lanes, substrate is unsubstituted 11-mer,dU1. 
Compared with ES concentration, lanes 1 and 2 contain no Cis Pt; lanes 2 and 4, 0.1x Cis 
Pt; lanes 5 and 6, 1x Cis Pt; lanes 7 and 8, 3x Cis Pt. C) Time-dependent crosslinks 
visualized using 13-mer 32P 5’ end-labeled substrate strand, with an observed rate 
constant of kobs = .014 ± 0.002 min-1, and a pseudo second-order rate constant 
calculated to be k2, calc = 3.97 ± 0.47 M-1 s-1 (Chapman and DeRose, 2012). D) 
Cisplatin and 2-ADAP Pt each induce approximately 40% crosslinking between ES and 
PS-11, as compared with no platinum control (quantification not shown). Briefly, HDV 
ribozyme ES and SS strands were folded by heating and slow cooling under conditions 
described in appendix A. Mg(NO3)2 and either cisplatin or 1,3-platin were added to 
initiate crosslinking. Reactions were quenched in formamide loading buffer and run on 
denaturing 1X TBE 8 M urea polyacrylamide gels. 
 
In this paper, we demonstrate platinum(II) crosslinking of HDV ribozyme 
constructs with a phosphorothioate substitution at the scissile phosphate and map where 
these crosslinks are occurring. We obtained results consistent with geometric predictions 
from the current HDV active site models. Major sites of Pt(II) crosslinking throughout 
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the ribozyme are also identified, providing benchmark information on the utility of these 
compounds for RNA structure analysis. Additionally, we demonstrate the first 
crosslinking use of 2-ADAP Pt (Figure 2.1B), a cisplatin derivative capable of 
participating in click reactions, which are a class of fast, high-yielding, bio-orthogonal 
reactions that occur under mild conditions (Kolb and Sharpless, 2003) and are of great 
interest to biochemists for use in attaching affinity tags (Speers and Cravatt, 2004). 
 
Results and Discussion 
Treatment of pre-folded HDV ribozyme complexes containing a 
phosphorothioate-substituted substrate strand results in Pt-RNA crosslinks with yields of 
up to 40% (Figure 2.3). Cisplatin-induced crosslinks are visible using both 32P 5’ end-
labeled enzyme strand and substrate strand after three hours, indicating that both strands 
are present in the final crosslinked product (Figure 2.3A). Crosslinks were found to be 
phosphorothioate-dependent, with very low yields in a non-phosphorothioate SS, and 
increase with increasing cisplatin concentration (Figure 2.3B). Furthermore, crosslinked 
complexes collapse to a single band corresponding to an uncrosslinked enzyme strand 
after treatment with thiourea at 37 °C, consistent with reversal of cisplatin- induced 
crosslinks (Figure A.2). The observed crosslinking rate was kobs = .0143 ± 0.0017 min-1, 
with a pseudo second-order rate constant calculated to be k2, calc = 3.97 ± 0.47 M-1 s-1 
(Figure 2.3C). This is an order of magnitude slower than cisplatin crosslinking observed 
for the hammerhead ribozyme (kobs = 0.14 ± 0.01 min-1, k2,calc = 19 ± 1 M-1 s-1 under 
10 mM Mg(NO3)2, the closest conditions tested (Chapman and DeRose, 2012). This 
likely reflects differences in the organization of these active sites. The HDV ribozyme 
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enzyme strand lacks guide nucleotides that interact upstream of the scission site on the 
substrate strand, so a certain degree of disorder is inherent in the active site (Chen et al., 
2010; Golden, 2011). This is reflected in the fact that the highest-resolution crystal 
structure of a pre-cleavage HDV ribozyme is lacking density for nucleotides immediately 
surrounding the scissile phosphate (Chen et al., 2010). The hammerhead ribozyme, on the 
other hand, has a more structured active site, with a number of base pairs between the 
substrate strand and the enzyme strand both upstream and downstream of the scissile 
phosphate (Martick et al., 2008). To test whether our trans-acting system is folding 
correctly, we substituted our inhibited 11-mer substrate strand for a cleavable version 
(11-mer,PO) and found that it cleaves at rate comparable to published rates for a trans-
acting HDV ribozyme (Ananvoranich and Perreault, 1998), suggesting our deoxy-
inhibited and phosphorothioate substituted complex represents an active complex (Figure 
A.3). 
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Figure 2.4. Alkali hydrolysis mapping of Pt(II)-crosslinked HDV ribozyme enzyme 
strand and 11mer phosphorothioate substituted substrate strand. Cleavage products 
generated by alkali hydrolysis of folded and A) cisplatin or B) 2-ADAP Pt crosslinked 
ES-SS(11-mer,PS,dU1) complex are shown using 5’-end-labeled HDV ribozyme ES. 
Band intensity down each lane is plotted next to each experiment. Lanes as labeled 
represent, in the order seen in A): Control (C); two lanes of partial digestion by two 
concentrations of RNase T1 (T1); Pt(II) crosslinked complex hydrolyzed for increasing 
time (overline); fully hydrolyzed reference ladder (-OH); asterisks designate predicted 
crosslink partners based on these results.  
 
Cisplatin and the more sterically hindered 2-ADAP Pt are both capable of 
approximately 40% crosslinking (Figure 2.3D), which is consistent with accessibility 
around the active site of the HDV. The phosphorothioate-dependent crosslinks formed in 
Figure 2.3 are predicted to occur due to Pt(II) coordination to the phosphorothioate sulfur 
of the substrate strand and a second coordination to a nucleobase of the HDV enzyme 
strand. This is further supported by thiourea reversal of crosslinked complex (Figure 
A.1). 
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Crosslinking partners on the HDV enzyme strand were identified by hydrolysis 
mapping following isolation of cisplatin- and 2-ADAP Pt crosslinks (Figure 2.3D). 
Hydrolysis yields a ladder of the 5’-end labeled HDV enzyme sequence that is 
interrupted by the crosslinked partner(s) (Juzumiene et al., 2001; Chapman and DeRose, 
2012). Hydrolysis mapping of cisplatin and 2-ADAP Pt crosslinked ES PS-11 suggests 
the two platinum(II) compounds react very similarly (Figure 2.4). Distinct changes in 
relative peak intensities at specific sites indicates crosslinks to both C19 and C26 for both 
compounds. Crosslinks to a cytosine, presumably the C3 imino nitrogen, are surprising 
because it has been demonstrated that the preferred Pt(II) binding site is the N7 position 
on guanine. Platination at cytosine is not unprecedented (Sherman and Lippard, 1987), 
however, and cisplatin and its structural isomer transplatin have both been observed to 
form interstrand GC crosslinks in vitro that include the C3 imino nitrogen of cytosine 
(Dalbiès et al., 1994). 
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Figure 2.5. Reverse transcription primer extension analysis of cisplatin crosslinked HDV 
enzyme strand. Reverse transcriptase is stalled by platinum adducts on RNA, which 
results in a buildup of cDNA transcripts 3’ of the platinum site. We found high 
concentrations of platinum in purine rich regions of the HDV ribozyme, as well as 
several candidate interstrand and sequentially distant intrastrand crosslinks.  
 
In the HDV crystal structure by Chen et al. (2010), C26 is close to the active site 
but flipped outward away from the predicted phosphorothioate sulfur position (Figure 
2.6). In this static model, C26 would be prohibitively far away for a Pt(II) crosslink, but 
the nature of this ribozyme suggests the 5’-end of the substrate strand is very flexible 
(Chen et al., 2010; Golden, 2011) which may make C26 more accessible to the 
phosphorothioate substitution in solution. C19 is located near the active site, base paired 
with G27, and the C19 C3 imino nitrogen is pointed toward the active site magnesium 
ion, with distances to the active-site scissile bond of 8.6 Å from the pro-Rp and 9.3 Å 
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from the pro-Sp position (not shown). These observations are consistent with a 
phosphorothioate-directed crosslink between an active-site phosphorothioate and C19 for 
both platinum compounds. 
In addition to the crosslinks described above, cisplatin and 2-ADAP Pt each 
exhibit a unique crosslink, with the difference likely due to the steric difference between 
the two molecules. Cisplatin appears to additionally crosslink G28 (Figures 4A, 6A). G28 
is located in the active site but not predicted to participate in catalysis (Chen et al., 2010). 
Furthermore, in the crystal structure G28 is oriented so its N7 position is pointed away 
from the scissile phosphate, but it is still within crosslinking distance (8.4 Å, Figure A.6). 
2-ADAP Pt appears to crosslink C29 (Figure 2.4B, 6B). The N3 position on C29 also 
faces away from the active site in the HDV crystal structure. An interesting possibility 
that agrees with crosslinks to C19, G28, and C29 is shown in Figure 2.7. C19, observed 
as a crosslinking partner for both cisplatin and 2-ADAP Pt via hydrolysis mapping 
(Figure 2.4), is proximal to both G28 and C29 and oriented so that its nucleophilic N3 
position points toward the active site. This puts its N3 nucleophile within reach of not 
only the scissile phosphate but also the N7 position on G28 and the N3 position on C29 
(measured in Figure 2.7). Thus, all three of these hydrolysis-mapped crosslinks could be 
explained by intrastrand crosslinks between C19-G28 for cisplatin and C19-C29 for 2-
ADAP Pt. Though these would not be phosphorothioate-directed crosslinks, they report 
on the arrangement of sequentially distant nucleobases near the active site and represent 
structurally relevant crosslinks. To our knowledge, cytosine has only been observed 
crosslinking to a base-paired guanine residue in vitro (Dalbiès et al., 1994). Because 
Pt(II) would be expected to first bind to a more reactive site, such as a purine N7 or a 
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phosphorothioate, a direct C-C crosslink is less likely to occur. All observed crosslinks 
are consistent with distances measured from the crystal structure (Figure 2.8C). The 
hydrolysis patterns were distinct from a mock-crosslinked and identically hydrolyzed 
control (Figure A.5).  
 
Figure 2.6. Observed Pt(II) crosslink sites between an active-site phosphorothioate and 
the HDV ES based on hydrolysis experiments. A) cisplatin-induced crosslinks are 
colored in blue and numbered. B) 2-ADAP Pt-induced crosslinks are colored in red and 
numbered. The hydrated magnesium ion resolved in the crystal structure is shown as 
spheres. Figures derived from PDB 3NKB. 
 
In order to identify additional Pt binding sites on the HDV enzyme strand, the 
crosslinked complex was subject to reverse transcription using a 32P 5’-end labeled RT 
primer complementary to the 3’-end of the HDV ES (Figure 2.5). Platinum adducts stall 
reverse transcriptase, causing a build up of cDNA transcripts 3’ to the adduct site 
(Chapman and DeRose, 2010). Several of these ‘stop sites’ are observed to occur with 
increasing intensity in samples treated with increasing concentrations of cisplatin (Figure 
2.5). The majority of sites indicate Pt adduct formation on a purine of the HDV ES. Since 
 28 
 
the most stable Pt adducts are expected to form with two RNA ligands, comparison of RT 
results with the HDV crystal structure further allows us to predict whether a particular 
stop site is due to a Pt adduct on neighboring purines, or due to a crosslink within the 
complex (Figure 2.8). It is believed that purine residues within 10 Å of a platination site 
may be bridged by cisplatin (Chapman and DeRose, 2012). Shown in Figure 2.8 are all 
possible partners for each Pt adduct site identified by RT.  
C19 
C29 
G28 
G27 
6.7 Å 
6.0 Å 
 
Figure 2.7. Distance measurements between N3 on C19 and N7 on G28 and N3 on C29. 
G27, which base pairs with C19, is shown as lines. From PDB 3NKB (Chen et al., 2010). 
 
From prior work we expect platinum(II) crosslinking reagents to bind to 
sequential purine residues (Hostetter et al., 2012). In some cases our observed stop sites 
lack sequential purines, but a closer look at the three-dimensional crystal structure reveals 
purines in close proximity that could represent long-distance crosslink partners (Figure 
2.8B). We observe several potential long-distance intrastrand crosslinks through three-
dimensional space. The first, identified as a stop on U45 suggesting platination at A44 
(Figure 2.5), is likely a sequentially distant intrastrand crosslink, and the only guanine N7 
within reach of A44 is G59, on the complementary strand of the P4 stem (Figure 2.8B). 
G30 is likely a non-phosphorothioate directed interstrand crosslink between the ES and 
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SS strand to either G-6 or A-8 on the substrate strand, because in the crystal structure 
there are no other nearby nucleophiles (Figure 2.8B). G39 has sequential purine residues 
and could be a 1,2 adduct to G38, a 1,3 adduct to G37, or a sequentially distant 
intrastrand crosslink to either G60 or G59, since these purines are close in space to the 
platinated nucleotide. A mix of stop sites was observed in the P4 region GAAA tetraloop 
(Figures 5, 8B). This region is very purine rich and results in a complicated RT mapping 
profile, suggesting platinum likely forms numerous 1,2 and higher-order crosslinks. The 
final stop site observed is U36 (Figures 5, 8A). This is not likely a crosslink, as uracil 
does not have a nucleophilic imine and hasn’t been observed as a platination site. Rather, 
it appears to be a stop caused by the 5’ end of our substrate strand still annealed to the 
template enzyme strand.  
 
Conclusions 
Toward the goal of developing platinum(II)-derived compounds as RNA 
crosslinking reagents, we have investigated Pt-derived crosslinking in the HDV 
ribozyme, a highly structured RNA. We explored phosphorothioate-directed crosslinking 
using a substrate strand containing active-site phosphorothioate substitutions, and using 
two Pt(II) crosslinking complexes. Pt-directed adducts throughout the HDV were also 
identified using RT extension. The results are compared to crystallographic models of the 
HDV. As a divalent metal ion, we predict that aquated cisplatin will be drawn toward 
metal ion binding sites. In these experiments, we observe the majority of our platination 
sites correlate with locations where magnesium ions were co-crystallized with the HDV 
ribozyme (Figure 2.8A, (Chen et al., 2010)). This trait is useful because divalent metal 
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ions often mediate RNA interactions that form interesting tertiary structures (Ward et al., 
2014). 
 
Figure 2.8. Potential cisplatin crosslink partners. A) Tertiary structure of the HDV 
ribozyme with observed RT stop sites indicated in green. B) Relevant platination sites as 
discerned by RT experiments are shown. Nucleotides observed to be platinated are in 
green, purine residues within 10 Å are in white. N7 positions are shown as spheres, and 
measured distances are presented. C) G28 was an observed crosslinking partner to the 
phosphorothioate-substituted scissile phosphate, its orientation with respect to the 
modeled in hammerhead ribozyme cleavage site is depicted here, next to the expected 
crosslinking partner G25. Measurements from the pro-Rp and pro-Sp positions are 
presented in Figure A.6. Figures derived from the HDV ribozyme crystal structure (PDB 
ID 3NKB, Chen et al., 2010) and the hammerhead ribozyme crystal structure (PDB ID 
2OEU, Martick et al., 2008).  
 
Crosslinks observed are consistent with known reactivity of platinum(II) 
compounds and fit crystal structures of the HDV ribozyme. This work demonstrates the 
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utility of platinum(II) compounds as crosslinking reagents. Platinum(II) compounds are 
interesting multifunctional crosslinking tools, capable of both directed recruitment to 
synthetically added nucleophilic positions as well as nonspecific recruitment to 
endogenous nucleophiles, allowing specific crosslinks (such as PS-G28, Figure 2.6A) and 
general crosslinks (G39-nearby nucleophiles, Figure 2.8B) to be resolved in a single 
experiment. Furthermore, as a divalent metal ion, cisplatin-derived crosslinking reagents 
are well-poised for interacting with interesting tertiary structures in RNA. The 
demonstrated reactivity of our click-functionalized crosslinker 2-ADAP Pt shows 
promise for adding the ability to purify using the same crosslinking tool, making 
functionalized platinum reagents a unique class of all-in-one affinity tagging, specific, 
and general crosslinking reagents. Given that cisplatin and 2-ADAP Pt crosslink very 
similarly (Figures 4 and 6), we believe that 2-ADAP Pt shows promise as a 
functionalized cisplatin mimic which will be useful for studying cisplatin’s reactivity 
both in-vitro and in-vivo.  
 
Summary of Chapter II and bridge to Chapter III 
In this chapter, we describe the use of platinum complexes for studying metal ion 
coordination and RNA tertiary structure in the hepatitis delta virus (HDV) ribozyme. 
Crosslinked complexes were isolated and mapped using primer extension and hydrolysis, 
and compared to a current crystal structure. We show that cisplatin crosslinking in the 
HDV ribozyme reaches efficiency as high as ~40%, and demonstrate that cisplatin and a 
functionalized cisplatin derivative, 2-azido 1,3 diaminopropane Pt(II) (2-ADAP Pt), 
result in similar crosslinks and report structurally relevant information. Chapter II 
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introduces a novel high-throughput sequencing method to map all sites of Pt(II) small 
molecule binding in cellular RNA. 
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CHAPTER III 
 
PT-SEQ: HIGH-THROUGHPUT MAPPING OF SMALL-MOLECULE 
PLATINUM ADDUCTS ON CELLULAR RNA 
 
  This chapter contains contributions from Victoria DeRose in the form of advice 
and direction throughout the project, as well as editing of the final manuscript. I 
performed and analyzed the experiments and wrote the text. 
 
Introduction 
Noncoding RNA makes up a significant portion of the eukaryotic genome 
(Mattick, 2001). Work has attributed regulatory roles to much of this noncoding RNA 
(Mattick and Makunin, 2006), highlighting RNA’s importance in the functional 
landscape of cells (Sharp, 2009). Recent work has focused on the potential for RNA 
targeting small molecules as potential drug candidates (Thomas and Hergenrother, 2008). 
Cisplatin (Figure 3.1A), one of the most widely use anticancer drugs and the focus of this 
work, is a known RNA binder (Rijal and Chow, 2008; Hostetter et al., 2012; Dedduwa-
Mudalige et al., 2015). Many RNA-based processes are disrupted by Pt compounds 
(reviewed in Chapman et al., 2011), but there is little information on global accumulation 
of Pt in cells.  
 Cisplatin is a widely prescribed anticancer drug which forms Pt(II)-coordinate 
bonds with a wide range of biomolecules (Harper et al., 2010). First approved by the 
FDA in 1978 (Sherman and Lippard, 1987), cisplatin and related Pt therapeutics are used 
in 40-50% of all chemotherapy treatments (Dyson and Sava, 2006; Harper et al., 2010). 
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Cisplatin is administered as an uncharged dichloro salt, cis-Pt(NH3)2Cl2 which is favored 
in the high chloride concentrations of the bloodstream. When cisplatin enters the cell, 
chloride ligands are exchanged for water resulting in positively charged mono- and di-
aquated species. It is generally accepted that a major target for cisplatin is cellular DNA, 
primarily the nucleophilic N7 position of purine residues, and DNA-Pt adducts induce 
downstream apoptosis (Siddik, 2003). 
 
 
Figure 3.1. Platinum compounds used in this work. A) Cisplatin. B) Azaplatin (Wirth et 
al., 2015). 
 
 Much work has supported the hypothesis that cellular RNA is also a major target 
of cisplatin (Rijal and Chow 2008; Hostetter et al., 2012; Dedduwa-Mudalige et al., 
2015). Research has suggested that Pt adducts from cisplatin treatment accumulate to a 
greater degree on RNA than DNA (Akaboshi and Miyahara, 1992; Hostetter et al., 2012), 
and that most Pt-RNA accumulation is on ribosomal RNA (Hostetter et al., 2012). 
Ribosomes present an attractive target for cisplatin as they are large RNA structures, 
crucial for cellular reproduction, and unlike DNA, present in the cytoplasm. Pt adduct 
accumulation on ribosomal RNA is particularly interesting because the ribosome is 
required for protein synthesis and is, in fact, a ribozyme (Moore and Steitz, 2003). Toxic 
agents such as sarcin and ricin act on the ribosome (Tumer and Li, 2012), as well as 
numerous ribosome targeting antibiotics, demonstrating its susceptibility to small 
molecule modification (Garreau de Loubresse, 2014). Platinum adducts from cisplatin 
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treatment have been observed on ribosomal RNA from E. coli and S. cerevisiae and have 
been mapped to single-nucleotide resolution using targeted primer extension (Rijal and 
Chow 2009; Hostetter et al., 2012; Osborn et al., 2014; Dedduwa-Mudalige and Chow, 
2015). Recent crystallography work has also identified platinum binding sites on purified 
T. thermophilus ribosomes complexed in vitro with mRNA and tRNA, then treated 
briefly with cisplatin (Melnikov et al., 2016). This work provides an interesting 
molecular view of potential adduct types, but its relation to adducts found from in-cell 
treatment is not established.  
A comprehensive picture of platinum accumulation on cellular RNA resulting 
from drug treatment is still missing. Current methods of mapping platinum adducts on 
RNA are largely confined to reverse transcription primer extension analysis (Rijal and 
Chow, 2009; Hostetter et al., 2012; Osborn et al., 2014) or mass spectrometry (Dedduwa-
Mudalige and Chow, 2015). While well-represented in the literature, gel-based primer 
extension is time consuming, limited in scope, and poorly suited for high-throughput 
analysis. 
 Recent work has combined primer extension principles with high-throughput 
sequencing library generation in order to identify RNA modifications on a genome-wide 
scale. Notable examples are StructureFold and Mod-seq, in which cellular RNA is treated 
with DMS to methylate cytosine and adenine residues (Talkish et al., 2014; Tang et al., 
2015), and methods based on SHAPE (selective 2’-hydroxyl acylation followed by 
primer extension) chemistry, which uses a library of alkylating reagents to modify the 2’ 
hydroxide of RNA (Incarnato et al., 2014; Spitale et al., 2015). Both approaches initially 
used gel-based primer extension but have since been adopted for high-throughput 
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sequencing for comprehensive analysis of all reactive sites in cellular RNA. Toward a 
similar goal, we have developed Pt-seq, which harnesses the power of high-throughput 
sequencing to map all platinum adducts on cellular RNA in a single sequencing 
experiment (Figure 3.2). 
 
 
Figure 3.2. Pt-seq workflow. Pt-seq uses a modified Mod-seq workflow (Talkish et al.) to 
identify sites of platinum adducts on cellular RNA following cisplatin treatment. 
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Results and Discussion 
To establish this method, yeast cultures were treated with cisplatin and a novel 
azide-modified compound azaplatin (Figure 3.1A and B). S. cerevisiae was chosen for 
this initial study based on our prior work using S. cerevisiae to explore cisplatin 
accumulation on cellular RNA (Hostetter et al., 2012). Yeast share many conserved 
cellular processes with mammals and like all eukaryotic organisms express large amounts 
of noncoding RNAs (Wu et al., 2012). Numerous cisplatin adducts have already been 
mapped on S. cerevisiae rRNA using reverse transcription primer extension analysis 
(Hostetter et al., 2012; Osborn et al., 2014). Because of this, S. cerevisiae are a good 
model system for developing our high-throughput platinum mapping technique. 
The [Pt(NH3)2]-RNA adduct formed by cisplatin treatment is known to cause 
stalling of processive enzymes such as reverse transcriptases (Rijal and Chow, 2009). 
Current methods of mapping cisplatin adducts that are based on extending radiolabeled 
RT primers rely on bands of increased intensity relative to background under treatment 
conditions on sequencing gels. While effective, these techniques are poorly suited for 
high-throughput analysis of large structured RNAs as the resolvable window is limited to 
approximately 100 nucleotides per experiment and each primer needs to be individually 
optimized and labeled. Pt-seq is based on work by Talkish et al. (2014) and adapts RT 
primer extension for high-throughput sequencing (Figure 3.2). Briefly, RNA is extracted 
from treated and untreated cells, fragmented, and an adapter annealed to its 3’ end. This 
adapter serves as a priming site for the Mod-seq primer designed by Ingola et al. (2012). 
This primer is extended using reverse transcriptase, the resulting cDNA fragments are 
size-selected and 5’ phosphorylated, and then the construct is circularized using 
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Circligase (Epicentre). After circularization, PCR is performed using indexed primers 
containing Illumina adapters to generate sequencing libraries. After sequencing, reads are 
adapter trimmed, aligned to the yeast genome, and fed into the Mod-seq pipeline (Talkish 
et al., 2014) to identify platinum adduct sites (Figure 3.3). 
 
 
Figure 3.3 Post-sequencing data analysis workflow. Reads are adapter trimmed using 
CutAdapt (Martin et al., 2011), aligned to a reference genome using Bowtie (Langmead 
et al., 2009), and each treatment is fed separately into the Mod-seq pipeline with 
appropriate control reads to generate stop sites (Talkish et al., 2014). From these, we set a 
minimum 1.5-fold enrichment over background, merge the two datasets to consider only 
overlapping features, and remove modified nucleotides, if applicable.  
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Count Min Median Max
100 µM 141 1.5 1.8 13.9
200 µM 304 1.5 1.9 17.4
Count Min Median Max
100 µM 835 1.5 2 30.8
200 µM 1188 1.5 2.2 114
Cisplatin
Azaplatin
0
50
100
150
200
250
300
350
100 µM 200 µM
Cisplatin induced
25S rRNA stops
0
200
400
600
800
1000
1200
1400
100 µM 200 µM
Azaplatin induced
25S rRNA stops
A) B)
Treatment Reads
Aligned	
reads
Percent	
Aligned	
Aligned	
reads
Percent	
Aligned	
Control-1 4,113,364 2,287,036 56 3,438,006 84
Control-2 7,218,695 4,432,691 61 6,558,954 91
Cis100-1 4,851,790 3,008,974 62 4,389,827 90
Cis100-2 7,294,189 4,499,760 62 6,598,688 90
Cis200-1 5,925,462 3,292,636 56 4,996,450 84
Cis200-2 3,843,239 1,901,225 49 3,145,008 82
Rg100-1 5,152,589 3,811,213 74 4,735,210 92
Rg100-2 7,164,539 4,988,488 70 6,533,292 91
Rg200-1 5,549,454 4,106,606 74 5,081,328 92
Rg200-2 6,598,879 4,864,861 74 6,035,212 91
TOTAL	READS 57,712,200
No	mismatches One	mismatch
C) D)
 
Table 1.1. Pt-seq sequencing results and 25S rRNA Pt-RNA adduct statistics. A) Number 
of total and aligned reads for each sequenced treatment. B) Count of significant stops 
with greater than 1.5-fold increased threshold for 100 µM and 200 µM cisplatin and 
azaplatin treatment. Median and max stop intensities shown. C) Total adduct counts on 
the yeast large ribosomal subunit for each cisplatin treatment. Doubling cisplatin 
treatment concentrations doubles the number of observed platinum adducts. D) Total 
adduct counts on the yeast large ribosomal subunit for each azaplatin treatment. 
 
For this study, five treatments were chosen: mock treatment control, 100 µM 
cisplatin, 200 µM cisplatin, 100 µM azaplatin, and 200 µM azaplatin. Two biological 
replicates were performed for each condition. Approximately 58 million reads were 
obtained across the five treatments. Reads per condition vary from 3.8-7.3 million (Table 
1.1). Between 50 – 74% of reads aligned to the yeast genome with no mismatches, and 
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80-90% align with one mismatch. Estimated distribution across genes was generated 
using HTSeq-count (Anders et al., 2005) which counts reads within gene features. Read 
distribution was predominantly on ribosomal RNA, as expected (Tables B.1-B.4). 
We chose to use only reads with no mismatches to explore platinum accumulation 
on ribosomal RNA. We fed our trimmed and aligned reads (see Methods) into the Mod-
seq script by Talkish et al. (2014), to identify sites of RT stalling, setting a minumum 
fold-enrichment threshold of 1.5, and compared cisplatin and azaplatin treatments vs. 
control to derive the location of platinum adducts to single-nucleotide resolution. Stops 
were seen on numerous cellular RNA’s, including tRNA’s, rRNA’s, snoRNA’s, and 
cytoplasmic RNA’s (Table B.3 through B.6). We chose to focus on the ribosomal 
component of the large ribosomal subunit, 25S rRNA. Pt-seq results demonstrate a 
treatment effect by cisplatin. For cisplatin, as drug concentration is increased 2-fold, the 
number of sites demonstrating >1.5-fold stop enrichment increase 2.2-fold for 25S rRNA 
(Table 1.1 C). Median and maximum stop intensity also increases as drug concentration 
increases (Table 1.1 B). Cisplatin-induced stops are scattered across the 25S rRNA 
(Figure 3.4). Higher treatment concentration results in some overlapping and many new 
stop sites. Interestingly, for overlapping sites, increasing cisplatin treatment concentration 
from 100 to 200 µM did not always result in an increase in relative stop intensity, and 
occasionally higher concentrations of cisplatin result in decreased relative stop intensity 
(Figure 3.4A and B). Azaplatin treatment likewise exhibits a dose-dependent effect, 
though not as pronounced (Table 1.1B, D).  
We were interested in whether the predicted platinum adducts exhibit preference 
toward solvent accessible platinum binging sites. Cisplatin is known to form adducts with 
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the N7 position of purine residues as well as the N3 position of cytosine (Sherman and 
Lippard 1987). Using CCP4’s AreaImol software (Winn et al., 2011) we calculated the 
solvent accessible surface area across all ribosomal RNA atoms in the yeast 80S 
ribosome (25S, 18S, 5S, and 5.8S rRNA, PDB 4V7R) to a cisplatin-sized sphere with a 
radius of 2.2 Å (Melnikov et al., 2016), then plotted the natural log of solvent 
accessibility of each N7 and cytosine N3 against the location and intensity of each 
cisplatin-induced stop at both treatment concentrations (Figure 3.5). We found, 
surprisingly, that though the mean solvent accessibility was 3.4 Å2 for 100 µM stops and 
3.6 Å2 for 200 µM cisplatin stops, we see a number of stops mapped to positions with 0 
Å2 calculated solvent accessibility, and no strong correlation between stop location or 
intensity and solvent accessibility. This is consistent with recent results from x-ray 
crystallography experiments by Melnikov et al. (2016) who found that Pt adducts formed 
on T. thermophilus 70s ribosomes following in vitro cisplatin treatment are not solely 
predicted by solvent accessibility. 
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Figure 3.4. Cisplatin treatment effect on yeast large ribosomal subunit (25S). A) 100 µM 
cisplatin adducts. B) 200 µM cisplatin adducts. Increasing cisplatin concentration results 
in increased stop site observation. C) Stops present in both treatment concentrations, with 
a cutoff of 1.5-fold enrichment as described in text.  
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A) 
 
B) 
 
Figure 3.5. Calculated solvent accessible surface area for all 25S ribosomal subunit N7 
and cytosine N3 positions in context of the 25S ribosome structure to a platinum-sized 
sphere of radius 2.2 Å. A) 100 µM cisplatin. B) 200 µM cisplatin. Platinum binding 
positions across the 25S sequence are plotted against the natural log of each solvent-
accessible surface area, as calculated using CCP4’s Area Imol package (Winn et al., 
2011) (gray dots). Large dots are platinum binding sites as determined using our Pt-seq 
approach and are colored according to the natural log of their fold-enrichment as reported 
by the Mod-seq script (Talkish et al., 2014). Each treatment exhibits a number of binding 
sites in regions of no calculated solvent accessibility, represented as large half-dots along 
the x-axis. Gaps in coverage are due to missing nucleotides in the crystal structure. Only 
stops with greater than 1.5-fold increase over control are considered. 
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To narrow our focus for closer analysis we initially looked at the 25S large 
ribosomal subunit, compared stops across 100 and 200 µM cisplatin treatment conditions 
that are greater than 1.5-fold enriched over background, and then considered only those 
which were present in both treatments. Stops which were present in both conditions were 
then compared with a list of known modified nucleotides (Piekna-Przybylska et al., 2007) 
and any matches removed to ensure no overlap (Figure 3.6). Out of the 141 and 304 stop 
sites observed at 100 and 200 µM cisplatin, 26 are shared by both treatments (Figure 3.6). 
The median stop intensity for these paired stops was 1.8 at 100 µM cisplatin and 1.95 at 
200 µM cisplatin, further exhibiting a treatment effect.  
For this subset of 26 sites, the five sites with highest fold-enrichment are at 
positions G345, U382, C803, C1171, and G2824 (Figure 3.6). C1711 is located on helix 
58, which is the binding site for ribosomal protein L30e, an indispensable ribosomal 
protein. Solvent accessible surface area calculations suggest that the C1711 N3 position 
is inaccessible to cisplatin, but that as a whole helix 58 is highly exposed (Figure 3.5, 
residues 1698-1748). Helix 58’s interaction with protein L30e primarily relies on the 
unusual tertiary structure of helix 58, a kink-turn motif (Jenner et al., 2012; Bifano et al., 
2013). C1711 is located just before this motif. Together, H58 and L30e form an 
intersubunit bridge, one of several contacts between the large and small ribosomal 
subunits (Halic et al., 2005; Jenner et al., 2012).  
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Figure 3.6. Stop fold-enrichment for cisplatin induced stops on the yeast large ribosomal 
subunit (25S rRNA). Shown are stops shared between the top-50 strongest stop sites after 
200 µM cisplatin treatment and all stops observed in 100 µM cisplatin. Asterisks mark 
stops discussed further in the text. 
 
 G2824 is located at the base of helix 89, in the “accommodation corridor,” a 
passageway located along the interface between H89 and the H90-92 structure of the 
large ribosomal subunit (Petrov et al., 2008). It is immediately adjacent to the peptidyl 
transfer center (Rakauskaite and Dinman, 2008), and close to the tRNA A-site. 
Interestingly, it is close to the binding sites of anisomycin and narciclasine, eukaryotic 
ribosome-targeting antibiotics that inhibit peptide bond formation (Garreau de Loubresse 
et al., 2014). Furthermore, mutations to nearby residues (2820, A2829) result in non-
viable ribosomes (Rakauskaitė and Dinman, 2008), suggesting this is a region 
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particularly sensitive to modification. This implies a previously unexplored model for 
cisplatin inhibition of the ribosome. G345 and U382 are located near helix 23 and 24, 
respectively. U382 is highly solvent exposed, located near the surface of the large 
ribosomal subunit opposite the small subunit (Figure 3.10). G345 is near the surface of 
the large ribosomal subunit but behind the 5.8S ribosomal RNA (Figure 3.10).  
 In addition to cisplatin, we have also applied Pt-seq to map RNA accumulation of 
azaplatin, a novel click-functionalized platinum compound developed in our lab (Wirth et 
al., 2015). Pt-seq suggests that azaplatin either binds to more sites than cisplatin or that it 
causes a stronger stalling effect, as evidenced by increased stop site locations and higher 
intensities (Figure B.1 as compared with Figure 4). This could be due to structural 
differences, as azaplatin is a significantly bulkier molecule than cisplatin (Figure 3.1). As 
with cisplatin, we have plotted stop intensity vs solvent accessibility of all azaplatin 
binding sites and find no correlation between calculated solvent accessibility of Pt(II) 
binding sites and stop intensity (Figure 3.7). 
Azaplatin induces 835 stops at 100 µM treatment and 1188 stops at 200 µM 
treatment with greater than 1.5-fold enrichment over control (Figure 3.4). Of these, 513 
are shared stops between the two treatment levels (Figure B.1). We decided to consider 
only the top 50 strongest stops at 200 µM azaplatin treatment, then matched those with 
100 µM azaplatin treatment to narrow down a smaller subset to investigate further. This 
results in 16 shared stop sites (Figure 3.8). These stops are more intense than similarly 
selected cisplatin stops (Figure 3.6), and only one site is shared among the two datasets 
(C1711, Figures 6 and 8). 
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A)
B)
 
Figure 3.7. Calculated solvent accessible surface area for all 25S ribosomal subunit N7 
and cytosine N3 positions in context of the 25S ribosome structure to a platinum-sized 
sphere of radius 2.2 Å. A) 100 µM azaplatin. B) 200 µM azaplatin. Platinum binding 
positions across the 25S sequence are plotted against the natural log of each solvent-
accessible surface area, as calculated using CCP4’s Area Imol package (Winn et al., 
2011) (gray dots). Large dots are platinum binding sites as determined using our Pt-seq 
approach and are colored according to the natural log of their fold-enrichment as reported 
by the Mod-seq script (Talkish et al., 2014). Each treatment exhibits a number of binding 
sites in regions of no calculated solvent accessibility, represented as large half-dots along 
the X axis. Gaps in coverage are due to missing nucleotides in the crystal structure. Only 
stops with greater than 1.5-fold increase over control are considered. 
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 Three azaplatin stops, at G805, A807, and A808, are close to an observed 
cisplatin stop (C803, Figure 3.6). Each of these sites is located on helix H32, an internal 
loop which supports the PTC wall. In a random mutagenesis study searching for 
structurally important residues in E. coli ribosomes, Yassin and Mankin found a cluster 
of deleterious mutations at this internal loop and suggest it plays an important structural 
role in the ribosome, suggesting it could be a target for ribosome inactivating antibiotic 
development (Yassin and Mankin, 2007). The azaplatin stop at position 596 is located on 
an expansion segment, the third arm of 25ES7c, and the stop at 1972 (in which 100 µM 
induced a stronger stop than 200 µM) is on expansion segment ES27a. Expansion 
segments are poorly understood domains found in eukaryotic ribosomes, located outside 
the conserved core of the ribosome and responsible for a majority of the increased size of 
eukaryotic ribosomes relative to prokaryotic ribosomes (Ramesh and Woolford, 2016). 
Deletion of ES7 in S. cerevisiae results in defects in ribosome biosynthesis and inhibits S. 
cerevisiae growth (Jeeninga et al., 1997; Ramesh and Woolford, 2016). Deletion of ES27 
in Tetrahymena also prevents growth, demonstrating an important yet still poorly 
understood role (Sweeny et al., 1994). The azaplatin stop at G2249 is located at the base 
of helix H69, which itself is at the subunit interface and plays a key role in translation. 
This helix has been assessed for cisplatin binding in an in vitro modeled E. coli H69 by 
Dedduwa-Mudalige and Chow (2015) using a combination of mass spectrometry and 
RNAse T1 digestion, and cisplatin was found to accumulate to the equivalent G1906 (E. 
coli numbering) and its upstream neighbor G1907 (E. coli numbering).  
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Figure 3.8. Stop fold-enrichment for azaplatin induced stops on the yeast large ribosomal 
subunit (25S rRNA). Shown are stops shared between the top-50 strongest stop sites after 
200 µM azaplatin treatment and all stops observed in 100 µM azaplatin. Asterisks mark 
stops discussed further in the text. 
 
  We utilized reverse transcription primer extension analysis to verify our high-
throughput sequencing approach. Yeast cultures were grown overnight and then treated 
with 200 µM cisplatin for six hours. RNA was isolated and reverse transcribed (see 
Methods) and results were visualized via autoradiography. We chose to analyze the 
region near C1711 since that was our strongest stop and helix 58 is highly solvent 
exposed, making it a good candidate for RT primer extension. Using a RT primer 
spanning 1761-1779 we were unable to verify a C1711 stop (Figure B.2), however a 
number of stops are observed upstream of C1711 in the region spanning G1599 through 
G1646 (Figure 3.9A). 
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Figure 3.9. Comparison of gel-based reverse transcription primer extension analysis with 
results predicted by Pt-seq. Two regions of the yeast 25S large ribosomal subunit were 
subject to traditional gel-based primer extension analysis. A) positions 1600-1650 and B) 
positions 2510-2560 are shown. For both gels, lanes 1-4 are dideoxy sequencing ladders, 
lane 5 is 0 µM platinum control, and lane 6 is 200 µM cisplatin (6 hours treatment). Stop 
sites are marked with arrows. Band intensity down each lane was plotted using ImageJ 
and overlaid on a bar plot of Pt-seq results for both 100 and 200 µM cisplatin, shifted one 
nucleotide 3’ to illustrate RT stop sites. C) 1600-1646 and D) 2508-2563 are shown. 
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We used ImageJ to generate an intensity plot of control and 200 µM cisplatin 
treatment lanes, then picked peaks (stop sites) unique to 200 µM cisplatin treatment and 
plotted these on a barplot of Pt-seq stop site intensities for both 100 and 200 µM cisplatin 
treatment (Figure 3.9C). The results suggest overlap of Pt-seq stops with those generated 
by traditional primer extension analysis, comparable to a similar analysis of DMS 
modification by (Tang et al., 2015). We see stops at G1599, G1618, G1624, and A1643 
(Figure 3.8 A and C, gray arrows). The strongest stop observed on our RT gel (1643, 200 
µM cisplatin) is represented by a cluster of Pt-seq 100 µM cisplatin stops but does not 
match Pt-seq 200 µM cisplatin stops. 
A second primer intended to anneal near C1711 (1733-1753) instead annealed 
near helix 80 (3’ end 2605) due to its high GC content and the highly single stranded 
nature of the region to which it bound. Repeated experiments verified that this primer 
reliably extended through U2508 and generated strong dideoxy sequencing ladders 
covering G2563 through U2510 (Fig. 3.9B). Under 200 µM cisplatin treatment this 
primer generates a strong stop at U2514 / A2515, a stop at C2518, and a weak stop at 
G2533/G2534 (Fig. 3.9B, D). As described, we quantified these lanes and plotted stop 
site intensities compared with sequenced stops and found a correlation between the two. 
Pt-seq determined stops from 2511-2521 reflect the broad set of stops from 2511-2522 
observed via primer extension and suggest this region is particularly prone to 
modification.  
Replicate experiments are important to the Platinum-seq approach. In the 
preceding analysis, biological replicates were combined to reduce experimental 
background (Talkish et al. 2014, Tang et al. 2015). In order to assess reproducibility of 
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our approach, we also performed analysis by treating each biological replicate as an 
individual experiment. Original alignments were fed into the Mod-Seq script (Talkish et 
al. 2014) and stop sites for each replicate were found by comparing against the same 
control to generate fold-enrichments by replicate. We isolated stops on just the 25S 
rRNA, then merged fold-enrichments for each replicate pair by position, and plotted pairs 
by stop intensity (replicate 2 vs. replicate 1 for each treatment, Figure B.4). These plots 
demonstrate a rough correlation between replicates for stop site position and intensity, 
especially with azaplatin treatment (R2 values approximately 0.8 for both, figure B.4 C 
and D). Numerous stops were observed in one replicate but not the other (best 
demonstrated by Figure B.4 A, points at X=0 and Y=0). Since we are interested in 
“significant stops,” which we define as stops present in two treatment concentrations 
above a certain threshold, we decided to remove stops from further analysis that were not 
present in both replicates. In total, 7% of the total stops with >1.5-fold enrichment 
observed in 100 µM cisplatin were reproduced in both replicates, 43% were reproduced 
by both 200 µM cisplatin replicates, 58% were reproduced by both 100 µM azaplatin 
replicates, and 64% were reproduced by both 200 µM azaplatin replicates. Considering 
only stops present in both replicates reveals a much stronger correlation between stop site 
position and strength by replicate, with R2 values closer to 1 (Figure B.5). Natural-log 
transformation of this data further reveals this correlation (Figure B.6). 
These analyses combined with primer extension results (Figure 3.9) provide early 
indications that our approach is reproducible for strong stop sites. C1711, for example, 
was the strongest significant stop for cisplatin treatment, and is reproduced across all 
replicates here (Table B.1). Interestingly, strong stops often show a clustering effect 
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across replicates (Table B.2). For example, the strong stop at 807 under azaplatin 
treatment, discussed above, is reproduced across all azaplatin replicates, as well as 200 
µM cisplatin treatment and one of the two 100 µM cisplatin replicates. A tight cluster of 
highly replicated stops is seen from 804 through 808 in a purine-rich, single-stranded 
region (5’-G800ACCCGAAAGA810). This suggests there may be heavy accumulation of 
our platinum reagents to this region or a distribution of platinum adducts across this 
purine-rich stretch. 
In this study, we have performed a high-throughput sequencing-based survey of 
Pt-RNA adducts formed following treatment of S. cerevisiae with cisplatin. ‘Platinum-
seq’ identifies modification sites based on truncated cDNAs formed from random RT 
primer extension of RNA isolated from cells after treatment. A majority of predicted Pt-
RNA sites were located on ribosomal RNA which comprises the vast majority of yeast 
RNA (>80% by nucleotide) (Warner 1999). Platinum-induced stops are also observed on 
tRNAs and cytoplasmic RNAs such as SCR1 as well as transposable elements (Tables 
B.1-B.4). Since most research on RNA-associated platinum adducts has been performed 
on ribosomal RNA, we decided to focus on the large ribosomal subunit (in yeast, 25S 
rRNA). Our high-throughput sequencing method found numerous platinum-induced RT 
stops on the 25S ribosomal subunit. We see a clear dose-dependent response as we 
increase cisplatin treatment concentration, with an increase in the number, median, and 
maximum stop intensity seen with doubling concentration of cisplatin (Table 1.1). Our 
Pt-seq results compare well with gel-based RT mapping methods and infer regions highly 
prone to modification (Figure 3.9). 
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Figure 3.10. Conserved strong cisplatin-derived adducts present at 100 and 200 µM 
cisplatin mapped on a secondary structure of the large ribosomal subunit (Petrov et al., 
2014), shown in pink. All strong stops except C1711 are located in the highly conserved 
core of the large ribosomal subunit. 
 
 
 55 
 
 Our strongest cisplatin-derived stops are located primarily in the highly conserved 
core of the ribosome (Figure 3.10). C1711 and U382 are located on the solvent-exposed 
surface of the 25S large ribosomal subunit (Figure 11A). G345 is also on the surface of 
the 25S but hidden behind the 5.8S ribosomal subunit (Figure 3.11B), close to the nascent 
peptide exit tunnel, the interior cavity from which newly synthesized peptides exit the 
ribosome. Adjusting the transparency of the 25S reveals the internal location of C803 and 
G2824 (Figure 3.11C). C803 is in a solvent-exposed cavity just off the exit tunnel, and is 
part of helix H32, which supports the PTC wall (Yassin and Mankin). G2824 is 
particularly interesting, as it is located in the core of the ribosome, near the peptidyl 
transferase center, where peptide bond formation occurs. Numerous eukaryotic-specific 
antibiotics bind in this region, just two nucleotides away (Anisomycin shown, Figure 
3.12) and mutations to this region results in nonviable ribosomes, suggesting this region 
is particularly sensitive to modification. Cisplatin has previously been crystallized to 
regions near ribosome-targeting antibiotics (Melnikov et al., 2016). The authors suggest 
cisplatin may inhibit ribosomes similar to certain antibiotics. Our work suggests this is a 
subject worth investigation. 
 Our strongest azaplatin stops occur on more diverse regions. Two were on 
expansion segments ES7 and ES27 (C596 and A1972), which have previously shown to 
be important for ribosome function and biogenesis (Sweeney et al., 1994; Jeeninga et al., 
1997). Three stops were located on H32 (G805, A807, and A808), near the cisplatin stop 
previously discussed. It is suggested this purine-rich internal loop plays an important 
structural role, as it supports the PTC wall, and single-nucleotide mutations to this region 
are lethal (Yassin and Mankin., 2007). We see reproducible stops across biological 
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replicates in this region (Figure B.6), as well as a tight clustering effect to nucleotides 
from 804-808, lending more evidence this region may be heavily modified by platinum 
reagents (Table B.1). Finally, G2249 is at the base of an important loop (H69), and a 
cisplatin lesion has previously been mapped to this location in in vitro modeled E. coli 
H69 (Dedduwa-Mudalige and Chow, 2015). 
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Figure 3.11. Three-dimensional views of the yeast ribosome from the solvent-exposed 
side of the large ribosomal subunit with major cisplatin adduct sites noted in red. 25S 
rRNA is shown in white surface, 5S and 5.8S rRNA are shown as cyan surface, 
ribosomal proteins as purple cartoon. A) Looking down the exit tunnel with 5S and 5.8S 
rRNA present. B) removing the 5S and 5.8S ribosomal subunits reveals adduct 345, just 
above the exit tunnel in this view. C) Partially transparent surface render reveals adducts 
803 and 2824 and demonstrates how these strong stops are each located near the nascent 
peptide exit tunnel. 2824 is actually located at the core of the ribosome, in the peptidyl 
transferase center, and 803 is in a solvent-exposed cleft just off the exit tunnel. Figure 
created using PyMol, based on crystal structure PDB 4V7R 
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Figure 3.12. Pt-seq predicts a cisplatin-derived adduct at G2824, a residue near the PTC. 
Anisomycin is one of several eukaryotic-specific antibiotics which bind in a nearby 
pocket. (Garreau de Loubresse et al., 2014) 
  
Notably, not all strong PT-SEQ stop sites are represented in the gel-based RT 
assays and vice-versa. We used Circligase to create single-stranded circular vector-like 
products post-RT for PCR amplification as described by Talkish et al. (2014). 
Circularization avoids a second potentially low-yielding ligation step and Circligase itself 
is very efficient: the manufacturer reports near 100% conversion from linear to circular 
products of control sequences. Circligase does have a 3’ substrate bias toward primarily 
A and T residues in the 3’ position for circularization (Epicentre). Transforming our Pt-
seq results from adduct site to stop site (+1 nt) demonstrates a strong preference for A 
and T residues in the 3’ position at both treatment concentrations (Figure B.3). This bias 
is present for both concentrations of cisplatin and also observed in control treatment (not 
shown), and suggests that results are biased towards those adjacent to a preferred 
Circligase substrate. This factor may explain the failure to recapitulate some strong stops 
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seen by others by traditional RT analysis in the yeast peptidyl transferase center 
(Hostetter et al., 2012; Osborn et al., 2014). 
 
Conclusions 
Our work using high-throughput sequencing demonstrates cisplatin binds to a 
broad number of ribosomal sites and numerous cellular RNAs (Tables B.1-B.4). The 
presence of stops significantly stronger than background suggests there are some highly 
preferred sites, as previously observed (Osborn et al., 2014; Melnikov et al., 2016). Work 
here has discovered interesting potential sites modified by cisplatin, including G2824 in 
the peptidyl transferase center and in a region near ribosome inhibitor binding sites 
(Garreau de Loubresse et al., 2014). This suggests a previously unexplored mechanism 
for cisplatin inhibition of the ribosome which warrants further investigation. Furthermore, 
our approach has been demonstrated for another platinum-based compound (azaplatin), 
demonstrating broader applicability for determination of ribosome modification sites by 
small molecule platinum reagents.  
 
Summary of Chapter III and bridge to Chapter IV 
In this chapter we presented a method which couples reverse transcriptase stalling 
at Pt(II) lesions with high-throughput sequencing to map all sites of platinum 
accumulation in cellular RNA, which we have termed “Platinum-seq.” Using 
Saccharomyces cerevisiae as a model system, we have demonstrated Platinum-seq’s 
utility by mapping Pt adducts following treatment with cisplatin and a derivative, 
azaplatin, on the large ribosomal subunit at two concentrations. We find dose-dependent 
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responses with both compounds, and map numerous binding sites to single-nucleotide 
resolution on the yeast large ribosomal subunit. High-throughput sequencing data 
gathered in this work is further expanded upon in Chapter III, in which we perform 
preliminary differential expression analysis and compare cellular response to treatment 
with the two different drugs. 
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CHAPTER IV 
DIFFERENTIAL GENE EXPRESSION OF S. CEREVISIAE CELLS TREATED 
WITH CISPLATIN AND AZAPLATIN, A NOVEL CLICK REACTIVE PT(II)-
BASED SMALL MOLECULE 
 
This chapter contains contributions from Emily E. Reister and Victoria DeRose. 
Vickie provided guidance and direction throughout the project, and edited the final 
manuscript. Emily provided advice and assistance with differential expression, 
specifically performing analysis in R. I performed and analyzed the experiments and 
wrote the text. 
 
Introduction 
Cisplatin and related platinum-based anticancer compounds are present in 40-50% 
of all chemotherapy treatments (Dyson and Sava, 2006; Harper et al., 2010). Despite 
being used for approximately 40 years, mechanisms of cisplatin action are not fully 
understood (Siddik, 2003). Cisplatin is capable of forming exchange-inert complexes 
with DNA, RNA, proteins, membrane components, and small molecules (Harper et al., 
2010). To better understand this important compound, we have developed a suite of 
cisplatin-derived small molecules capable of participating in click chemistry (White et 
al., 2016). Click chemistry describes a class of reactions which are fast, high-yielding, 
and bio-orthogonal and are well suited for adding unique functionality to small molecules 
(Kolb et al., 2001). We have used our click-functionalized platinum(II) compounds to 
append fluorescent molecules for monitoring platinum accumulation on synthetic DNA, 
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ex vivo RNA, extracted RNA, and begun cellular colocalization studies by click labeling 
platinum compounds in cells post-fixation (reviewed in White et al., 2016). We have 
recently developed a high-throughput sequencing approach to identify to single-
nucleotide resolution cisplatin and azaplatin (Figure 4.1) binding sites on cellular RNA 
(“Pt-seq,” Plakos and DeRose, 2016). Here, using data gathered from that experiment, we 
present preliminary differential expression analysis on non-housekeeping genes in S. 
cerevisiae cells treated with cisplatin and azaplatin (Figure 4.1). 
Cisplatin treatment elicits a variety of cellular responses, including DNA damage 
response pathways and P53 activation (Jung and Lippard 2007; Basu and Krishnamurthy, 
2010). RNA expression analysis has suggested that cisplatin treatment results in 
differential expression of a number of oncogenes (Jung and Lippard, 2007). Furthermore, 
a recent microarray study demonstrated that cisplatin and one of its two approved 
derivatives, carboplatin, exhibit unique differential gene expression profiles (Bicaku et 
al., 2012), likely stemming from their inherent differences in reactivity. Given this, it is 
important to understand how our modified Pt(II) compounds influence gene expression in 
comparison with the parent compound cisplatin, and to further develop a contextual 
understanding of their various effects on cellular function.  
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Results and Discussion 
 
Figure 4.1. Platinum compounds used in this work. A) Cisplatin. B) Azaplatin (Wirth et 
al., 2015). 
 
In our Pt-Seq experiment (Plakos and DeRose, 2016), Saccharomyces cerevisiae 
were treated with 100 and 200 µM of either cisplatin or azaplatin (Figure 4.1) for six 
hours. Total RNA was isolated and libraries prepared as described (Plakos and DeRose, 
2016). From these samples, 35.8 million reads were obtained across six samples (two 
biological replicates each of control, 100 µM, and 200 µM azaplatin, Table 4.1). Data 
were aligned to the yeast genome using Bowtie (v1.1.2, Langmead et al., 2009), allowing 
3 mismatches. Despite using data from an experiment designed for detecting RNA 
modifications (Plakos and DeRose, 2016), we found sufficient non-ribosomal 
transcriptome coverage to perform preliminary differential expression analysis of non-
housekeeping genes. To do so, we masked ribosomal RNA, mitochondrial ribosomal 
RNA, and tRNA genes, and then counted all aligned reads across remaining genome 
features using HTSeq-count (Anders et al., 2005). Comparison of read counts across non-
housekeeping shows that biological replicates correlate strongly (r2 > 0.95 (data not 
shown), Figure C.1). We then performed differential expression analysis using the R 
package DESeq2 (Love et al., 2014).  
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Total 
sequencing 
reads
Reads aligned 
to yeast genome
Percent aligned 
to yeast genome
Reads on non-
housekeeping 
RNAs*
Control-1 4,113,364 3,826,004 93.0 213,627
Control-2 7,218,695 6,897,208 95.5 455,296
100 µM CisPt-1 4,851,790 4,608,522 95.0 294,912
100 µM CisPt-2 7,294,189 6,979,260 95.7 435,655
200 µM CisPt-1 5,925,462 5,548,737 93.6 294,181
200 µM CisPt-2 3,843,239 3,560,316 92.6 180,119
100 µM AzPt-1 5,152,589 4,925,655 95.6 365,552
100 µM AzPt-2 7,164,539 6,801,095 94.9 523,765
200 µM AzPt-1 5,549,454 5,305,073 95.6 379,955
200 µM AzPt-2 6,598,879 6,290,981 95.3 458,769
total 57,712,200
* sum of reads aligned to regions other than rRNA and tRNA genes  
Table 4.1. Sequencing read counts. Data represent two biological replicates each of 
control, 100 µM cisplatin (CisPt) treatment, 200 µM cisplatin treatment, 100 µM 
azaplatin treatment (AzPt), and 200 µM azaplatin treatment. Total obtained reads are 
presented, along with the count of reads that aligned to the yeast genome, percent 
alignment, and counts of reads aligned excluding rRNA and tRNA genes. Reads from the 
final column are used for differential expression analysis. 
 
Data were regularized-log transformed using blind dispersion estimation for 
principal component analysis. PCA results show that samples cluster by treatment (Figure 
4.2). The two cisplatin treatments are more closely related to control than azaplatin 
treatment, together constituting 12% of the sample variance. By contrast, 58% of sample 
variance is attributed to azaplatin treatment (Figure 4.2). Interestingly, while the two 
cisplatin concentrations deviate in the PCA, the two concentrations of azaplatin cluster 
extremely closely. We have not yet established an LD50 for azaplatin in yeast, but this 
compound has poor solubility in water and it is possible that the effective concentration is 
not actually doubled with 200 µM treatment.  
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Figure 4.2. Principal component analysis of differential expression data for yeast cells 
treated with 100 µM cisplatin (yellow triangles), 200 µM cisplatin (green squares), 100 
µM azaplatin (blue plus), 200 µM azaplatin (pink crossed boxes), and untreated control 
(orange circles). Most variance is attributed to treatment with azaplatin. Controls cluster 
most closely with cisplatin treatments, and azaplatin treatments cluster together. 
 
Differential expression analysis reveals 12 total significantly differentially 
expressed genes under 100 µM cisplatin treatment, 55 under 200 µM cisplatin treatment, 
213 under 100 µM azaplatin treatment, and 233 under 200 µM azaplatin treatment (Table 
4.2). MA plots show that significantly expressed genes (padj < 0.1) are biased toward 
higher gene expression (Figure C.2, red points). Significantly differentially expressed 
genes are generally upregulated. Of note, the results from these exeriments are subject to 
bias due to low coverage, as upregulated genes are more likely to be sequenced since they 
represent a greater proportion of the RNA population (Table 4.2, Figure C.2). The 10 
most upregulated and 10 most downregulated genes of each pairwise comparison are 
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shown in Tables 4.3, 4.4, and 4.5. Human homologs, when available, were determined 
using SGD’s YeastMine and are also included (Cherry et al., 2012). 
 
100 µM cisplatin count percent 100 µM azaplatin count percent
Upregulated 4 0.07% Upregulated 160 2.60%
Downregulated 8 0.13% Downregulated 53 0.88%
200 uM cisplatin count percent 200 uM azaplatin count percent
Upregulated 38 0.63% Upregulated 174 2.90%
Downregulated 17 0.28% Downregulated 59 0.98%
padj < 0.1
Out of 6049 genes with nonzero read count
 
Table 4.2. Counts of genes upregulated and downregulated by treatment with cisplatin 
and azaplatin, each at 100 µM and 200 µM. Gene expression is considered significantly 
different if adjusted p-value is less than 0.1. 
 
 Among the most highly expressed genes in both cisplatin treatments are RNR2 
and RNR4 (Table 4.3). RNR2 and 4 are genes encoding the small subunit of 
ribonucleotide reductase, an essential enzyme responsible for the rate-limiting step of 
dNTP synthesis (Yao et al., 2003; Tsaponina et al., 2011). RNR2 and 4 are known to 
distribute to the cytoplasm upon DNA replication stress, such as induced by the 
alkylating agent methane methylsulfonate (MMS), which methylates the N7 position of 
guanine and the N3 position of adenine and is commonly used to induce DNA damage 
response pathways (Hurd et al., 1987; Lundin et al., 2005; Tkach et al., 2012). MMS’s 
similarity to cisplatin is striking: cisplatin also modifies the N7 position of guanine, and 
adenine N3 is a preferred adenine platination site in gas-phase studies but is blocked from 
in-vivo DNA adduct formation by its location within the interior groove of the DNA 
double-helix (Chiavarino et al., 2015). RNR2 and RNR4 are upregulated upon cisplatin 
but not azaplatin treatment, and follow a dose-dependent response (RNR4 log2-fold 
response from 1.7 to 2.3 under 100 and 200 µM cisplatin treatment, respectively; RNR2 
 66 
 
log2-fold response from 1.6 to 2.2 under 100 and 200 µM cisplatin treatment, 
respectively (Table 4.3)). 
 Several other cisplatin-induced genes are shared between the two cisplatin drug 
concentrations. HPF1 is upregulated in a dose-dependent response. Aside from its wine-
clarifying attributes, no biological function has yet been ascribed to this gene (Brown et 
al., 2007). PDR5 (Pleiotropic Drug Resistance 5), a multidrug resistance protein involved 
in cation resistance (Miyahara et al., 1996; Bauer et al., 1999), is likewise upregulated in 
both treatments. Downregulated genes observed in both cisplatin treatments include 
DSE1, which is observed localizing to the cytoplasm upon DNA damage (Tkach et al., 
2012), as well as INO1, CTS1, SCW11, PRY3, DSE2, and EGT2. Downregulated genes 
consistently show a dose-dependent response, with a greater log2-fold change observed 
upon greater cisplatin treatment (Table 4.3). 
TSL1, TPS1, TPS2, and TPS3 are all upregulated upon azaplatin treatment. All 
three of these are slightly more upregulated under 100 µM azaplatin than 200 µM 
azaplatin (Tables 4.4 and 4.5). These genes are part of the trehalose synthesis pathway 
and are upregulated upon heat, nutrient, and osmotic stress (Winderickx et al., 1996). 
PHM7 is equally upregulated under both treatment conditions (2.9 log2-fold increased for 
both 100 and 200 µM azaplatin) and is known to localize to the cytoplasm upon DNA 
damage (Tkach et al., 2012). Numerous heat shock proteins are upregulated upon both 
azaplatin treatments, including MGA1, SSE2, HSP104, HSP78, and SSA4. No significant 
treatment effect was observed (Tables 4.4 and 4.5). Continuing the theme of DNA 
damage response, TMA10, a protein of unknown function which accumulates upon DNA 
damage (Fleischer et al., 2006), is upregulated equally in both azaplatin treatment 
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conditions (2.5 log2-fold). YNL194C is an unknown protein which, like the RNR genes 
seen to increase with cisplatin treatment, increases upon MMS treatment (Lee et al., 
2007). YNL194C is increased upon both azaplatin treatments (Tables 4.4 and 4.5).  
 Azaplatin treatment downregulates the mitochondrial decarboxylase complex 
(GCV1, GCV2, GCV3) (Tables 4.4 and 4.5). PHO11 and PHO12 are paralogs, both seen 
downregulated under azaplatin treatment. PHO11 is significantly downregulated in 100 
µM azaplatin (-2.2), PHO12 is downregulated under both treatments, in a slight dose-
dependent manor (-2.2 at 100 µM azaplatin, -2.5 at 200 µM azaplatin). URA3, part of the 
pyrimidine synthesis pathway, is downregulated by both treatment conditions. PHO84 is 
downregulated in a slight dose-dependent manner by azaplatin (-3.1 Log2-fold increase 
under 100 µM azaplatin and -3.8 log2-fold increase under 200 µM azaplatin) (Tables 4.4 
and 4.5). This gene is known as an inorganic phosphate transporter but has also been 
implicated in metal ion accumulation (Bun-Ya et al., 1991; Jensen et al., 2003). PHO84Δ 
yeast strains have reduced metal ion uptake and greater resistance to the toxic effects of 
manganese accumulation (Jensen et al., 2003).  
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SGD ID
Common 
Name log2(FC) padj Human Homolog Brief Description
YGR180C RNR4 1.7 1.03E-05 RRM2B RRM2 Ribonucleotide-diphosphate reductase (RNR) small subunit
YJL026W RNR2 1.6 1.03E-05 RRM2B RRM2 Ribonucleotide-diphosphate reductase (RNR), small subunit
YOL155C HPF1 0.9 1.77E-02 NA Haze-protective mannoprotein
YOR153W PDR5 0.9 2.10E-02 ABCG4 ABCG1 Plasma membrane ATP-binding cassette (ABC) transporter
YNL327W EGT2 -1.0 4.98E-03 NA Glycosylphosphatidylinositol (GPI)-anchored cell wall endoglucanase
YHR143W DSE2 -1.0 2.50E-02 NA Daughter cell-specific secreted protein with similarity to glucanases
YJL078C PRY3 -1.1 9.95E-02 GLIPR2 Cell wall-associated protein involved in export of acetylated sterols
YGL028C SCW11 -1.2 2.06E-02 NA Cell wall protein with similarity to glucanases
snR67 SNR67 -1.2 2.66E-02 NA C/D box small nucleolar RNA (snoRNA)
YLR286C CTS1 -1.2 1.87E-03 NA Endochitinase
YJL153C INO1 -1.2 6.50E-02 ISYNA1 Inositol-3-phosphate synthase
YER124C DSE1 -1.4 9.97E-03 NA Daughter cell-specific protein
SGD ID
Common 
Name log2(FC) padj Human Homolog Brief Description
YOR382W FIT2 2.5 1.09E-06 NA Mannoprotein that is incorporated into the cell wall
YGR180C RNR4 2.3 2.14E-11 RRM2B RRM2 Ribonucleotide-diphosphate reductase (RNR) small subunit
YJL026W RNR2 2.2 3.88E-12 RRM2B RRM2 Ribonucleotide-diphosphate reductase (RNR), small subunit
YOR383C FIT3 2.1 1.50E-03 NA Mannoprotein that is incorporated into the cell wall
YOL155C HPF1 1.6 4.66E-09 NA Haze-protective mannoprotein
YBR072W HSP26 1.6 7.38E-03
HSPB6 CRYAA 
CRYAB HSPB8 
HSPB7 HSPB1 
HSPB2 HSPB3 
HSPB9
Small heat shock protein (sHSP) with chaperone activity
YDR001C NTH1 1.5 2.78E-03 TREH Neutral trehalase, degrades trehalose
YNL160W YGP1 1.5 8.12E-07 ASPG Cell wall-related secretory glycoprotein
YMR011W HXT2 1.5 7.26E-03 SLC2A6 SLC2A8 High-affinity glucose transporter of the major facilitator superfamily
YLR034C SMF3 1.3 9.24E-02 SLC11A2 
SLC11A1
Putative divalent metal ion transporter involved in iron homeostasis
YKL164C PIR1 -1.3 1.74E-02 NA O-glycosylated protein required for cell wall stability
YGL028C SCW11 -1.3 2.75E-03 NA Cell wall protein with similarity to glucanases
YJL078C PRY3 -1.5 3.22E-03 GLIPR2 Cell wall-associated protein involved in export of acetylated sterols
YBR158W AMN1 -1.6 1.32E-02 NA Protein required for daughter cell separation
YNL327W EGT2 -1.6 1.25E-08 NA Glycosylphosphatidylinositol (GPI)-anchored cell wall endoglucanase
YDL128W VCX1 -1.6 1.41E-02 NA Vacuolar membrane antiporter with Ca2+/H+ and K+/H+ exchange 
activity
YER124C DSE1 -1.6 1.67E-03 NA Daughter cell-specific protein
YJL153C INO1 -1.8 9.44E-04 ISYNA1 Inositol-3-phosphate synthase
YLR286C CTS1 -1.9 2.69E-09 NA Endochitinase
YHR143W DSE2 -2.1 5.66E-09 NA Daughter cell-specific secreted protein with similarity to glucanases
100 µM cisplatin
200 µM Cisplatin 
 
 
Table 4.3. 10 most upregulated and 10 most downregulated genes for 100 µM and 200 
µM cisplatin treatment vs. control. Human homologs are given, when available. 
Expression level given as log2(fold change). All genes exhibit adjusted p-values less than 
0.1, as shown. Data from 100 µM cisplatin treatment only exhibited twelve genes with 
padj less than 0.1. Human homologs and gene descriptions found using SGD’s YeastMine 
(Cherry et al., 2012). 
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SGD ID
Common 
Name log2(FC) padj Human Homolog Brief Description
YML100W TSL1 4.0 1.78E-32 NA Large subunit of trehalose 6-phosphate synthase/phosphatase complex
YOL084W PHM7 2.9 3.46E-07 NA Protein of unknown function
YGR249W MGA1 2.8 3.07E-06 HSFX1 HSF5 
HSFY2 HSFY1
Protein similar to heat shock transcription factor
YDR074W TPS2 2.8 3.50E-11 NA Phosphatase subunit of the trehalose-6-P synthase/phosphatase 
complex
YBR169C SSE2 2.7 5.25E-12 HYOU1 HSPH1 
HSPA4L HSPA4
Member of Hsp110 subclass of the heat shock protein 70 (HSP70) 
family
YLL026W HSP104 2.7 2.58E-16 CLPB Disaggregase
YNL194C NA 2.6 4.45E-05 NA Integral membrane protein
YDR258C HSP78 2.5 4.43E-11 CLPB Oligomeric mitochondrial matrix chaperone
YLR327C TMA10 2.5 3.20E-04 HABP4 SERBP1 Protein of unknown function that associates with ribosomes
YER103W SSA4 2.5 1.08E-10
HSPA1A HSPA1B 
HSPA1L HSPA2 
HSPA6 HSPA7 
HSPA8
Heat shock protein that is highly induced upon stress
YNL250W RAD50 -1.9 1.90E-02 RAD50 Subunit of MRX complex with Mre11p and Xrs2p
YHR215W PHO12 -2.2 2.64E-03 NA One of three repressible acid phosphatases
YAR071W PHO11 -2.2 4.64E-03 NA One of three repressible acid phosphatases
YHR216W IMD2 -2.3 1.23E-04 GMPR IMPDH1 
IMPDH2 GMPR2
Inosine monophosphate dehydrogenase
YBR296C PHO89 -2.4 5.84E-04 SLC20A1 
SLC20A2
Plasma membrane Na+/Pi cotransporter
YDR019C GCV1 -2.5 2.38E-06 AMT T subunit of the mitochondrial glycine decarboxylase complex
YMR189W GCV2 -2.6 4.09E-09 GLDC P subunit of the mitochondrial glycine decarboxylase complex
YAL044C GCV3 -2.6 4.24E-05 GCSH H subunit of the mitochondrial glycine decarboxylase complex
YML123C PHO84 -3.1 9.63E-24 NA High-affinity inorganic phosphate (Pi) transporter
YEL021W URA3 -3.4 8.23E-32 UMPS Orotidine-5'-phosphate (OMP) decarboxylase
100 µM Azaplatin
 
 
Table 4.4. The 10 most upregulated and 10 most downregulated genes for 100 azaplatin 
treatment vs. control. Human homologs are given, when available. Expression level given 
as log2(fold change). All genes exhibit adjusted p-values less than 0.1, as shown. Human 
homologs and gene descriptions found using SGD’s YeastMine (Cherry et al., 2012). 
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SGD ID
Common 
Name log2(FC) padj Human Homolog Brief Description
YNR056C BIO5 4.6 2.11E-13
SLC7A9 SLC7A13 
SLC7A8 SLC7A11 
SLC7A10 SLC7A5 
SLC7A7 SLC7A6
Putative transmembrane protein involved in the biotin biosynthesis
YGR065C VHT1 4.0 3.19E-23 NA High-affinity plasma membrane H+-biotin (vitamin H) symporter
YNR058W BIO3 3.7 3.01E-09 NA 7,8-diamino-pelargonic acid aminotransferase (DAPA)
YML100W TSL1 3.3 6.25E-22 NA Large subunit of trehalose 6-phosphate synthase/phosphatase complex
YOL084W PHM7 2.9 3.90E-07 NA Protein of unknown function
YNL194C NA 2.8 1.15E-05 NA Integral membrane protein
YLR177W NA 2.7 1.20E-05 NA Putative protein of unknown function
YLL026W HSP104 2.5 1.13E-14 CLPB Disaggregase
YER103W SSA4 2.5 6.90E-11
HSPA1A HSPA1B 
HSPA1L HSPA2 
HSPA6 HSPA7 
HSPA8
Heat shock protein that is highly induced upon stress
YLR327C TMA10 2.5 3.59E-04 HABP4 SERBP1 Protein of unknown function that associates with ribosomes
YMR189W GCV2 -1.8 8.24E-05 GLDC P subunit of the mitochondrial glycine decarboxylase complex
YHR216W IMD2 -1.8 5.15E-03 GMPR IMPDH1 
IMPDH2 GMPR2
Inosine monophosphate dehydrogenase
YAL044C GCV3 -1.8 6.80E-03 GCSH H subunit of the mitochondrial glycine decarboxylase complex
YDL227C HO -2.0 6.92E-03 NA Site-specific endonuclease
YDR019C GCV1 -2.0 2.33E-04 AMT T subunit of the mitochondrial glycine decarboxylase complex
YBR296C PHO89 -2.1 5.54E-03 SLC20A1 
SLC20A2
Plasma membrane Na+/Pi cotransporter
YPL019C VTC3 -2.1 1.20E-05 NA Regulatory subunit of the vacuolar transporter chaperone (VTC) 
complex
YHR215W PHO12 -2.5 3.59E-04 NA One of three repressible acid phosphatases
YEL021W URA3 -3.3 1.00E-29 UMPS Orotidine-5'-phosphate (OMP) decarboxylase
YML123C PHO84 -3.8 1.09E-30 NA High-affinity inorganic phosphate (Pi) transporter
200 µM Azaplatin
 
 
Table 4.5. The 10 most upregulated and 10 most downregulated genes for 200 µM 
azaplatin treatment vs. control. Human homologs are given, when available. Expression 
level given as log2(fold change). All genes exhibit adjusted p-values less than 0.1, as 
shown. Human homologs and gene descriptions found using SGD’s YeastMine (Cherry 
et al., 2012). 
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We were next interested in which cellular processes were affected by cisplatin and 
azaplatin treatment. We took our list of differentially expressed genes under each 
condition with adjusted p-values less than 0.1 and performed KEGG pathway analysis 
and gene ontology (GO-term) analysis using the gage R package (Luo et al., 2009; 
Kanehisa et al., 2016). KEGG pathway analysis showed no significantly enriched 
pathways for either cisplatin treatment (p-value <0.1), which may be due to low 
coverage. Data from 100 µM azaplatin treatment shows significantly increased 
expression from “starch and sucrose metabolism” (p-value .009), and significantly 
decreased “purine metabolism” (p-value .03) and “metabolic pathways” (p-value .08), 
which is a broad category covering most metabolism in the cell. Samples from 200 µM 
azaplatin treatment show increased expression from “starch and sucrose metabolism” 
pathways (p-value .01) and no significantly decreased pathways. 
 A broader perspective of differential expression can be gained from exploring 
gene ontology of significantly expressed genes. Gene ontology (GO) classifies genes into 
categories describing their molecular function, biological process, and cellular 
component. We used SGD’s GO Slim mapper to classify our differentially expressed 
genes into GO terms relating to function and process. GO Slim specifically uses curated 
lists of GO terms and is suitable for a broad overview without the fine-grained 
distinctions offered by the full GO database. We submitted significant gene lists from 
each treatment to SGD’s GO Slim Process and Function categories, isolated the top 10 
GO terms for each treatment by category (Tables 4.6 through 4.9), combined results 
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across treatments, and calculated the percent each GO term is represented within each 
pool of genes (Figure 4.3).  
 
GO ID GO term Frequency Gene(s) GOID GO term Frequency Gene(s)
55086  nucleobase-containing small molecule metabolic process 2 RNR4,RNR2 71554  cell wall organization or biogenesis 6 SED1,GSC2,HSP150,PIR1,YGP1,HPF1
42221  response to chemical 2 DSE1,PDR5 9451  RNA modification 6 SNR13,SNR161,SNR56,SNR63,SNR64,SNR75
6873  cellular ion homeostasis 1 PDR5 42221  response to chemical 6 NTH1,DSE1,HSP104,AHP1,ASC1,PDR5
71554  cell wall organization or biogenesis 1 HPF1 6364  rRNA processing 6 SNR13,SNR161,SNR56,SNR63,SNR64,SNR75
7124  pseudohyphal growth 1 DSE2 32196  transposition 6 YBL005W-B,YDR210W-B,YLR157C-B,YLR256W-A,YPL257W-B,YPR158C-D
23052  signaling 1 DSE1 5975  carbohydrate metabolic process 5 NTH1,GSC2,INO1,HSP104,GPH1
6869  lipid transport 1 PRY3 43934  sporulation 3 HHT1,PRB1,GSC2
6364  rRNA processing 1 SNR67 55085  transmembrane transport 3 BAP2,VCX1,ITR1
746  conjugation 1 DSE1 55086  nucleobase-containing small molecule metabolic process 3 RNR1,RNR4,RNR2
5975  carbohydrate metabolic process 1 INO1 6873  cellular ion homeostasis 3 VCX1,SMF3,PDR5
GO ID GO term Frequency Gene(s) GOID GO term Frequency Gene(s)
16787  hydrolase activity 6 SCW11,DSE2,CTS1,EGT2,HPF1,PDR5 16787  hydrolase activity 16
YBL005W-B,NTH1,YDR210W-B,PRB1,SCW11,DSE2,HSP150,HSP104,YLR157C-
B,CTS1,SUN4,EGT2,HPF1,PDR5,YPL257W-B,YPR158C-D
16798  hydrolase activity, acting on glycosyl bonds 5 SCW11,DSE2,CTS1,EGT2,HPF1 3723  RNA binding 13
YBL005W-B,HSP26,YDR210W-B,YLR157C-B,YLR256W-A,YPL257W-B,YPR158C-
D,SNR13,SNR161,SNR56,SNR63,SNR64,SNR75
3674  molecular function unknown 2 DSE1,PRY3 16740  transferase activity 9 TLC1,YBL005W-B,YDR210W-B,MET6,GSC2,YLR157C-B,YPL257W-B,YPR158C-D,GPH1
16491  oxidoreductase activity 2 RNR4,RNR2 3674  molecular function unknown 8 DSE1,SPI1,PRY3,TOH1,YGP1,FIT2,FIT3,YPR108W-A
19843  rRNA binding 1 SNR67 16798  hydrolase activity, acting on glycosyl bonds 7 NTH1,SCW11,DSE2,CTS1,SUN4,EGT2,HPF1
30555  RNA modification guide activity 1 SNR67 22857  transmembrane transporter activity 7 BAP2,VCX1,ITR1,HXT4,SMF3,HXT2,PDR5
16853  isomerase activity 1 INO1 19843  rRNA binding 6 SNR13,SNR161,SNR56,SNR63,SNR64,SNR75
22857  transmembrane transporter activity 1 PDR5 30555  RNA modification guide activity 6 SNR13,SNR161,SNR56,SNR63,SNR64,SNR75
3723  RNA binding 1 SNR67 16779  nucleotidyltransferase activity 6 TLC1,YBL005W-B,YDR210W-B,YLR157C-B,YPL257W-B,YPR158C-D
16887  ATPase activity 1 PDR5 8233  peptidase activity 6 YBL005W-B,YDR210W-B,PRB1,YLR157C-B,YPL257W-B,YPR158C-D
Cellular Function
200 µM cisplatin
Biological Process
Cellular Function
100 µM cisplatin
Biological Process
 
 
Table 4.6. Gene ontology term analysis for 100 µM cisplatin treatment. Shown are 
Biological Process and Cellular Function GO terms for each treatment. Frequency is the 
number of significantly differentially expressed genes which fall into each category (padj 
<0.1).  
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GO ID GO term Frequency Gene(s) GOID GO term Frequency Gene(s)
55086  nucleobase-containing small molecule metabolic process 2 RNR4,RNR2 71554  cell wall organization or biogenesis 6 SED1,GSC2,HSP150,PIR1,YGP1,HPF1
42221  response to chemical 2 DSE1,PDR5 9451  RNA modification 6 SNR13,SNR161,SNR56,SNR63,SNR64,SNR75
6873  cellular ion homeostasis 1 PDR5 42221  response to chemical 6 NTH1,DSE1,HSP104,AHP1,ASC1,PDR5
71554  cell wall organization or biogenesis 1 HPF1 6364  rRNA processing 6 SNR13,SNR161,SNR56,SNR63,SNR64,SNR75
7124  pseudohyphal growth 1 DSE2 32196  transposition 6 YBL005W-B,YDR210W-B,YLR157C-B,YLR256W-A,YPL257W-B,YPR158C-D
23052  signaling 1 DSE1 5975  carbohydrate metabolic process 5 NTH1,GSC2,INO1,HSP104,GPH1
6869  lipid transport 1 PRY3 43934  sporulation 3 HHT1,PRB1,GSC2
6364  rRNA processing 1 SNR67 55085  transmembrane transport 3 BAP2,VCX1,ITR1
746  conjugation 1 DSE1 55086  nucleobase-containing small molecule metabolic process 3 RNR1,RNR4,RNR2
5975  carbohydrate metabolic process 1 INO1 6873  cellular ion homeostasis 3 VCX1,SMF3,PDR5
GO ID GO term Frequency Gene(s) GOID GO term Frequency Gene(s)
16787  hydrolase activity 6 SCW11,DSE2,CTS1,EGT2,HPF1,PDR5 16787  hydrolase activity 16
YBL005W-B,NTH1,YDR210W-B,PRB1,SCW11,DSE2,HSP150,HSP104,YLR157C-
B,CTS1,SUN4,EGT2,HPF1,PDR5,YPL257W-B,YPR158C-D
16798  hydrolase activity, acting on glycosyl bonds 5 SCW11,DSE2,CTS1,EGT2,HPF1 3723  RNA binding 13
YBL005W-B,HSP26,YDR210W-B,YLR157C-B,YLR256W-A,YPL257W-B,YPR158C-
D,SNR13,SNR161,SNR56,SNR63,SNR64,SNR75
3674  molecular function unknown 2 DSE1,PRY3 16740  transferase activity 9 TLC1,YBL005W-B,YDR210W-B,MET6,GSC2,YLR157C-B,YPL257W-B,YPR158C-D,GPH1
16491  oxidoreductase activity 2 RNR4,RNR2 3674  molecular function unknown 8 DSE1,SPI1,PRY3,TOH1,YGP1,FIT2,FIT3,YPR108W-A
19843  rRNA binding 1 SNR67 16798  hydrolase activity, acting on glycosyl bonds 7 NTH1,SCW11,DSE2,CTS1,SUN4,EGT2,HPF1
30555  RNA modification guide activity 1 SNR67 22857  transmembrane transporter activity 7 BAP2,VCX1,ITR1,HXT4,SMF3,HXT2,PDR5
16853  isomerase activity 1 INO1 19843  rRNA binding 6 SNR13,SNR161,SNR56,SNR63,SNR64,SNR75
22857  transmembrane transporter activity 1 PDR5 30555  RNA modification guide activity 6 SNR13,SNR161,SNR56,SNR63,SNR64,SNR75
3723  RNA binding 1 SNR67 16779  nucleotidyltransferase activity 6 TLC1,YBL005W-B,YDR210W-B,YLR157C-B,YPL257W-B,YPR158C-D
16887  ATPase activity 1 PDR5 8233  peptidase activity 6 YBL005W-B,YDR210W-B,PRB1,YLR157C-B,YPL257W-B,YPR158C-D
Cellular Function
200 µM cisplatin
Biological Process
Cellular Function
100 µM cisplatin
Biological Process
 
 
Table 4.7. Gene ontology term analysis for 200 µM cisplatin treatment. Shown are 
Biological Process and Cellular Function GO terms for each treatment. Frequency is the 
number of significantly differentially expressed genes which fall into each category (padj 
<0.1).  
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GOID GO term Frequency Gene(s) GO ID GO term Frequency Gene(s)
5975  carbohydrate metabolic process 26 TPS1,GID7,GLK1,CIT2,NTH1,TPS2,GLC3,HXK1,TOS3,GSC2,VID28,KAR2,TDH1,INO1,UGP1,HSP104,GSY2,TSL1,PGM2,GID8,TPS3,GAC1,BUD7,TYE7,GPH1,GDB1 6364  rRNA processing 31
UTP20,SAS10,HCA4,MTR4,UTP10,MRT4,EBP2,NOP56,RPS1B,RRP5,NOP4,NIP7,RPS23B,SNR128,SNR161,SNR
17A,SNR17B,SNR30,SNR39,SNR40,SNR41,SNR42,SNR47,SNR49,SNR5,SNR60,SNR8,SNR80,SNR81,SNR82,SN
R83
6364  rRNA processing 25 UTP20,NUG1,NOP7,MTR4,UTP10,RPS1A,RPS1B,RRP5,DBP2,PUS7,RRP12,SNR161,SNR17A,SNR17B,SNR30,SNR39,SNR41,SNR42,SNR43,SNR5,SNR60,SNR80,SNR81,SNR82,SNR83 5975  carbohydrate metabolic process 25
VID24,TPS1,GID7,GLK1,CIT2,NTH1,TPS2,GLC3,HXK1,TOS3,GSC2,ENO1,KAR2,TDH1,INO1,UGP1,HSP104,GSY2
,TSL1, PGM2,GPD2,GAC1,TYE7,GPH1,GDB1
8150  biological process unknown 22 AI3,AI5_BETA,YRO2,YBR287W,NRP1,JIP4,YER158C,YGR130C,RTS3,RIE1,PHO12,YLR177W,TMA10,STP3,YNL144C,PHM7,DUF1,YPL247C,YPR108W-A,YPR117W,SNR190,SNR4 42221  response to chemical 21
FES1,TPS1,HSP30,RPN4,YDL124W,NTH1,ADR1,HSP12,HAC1,MTL1,YHB1,VHR1,KAR2,TMA19,HSP104,HAP1,O
RM2,SIS1,BXI1,DDR2,IRA2
55086  nucleobase-containing small molecule metabolic process 20 COX1,ATP8,ATP6,COB,OLI1,COX2,COX3,GLK1,URA3,RNR1,HXK1,PNC1,IMD2,TDH1,IMD3,APT1,AAH1,IRA2,VHS3,TYE7 8150  biological process unknown 21
YRO2,STP4,YDR186C,JIP4,YER158C,RTS3,RIE1,PHO12,TOH1,MHO1,YLR177W,TMA10,STP3,PHM7,ZPS1,YPL2
47C, YPR108W-A,YPR117W,TDA6,SNR190,SNR4
42221  response to chemical 19 FLO1,UGA2,FES1,TPS1,HSP30,NTH1,ADR1,MTL1,RIM101,VHR1,KAR2,IML2,TMA19,HSP104,HAP1,GAD1,SIS1,IRA2,AZF1 55085  transmembrane transport 18 ATP6,OLI1,SSA1,BAP2,AGP2,PHO89,AGP1,CCC2,HXT7,HXT6,HXT3,SIT1,PIC2,SSA4,PMC1,KAR2,SSA2,PHO84
55085  transmembrane transport 16 ATP8,ATP6,OLI1,SSA1,BAP2,AGP2,PHO89,AGP1,HXT7,HXT6,PIC2,SSA4,PMC1,KAR2,SSA2,PHO84 9451  RNA modification 16
NOP56,SNR128,SNR161,SNR39,SNR40,SNR41,SNR42,SNR47,SNR49,SNR5,SNR60,SNR8,SNR80,SNR81,SNR8
2,SNR83
6091  generation of precursor metabolites and energy 16 COX1,COB,COX2,COX3,GLK1,GLC3,HXK1,TDH1,UGP1,HAP1,GSY2,PGM2,GAC1,TYE7,GPH1,GDB1 71554  cell wall organization or biogenesis 16 TIP1,FMP45,PST1,SED1,MTL1,GSC2,KAR2,MHP1,HSP150,YPS1,LST8,YGP1,KRE1,HPF1,FLC1,NCE102
6457  protein folding 14 SSA1,HSP26,SSE2,AHA1,HSP78,SSA4,MDJ1,BTN2,SSA2,HSP104,SIS1,STI1,HSP82,CUR1 6091  generation of precursor metabolites and energy 16 COX1,COX3,GLK1,GLC3,HXK1,ENO1,TDH1,UGP1,PET10,HAP1,GSY2,PGM2,GAC1,TYE7,GPH1,GDB1
71554  cell wall organization or biogenesis 13 ZRG8,MTL1,GSC2,SNG1,RIM101,KAR2,MHP1,YPS1,LST8,YGP1,HPF1,AZF1,BUD7 55086  nucleobase-containing small molecule metabolic process 15 COX1,ATP6,OLI1,COX3,GLK1,URA3,RNR1,HXK1,PNC1,ENO1,IMD2,TDH1,GPD2,IRA2,TYE7
9408  response to heat 13 FLO1,HSP26,TPS1,HSP30,TPS2,AHA1,HSP78,SSA4,MDJ1,HSP104,GAC1,LSP1,CUR1 6457  protein folding 14 SSA1,HSP26,SSE2,AHA1,HSP78,SSA4,BTN2,PHB2,SSA2,HSP104,SIS1,STI1,FLC1,HSP82
Cellular Function Cellular Function
GO ID GO term Frequency Gene(s) GOID GO term Frequency Gene(s)
16787  hydrolase activity 42
AI3,AI4,ATP8,ATP6,OLI1,SCEI,RPR1,SSA1,PHO11,HO,NTH1,DOA4,TPS2,HSP78,PRB1,NUG1,SSA4,DUG1,PMC1
,PNC1, 
DSE2,PHO12,KAR2,MTR4,SMC3,CPS1,TIF1,SSA2,HSP104,YPS1,YEF3,NTE1,TSL1,TPS3,DBP2,AAH1,RAD50,HP
F1,STE13, NEW1,HSP82,GDB1
3674  molecular function unknown 49
YRO2,VID24,AGP2,SDS24,GID7,HSP30,YCR061W,PRM7,SAS10,FMP45,PST1,YDR186C,MTH1,JIP4,SPI1,YER15
8C,VTC2,MDS3,MTL1,RTS3,PHB2,NCA3,TOH1,MHO1,TMA19,PET10,YLR177W,MSC3,TMA10,ORM2,MSC1,DIA1,
YGP1,YNL194C,BXI1,DDR2,MAM3,PHM7,ZPS1,RIM20,VTC3,NIP7,YPL247C,ATG41,SPO24,YPR108W-
A,YPR117W,NCE102,TDA6
3674  molecular function unknown 41
AI5_BETA,YRO2,AGP2,SDS24,YBR287W,GID7,HSP30,NRP1,PAM1,MTH1,JIP4,ZRG8,SPI1,YER158C,VTC2,MDS
3,MTL1, 
YGR130C,RTS3,SNG1,VID28,IML2,TMA19,YLR177W,TMA10,MSC1,GID8,DIA1,YNL144C,YGP1,YNL194C,PHM7,R
IM20, BUD7,VTC3,YPL247C,ATG41,SPO24,YPR108W-A,YPR117W,PIN3
3723  RNA binding 44
LSR1,SSA1,UTP20,HSP26,MSS116,PUF6,HYP2,VTC1,MPT5,RIE1,IMD2,MTR4,UTP10,JSN1,MRT4,EBP2,SSA2,N
OP56,RRP5,STI1,NOP4,PUF2,SNR128,SNR161,SNR17A,SNR17B,SNR19,SNR190,SNR30,SNR39,SNR4,SNR40,S
NR41,SNR42,SNR47,SNR49,SNR5,SNR6,SNR60,SNR8,SNR80,SNR81,SNR82,SNR83
3723  RNA binding 41
LSR1,SSA1,UTP20,HSP26,NUG1,MPT5,NOP7,RIE1,IMD2,MTR4,UTP10,JSN1,RPL14A,TIF1,SSA2,YEF3,IMD3,CL
U1,RRP5, 
TIF11,STI1,RRP12,NEW1,SNR161,SNR17A,SNR17B,SNR19,SNR190,SNR30,SNR39,SNR4,SNR41,SNR42,SNR43
,SNR5, SNR6,SNR60,SNR80,SNR81,SNR82,SNR83
16787  hydrolase activity 35
ATP6,BI2,OLI1,RPR1,SSA1,TIP1,DUR1,2,APE3,HO,NTH1,TPS2,MSS116,HSP78,CCC2,PRB1,SSA4,DUG1,PMC1,
PNC1,ESP1,PHO12,HCA4,KAR2,MTR4,SMC3,HSP150,CPS1,SSA2,HSP104,YPS1,TSL1,HPF1,STE13,HSP82,GDB
1
16740  transferase activity 32 AI2,TLC1,TPS1,GLK1,CIT2,GIN4,GLC3,MET6,HXK1,TOS3,GSC2,VTC4,YAK1,HAL5,PTK2,UGP1,HSL1,PTK1,SHM2,GSY2, CAR2,APT1,TSL1,TPS3,RAD50,CMK2,HRK1,RPA190,PYK2,RPA135,GPH1,GDB1 16740  transferase activity 31
TLC1,HMT1,TPS1,GLK1,CIT2,GLC3,MET6,HXK1,TOS3,GSC2,BIO2,VTC4,YAK1,HAL5,OPI3,UGP1,HSL1,PTK1,SH
M2,SAM1,GSY2,CAR2,TSL1,BIO3,CMK2,HRK1,RPA190,PYK2,SPE3,GPH1,GDB1
22857  transmembrane transporter activity 19 COX1,ATP8,ATP6,COB,OLI1,COX2,COX3,BAP2,PHO89,AGP1,HXT7,HXT6,PIC2,PMC1,TPO2,PHO84,LYP1,TPO4,TPO3 19843  rRNA binding 21
MRT4,RRP5,SNR128,SNR161,SNR17A,SNR17B,SNR190,SNR30,SNR39,SNR40,SNR41,SNR42,SNR47,SNR49,S
NR5,SNR60,SNR8,SNR80,SNR81,SNR82,SNR83
16887  ATPase activity 18 ATP8,ATP6,OLI1,SSA1,HSP78,SSA4,PMC1,KAR2,MTR4,SMC3,TIF1,SSA2,HSP104,YEF3,DBP2,RAD50,NEW1,HSP82 22857  transmembrane transporter activity 21
COX1,ATP6,OLI1,COX3,BAP2,PHO89,AGP1,CCC2,HXT7,HXT6,HXT3,SIT1,PIC2,PMC1,TPO2,PHO84,LYP1,BIO5,
TPO4,FLC1,TPO3
19843  rRNA binding 16 RRP5,SNR161,SNR17A,SNR17B,SNR190,SNR30,SNR39,SNR41,SNR42,SNR43,SNR5,SNR60,SNR80,SNR81,SNR82,SNR83 3729  mRNA binding 16 UTP20,HSP26,MSS116,PUF6,VTC1,MPT5,RIE1,IMD2,MTR4,JSN1,EBP2,NOP56,RRP5,STI1,NOP4,PUF2
3729  mRNA binding 15 UTP20,HSP26,NUG1,MPT5,NOP7,RIE1,IMD2,MTR4,JSN1,IMD3,CLU1,RRP5,STI1,RRP12,NEW1 16887  ATPase activity 16 ATP6,OLI1,SSA1,MSS116,HSP78,CCC2,SSA4,PMC1,HCA4,KAR2,MTR4,SMC3,HSP150,SSA2,HSP104,HSP82
30234  enzyme regulator activity 14 FES1,SSE2,AHA1,MDJ1,TFS1,TSL1,TPS3,LST8,APJ1,IRA2,STI1,VHS3,GAC1,CIP1 30555  RNA modification guide activity 16 SNR128,SNR161,SNR190,SNR39,SNR40,SNR41,SNR42,SNR47,SNR49,SNR5,SNR60,SNR8,SNR80,SNR81,SNR82,SNR83
16491  oxidoreductase activity 13 COX1,COB,COX2,COX3,GCV3,UGA2,GCV1,RNR1,ERG1,IMD2,TDH1,IMD3,GCV2 16491  oxidoreductase activity 15 COX1,COX3,GCV3,YDL124W,GCV1,SUR2,RNR1,LPD1,YHB1,IMD2,TDH1,MAE1,HFD1,GCV2,GPD2
100 µM azaplatin
Biological Process
200 µM azaplatin
Biological Process
 
 
Table 4.8. Gene ontology term analysis for 100 µM azaplatin treatment. Shown are 
Biological Process and Cellular Function GO terms for each treatment. Frequency is the 
number of significantly differentially expressed genes which fall into each category (padj 
<0.1). 
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GOID GO term Frequency Gene(s) GO ID GO term Frequency Gene(s)
5975  carbohydrate metabolic process 26 TPS1,GID7,GLK1,CIT2,NTH1,TPS2,GLC3,HXK1,TOS3,GSC2,VID28,KAR2,TDH1,INO1,UGP1,HSP104,GSY2,TSL1,PGM2,GID8,TPS3,GAC1,BUD7,TYE7,GPH1,GDB1 6364  rRNA processing 31
UTP20,SAS10,HCA4,MTR4,UTP10,MRT4,EBP2,NOP56,RPS1B,RRP5,NOP4,NIP7,RPS23B,SNR128,SNR161,SNR
17A,SNR17B,SNR30,SNR39,SNR40,SNR41,SNR42,SNR47,SNR49,SNR5,SNR60,SNR8,SNR80,SNR81,SNR82,SN
R83
6364  rRNA processing 25 UTP20,NUG1,NOP7,MTR4,UTP10,RPS1A,RPS1B,RRP5,DBP2,PUS7,RRP12,SNR161,SNR17A,SNR17B,SNR30,SNR39,SNR41,SNR42,SNR43,SNR5,SNR60,SNR80,SNR81,SNR82,SNR83 5975  carbohydrate metabolic process 25
VID24,TPS1,GID7,GLK1,CIT2,NTH1,TPS2,GLC3,HXK1,TOS3,GSC2,ENO1,KAR2,TDH1,INO1,UGP1,HSP104,GSY2
,TSL1, PGM2,GPD2,GAC1,TYE7,GPH1,GDB1
8150  biological process unknown 22 AI3,AI5_BETA,YRO2,YBR287W,NRP1,JIP4,YER158C,YGR130C,RTS3,RIE1,PHO12,YLR177W,TMA10,STP3,YNL144C,PHM7,DUF1,YPL247C,YPR108W-A,YPR117W,SNR190,SNR4 42221  response to chemical 21
FES1,TPS1,HSP30,RPN4,YDL124W,NTH1,ADR1,HSP12,HAC1,MTL1,YHB1,VHR1,KAR2,TMA19,HSP104,HAP1,O
RM2,SIS1,BXI1,DDR2,IRA2
55086  nucleobase-containing small molecule metabolic process 20 COX1,ATP8,ATP6,COB,OLI1,COX2,COX3,GLK1,URA3,RNR1,HXK1,PNC1,IMD2,TDH1,IMD3,APT1,AAH1,IRA2,VHS3,TYE7 8150  biological process unknown 21
YRO2,STP4,YDR186C,JIP4,YER158C,RTS3,RIE1,PHO12,TOH1,MHO1,YLR177W,TMA10,STP3,PHM7,ZPS1,YPL2
47C, YPR108W-A,YPR117W,TDA6,SNR190,SNR4
42221  response to chemical 19 FLO1,UGA2,FES1,TPS1,HSP30,NTH1,ADR1,MTL1,RIM101,VHR1,KAR2,IML2,TMA19,HSP104,HAP1,GAD1,SIS1,IRA2,AZF1 55085  transmembrane transport 18 ATP6,OLI1,SSA1,BAP2,AGP2,PHO89,AGP1,CCC2,HXT7,HXT6,HXT3,SIT1,PIC2,SSA4,PMC1,KAR2,SSA2,PHO84
55085  transmembrane transport 16 ATP8,ATP6,OLI1,SSA1,BAP2,AGP2,PHO89,AGP1,HXT7,HXT6,PIC2,SSA4,PMC1,KAR2,SSA2,PHO84 9451  RNA modification 16
NOP56,SNR128,SNR161,SNR39,SNR40,SNR41,SNR42,SNR47,SNR49,SNR5,SNR60,SNR8,SNR80,SNR81,SNR8
2,SNR83
6091  generation of precursor metabolites and energy 16 COX1,COB,COX2,COX3,GLK1,GLC3,HXK1,TDH1,UGP1,HAP1,GSY2,PGM2,GAC1,TYE7,GPH1,GDB1 71554  cell wall organization or biogenesis 16 TIP1,FMP45,PST1,SED1,MTL1,GSC2,KAR2,MHP1,HSP150,YPS1,LST8,YGP1,KRE1,HPF1,FLC1,NCE102
6457  protein folding 14 SSA1,HSP26,SSE2,AHA1,HSP78,SSA4,MDJ1,BTN2,SSA2,HSP104,SIS1,STI1,HSP82,CUR1 6091  generation of precursor metabolites and energy 16 COX1,COX3,GLK1,GLC3,HXK1,ENO1,TDH1,UGP1,PET10,HAP1,GSY2,PGM2,GAC1,TYE7,GPH1,GDB1
71554  cell wall organization or biogenesis 13 ZRG8,MTL1,GSC2,SNG1,RIM101,KAR2,MHP1,YPS1,LST8,YGP1,HPF1,AZF1,BUD7 55086  nucleobase-containing small molecule metabolic process 15 COX1,ATP6,OLI1,COX3,GLK1,URA3,RNR1,HXK1,PNC1,ENO1,IMD2,TDH1,GPD2,IRA2,TYE7
9408  response to heat 13 FLO1,HSP26,TPS1,HSP30,TPS2,AHA1,HSP78,SSA4,MDJ1,HSP104,GAC1,LSP1,CUR1 6457  protein folding 14 SSA1,HSP26,SSE2,AHA1,HSP78,SSA4,BTN2,PHB2,SSA2,HSP104,SIS1,STI1,FLC1,HSP82
Cellular Function Cellular Function
GO ID GO term Frequency Gene(s) GOID GO term Frequency Gene(s)
16787  hydrolase activity 42
AI3,AI4,ATP8,ATP6,OLI1,SCEI,RPR1,SSA1,PHO11,HO,NTH1,DOA4,TPS2,HSP78,PRB1,NUG1,SSA4,DUG1,PMC1
,PNC1, 
DSE2,PHO12,KAR2,MTR4,SMC3,CPS1,TIF1,SSA2,HSP104,YPS1,YEF3,NTE1,TSL1,TPS3,DBP2,AAH1,RAD50,HP
F1,STE13, NEW1,HSP82,GDB1
3674  molecular function unknown 49
YRO2,VID24,AGP2,SDS24,GID7,HSP30,YCR061W,PRM7,SAS10,FMP45,PST1,YDR186C,MTH1,JIP4,SPI1,YER15
8C,VTC2,MDS3,MTL1,RTS3,PHB2,NCA3,TOH1,MHO1,TMA19,PET10,YLR177W,MSC3,TMA10,ORM2,MSC1,DIA1,
YGP1,YNL194C,BXI1,DDR2,MAM3,PHM7,ZPS1,RIM20,VTC3,NIP7,YPL247C,ATG41,SPO24,YPR108W-
A,YPR117W,NCE102,TDA6
3674  molecular function unknown 41
AI5_BETA,YRO2,AGP2,SDS24,YBR287W,GID7,HSP30,NRP1,PAM1,MTH1,JIP4,ZRG8,SPI1,YER158C,VTC2,MDS
3,MTL1, 
YGR130C,RTS3,SNG1,VID28,IML2,TMA19,YLR177W,TMA10,MSC1,GID8,DIA1,YNL144C,YGP1,YNL194C,PHM7,R
IM20, BUD7,VTC3,YPL247C,ATG41,SPO24,YPR108W-A,YPR117W,PIN3
3723  RNA binding 44
LSR1,SSA1,UTP20,HSP26,MSS116,PUF6,HYP2,VTC1,MPT5,RIE1,IMD2,MTR4,UTP10,JSN1,MRT4,EBP2,SSA2,N
OP56,RRP5,STI1,NOP4,PUF2,SNR128,SNR161,SNR17A,SNR17B,SNR19,SNR190,SNR30,SNR39,SNR4,SNR40,S
NR41,SNR42,SNR47,SNR49,SNR5,SNR6,SNR60,SNR8,SNR80,SNR81,SNR82,SNR83
3723  RNA binding 41
LSR1,SSA1,UTP20,HSP26,NUG1,MPT5,NOP7,RIE1,IMD2,MTR4,UTP10,JSN1,RPL14A,TIF1,SSA2,YEF3,IMD3,CL
U1,RRP5, 
TIF11,STI1,RRP12,NEW1,SNR161,SNR17A,SNR17B,SNR19,SNR190,SNR30,SNR39,SNR4,SNR41,SNR42,SNR43
,SNR5, SNR6,SNR60,SNR80,SNR81,SNR82,SNR83
16787  hydrolase activity 35
ATP6,BI2,OLI1,RPR1,SSA1,TIP1,DUR1,2,APE3,HO,NTH1,TPS2,MSS116,HSP78,CCC2,PRB1,SSA4,DUG1,PMC1,
PNC1,ESP1,PHO12,HCA4,KAR2,MTR4,SMC3,HSP150,CPS1,SSA2,HSP104,YPS1,TSL1,HPF1,STE13,HSP82,GDB
1
16740  transferase activity 32 AI2,TLC1,TPS1,GLK1,CIT2,GIN4,GLC3,MET6,HXK1,TOS3,GSC2,VTC4,YAK1,HAL5,PTK2,UGP1,HSL1,PTK1,SHM2,GSY2, CAR2,APT1,TSL1,TPS3,RAD50,CMK2,HRK1,RPA190,PYK2,RPA135,GPH1,GDB1 16740  transferase activity 31
TLC1,HMT1,TPS1,GLK1,CIT2,GLC3,MET6,HXK1,TOS3,GSC2,BIO2,VTC4,YAK1,HAL5,OPI3,UGP1,HSL1,PTK1,SH
M2,SAM1,GSY2,CAR2,TSL1,BIO3,CMK2,HRK1,RPA190,PYK2,SPE3,GPH1,GDB1
22857  transmembrane transporter activity 19 COX1,ATP8,ATP6,COB,OLI1,COX2,COX3,BAP2,PHO89,AGP1,HXT7,HXT6,PIC2,PMC1,TPO2,PHO84,LYP1,TPO4,TPO3 19843  rRNA binding 21
MRT4,RRP5,SNR128,SNR161,SNR17A,SNR17B,SNR190,SNR30,SNR39,SNR40,SNR41,SNR42,SNR47,SNR49,S
NR5,SNR60,SNR8,SNR80,SNR81,SNR82,SNR83
16887  ATPase activity 18 ATP8,ATP6,OLI1,SSA1,HSP78,SSA4,PMC1,KAR2,MTR4,SMC3,TIF1,SSA2,HSP104,YEF3,DBP2,RAD50,NEW1,HSP82 22857  transmembrane transporter activity 21
COX1,ATP6,OLI1,COX3,BAP2,PHO89,AGP1,CCC2,HXT7,HXT6,HXT3,SIT1,PIC2,PMC1,TPO2,PHO84,LYP1,BIO5,
TPO4,FLC1,TPO3
19843  rRNA binding 16 RRP5,SNR161,SNR17A,SNR17B,SNR190,SNR30,SNR39,SNR41,SNR42,SNR43,SNR5,SNR60,SNR80,SNR81,SNR82,SNR83 3729  mRNA binding 16 UTP20,HSP26,MSS116,PUF6,VTC1,MPT5,RIE1,IMD2,MTR4,JSN1,EBP2,NOP56,RRP5,STI1,NOP4,PUF2
3729  mRNA binding 15 UTP20,HSP26,NUG1,MPT5,NOP7,RIE1,IMD2,MTR4,JSN1,IMD3,CLU1,RRP5,STI1,RRP12,NEW1 16887  ATPase activity 16 ATP6,OLI1,SSA1,MSS116,HSP78,CCC2,SSA4,PMC1,HCA4,KAR2,MTR4,SMC3,HSP150,SSA2,HSP104,HSP82
30234  enzyme regulator activity 14 FES1,SSE2,AHA1,MDJ1,TFS1,TSL1,TPS3,LST8,APJ1,IRA2,STI1,VHS3,GAC1,CIP1 30555  RNA modification guide activity 16 SNR128,SNR161,SNR190,SNR39,SNR40,SNR41,SNR42,SNR47,SNR49,SNR5,SNR60,SNR8,SNR80,SNR81,SNR82,SNR83
16491  oxidoreductase activity 13 COX1,COB,COX2,COX3,GCV3,UGA2,GCV1,RNR1,ERG1,IMD2,TDH1,IMD3,GCV2 16491  oxidoreductase activity 15 COX1,COX3,GCV3,YDL124W,GCV1,SUR2,RNR1,LPD1,YHB1,IMD2,TDH1,MAE1,HFD1,GCV2,GPD2
100 µM azaplatin
Biological Process
200 µM azaplatin
Biological Process
 
 
Table 4.9. Gene ontology term analysis for 200 µM azaplatin treatment. Shown are 
Biological Process and Cellular Function GO terms for each treatment. Frequency is the 
number of significantly differentially expressed genes which fall into each category (padj 
<0.1).
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Figure 4.3. Gene ontology of differentially expressed genes from Saccharomyces 
cerevisiae treated with cisplatin (100 µM and 200 µM, blue and light blue) or azaplatin 
(100 µM and 200 µM, green and light green). Gene IDs from differential expression 
results (padj<0.1) were extracted and sorted by gene ontology using Go Slim Mapper by 
the Saccharomyces genome database (www.yeastgenome.org). Percent of each sample 
dataset within each GO term is shown as bars. A) Cellular function gene ontology of S. 
cerevisiae treated with 100 µM azaplatin. B) Cellular process gene ontology of S. 
cerevisiae treated with 200 µM azaplatin.  
 
GO Slim analysis reveals similarities in each differentially expressed gene set 
(Figure 4.3 A and B). It is important to note that these categories are not mutually 
exclusive. For example, numerous snoRNAs were sequenced, and these appear under 
“RNA binding,” “rRNA binding,” and “RNA modification guide activity” categories, 
explaining their high enrichment (Tables 4.6 through 4.9). These RNA classes are 
interesting because cisplatin is observed to accumulate on cellular RNA (Hostetter et al., 
2012) and the ribosome hypothesized to act as a platinum sink. We also observe 
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enrichment of “transmembrane transfer activity” genes (Figure 4.3, Tables 4.6 through 
4.9). Cisplatin results in increased expression of genes related to metal ion transfer across 
membranes (Table C.2), in accordance with the observation that cisplatin is primarily 
shuttled into cells by metal ion transporters (Roos and Kaina, 2012). 
 
Conclusions 
This work is a pilot study, using data from an experiment designed to analyze 
cisplatin and azaplatin adducts on yeast ribosomal RNA to derive additional information 
on differential gene expression. Because of the experimental design, read counts outside 
ribosomal RNA and tRNA are quite low (Table 4.1) and we likely only received 
sufficient coverage to derive statistically significant expression information on highly 
expressed genes (Figure C.2, Table 4.2). Nevertheless, we found that biological replicates 
of each treatment cluster with each other via principal component analysis (Figure 4.2), 
and plots of raw gene counts between replicates show strong correlation (Figure C.1). We 
were able to find 12 significantly differentially expressed genes for 100 µM cisplatin 
treatment, 55 for 200 µM cisplatin, 213 for 100 µM azaplatin, and 233 for 200 µM 
azaplatin. GO Slim analysis shows that our results comprise primarily genes associated 
with cellular function GO terms including RNA binding, hydrolase activity, transferase 
activity, transmembrane transporter activity, rRNA binding and RNA modification guide 
activity. These RNA-driven terms are enriched due to the large number of snoRNA’s 
sequenced (Table C.2). Similarly, rRNA processing is the most well-represented cellular 
process GO term, and RNA modification are well represented biological process GO 
terms. (Figure 4.3B).  
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 Taken together, these results indicate that S. cerevisiae responds differently to 
treatment with these two Pt(II) compounds. Coverage was extremely low for 100 µM 
cisplatin so we are unable to make many conclusions from that data. Considering 200 µM 
cisplatin, 12 of the 20 most upregulated genes are unique to cisplatin treatment. These 
include genes such as RNR2 and 4 (shared with 100 µM cisplatin and discussed above), 
which are involved in DNA damage response, SED1, which assists with translating 
ribosomes SMF3, a putative divalent metal ion transporter which increases under DNA 
replication stress (Cherry et al., 2012). In addition to inducing DNA damage, Azaplatin 
appears to activate a myriad of metal ion transporters. PMC1, PIC2, and CCC2 are all 
involved in either Calcium transportation (PMC1) or Copper transportation (PIC2, and 
CCC2). Additionally, ATP synthase genes are significantly overexpressed in azaplatin 
treatment, hinting that the compound may interact with the mitochondria. 
Cisplatin treatment follows a dose-dependent pattern much more than azaplatin 
treatment, which correlates with the relationships between treatments shown in Figure 
4.2. Azaplatin is a new Pt(II) compound, recently synthesized by our lab (Wirth et al., 
2015). Azaplatin has shown to be poorly soluble in water and we are working to establish 
its LD50 in yeast cells. In this study, principal component analysis reveals that 100 and 
200 µM azaplatin treatments cluster extremely closely with each other (Figure 4.2), 
which is reflected in their inconsistent dose-dependent gene expression profiles (Tables 
4.8 and 4.9). The similar responses seen by each treatment concentration indicate we may 
be working outside an effective treatment range for azaplatin. Future studies would 
benefit from titrating azaplatin’s dosage and analyzing differential expression. 
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Ultimately, despite low coverage we were able to perform a pilot differential 
expression analysis. This information is very valuable to have in a high-throughput 
sequencing strategy such as Platinum-seq. This work has hinted at differences in the way 
S. cerevisiae respond to cisplatin versus our click-functionalized cisplatin derivative 
azaplatin. Understanding the expression-level response organisms have to azaplatin, 
especially as compared with cisplatin, is crucial, as so much of cellular response will 
dictate how the compound interacts. Future studies would benefit from repeating this 
work using ribosomal depletion, to reduce background noise. 
 
Summary of Chapter IV and bridge to Chapter V 
 In this chapter we performed preliminary differential expression analysis of S. 
cerevisiae treated with 100 and 200 µM of either cisplatin or its click-functionalized 
derivative azaplatin. Using sequencing reads from Chapter III, we find azaplatin 
treatment resulted in more differentially expressed genes than cisplatin treatment. 
Cisplatin treatment follows a dose-dependent response more closely than azaplatin. 
Azaplatin upregulates numerous metal ion transporters not seen in cisplatin treatment. 
Together, these data suggest different responses of yeast cells to these two compounds. 
Chapter V is an exploration of a DNA hybridization-based method to enrich for 
platinated nucleic acids pre-sequencing. 
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CHAPTER V 
DNA HYBRIDIZATION PULLDOWN OF CLICK-BASED AFFINITY TAGGED 
DNA 
 
This chapter contains contributions from Anna Hickey and Victoria DeRose. 
Professor DeRose provided insight and direction throughout the work, and edited the 
final manuscript. Click reactions, pulldown experiments, and gels were performed by 
Anna Hickey. Methods were developed by myself and Anna Hickey. The writing is my 
own, and figures were assembled by myself with Anna’s assistance. 
 
Introduction 
Cisplatin is the founding member of a class of platinum anticancer drugs that are 
used in approximately 40-50% of all chemotherapy treatments (Dyson and Sava, 2006; 
Harper et al., 2010) (Figure 5.1A). Cisplatin treatment is accompanied by numerous 
problematic side effects, including nephrotoxicity, ototoxicity, and hair loss, and tumor 
resistance limits long-term effectiveness of the drug (Florea and Büsselberg, 2011). 
Cisplatin’s cytotoxic effects are attributed to its accumulation on cellular DNA, primarily 
forming covalent adducts with adjacent guanine residues (Fichtinger-Schepman et al., 
1985; Jung et al., 2007). Cisplatin can induce apoptosis, but the mechanisms are not yet 
fully described, as evidence supports both nucleus-dependent (Basu and Krishnamurthy, 
2010) and nucleus-independent pathways (Mandic et al., 2003). Despite the fact that 
cisplatin is a known DNA-binding drug, we have a surprisingly poor understanding of the 
genomic landscape of cisplatin-induced Pt adducts. It is, however, understood that 
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cisplatin can disrupt transcription through stalling RNA Pol II (Damsma et al., 2007), 
suggesting that cisplatin accumulation on certain genetic locations may play a role in 
cytotoxicity. 
Recent high-throughput sequencing approaches seek to better understand the 
genomic targets of small molecules (Rodriguez and Miller, 2014). Methods such as 
CHIP-seq probe DNA binding proteins and histone modifications using 
immunoprecipitation (Park, 2009). Researchers have also recently used 
immunoprecipitation techniques to identify novel sites of RNA modification 
(Dominissini et al., 2016). Chem-seq, a new technology inspired by CHIP-seq, seeks to 
identify and sequence the binding sites of small molecules via high-throughput 
sequencing (Anders et al., 2014). 
We have recently developed a suite of functionalized cisplatin-derived small 
molecules with the goal of applying similar methods to identify the cellular targets of 
Pt(II) compounds. Our compounds, one of which, azaplatin, is shown in Figure 5.1B, 
enable use of the prototypical azide-alkyne cycloaddition “click” reaction (Figure 5.1C, 
Kolb et al., 2001) to bioorthogonally label platinum compounds attached to biomolecules 
both in vitro and in cell culture (Wirth et al., 2015). Here we describe an in vitro 
approach to using these compounds in conjunction with a DNA hybridization-based 
streptavidin bead pulldown to selectively isolate a platinated DNA oligonucleotide. We 
are interested in methods of pre-enrichment of platinated nucleic acid fragments for high-
throughput sequencing analysis of platinated DNA and RNA. DNA hybridization-based 
methods are well represented in the literature (Horn, 2012) and are valued for their ease 
of use, sensitivity, and specificity (Mamanova et al., 2010). 
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Figure 5.1. Azaplatin is a Pt(II)-based click-reactive small molecule (Wirth et al., 2015). 
A) Cisplatin. B) Azaplatin. C) Copper catalyzed azide-alkyne cycloaddition (“click” 
reaction). 
 
We first prepared a control hybridization probe by clicking a fluorescent 
molecule, rhodamine-B azide (Rho), to a 5’-hexynyl functionalized synthetic DNA 
(HEX) (Figure 5.2, lane 2, bands B and C). This fluorescently labeled DNA (HEX-Rho) 
was used to optimize our bead binding and pulldown conditions. We found our most 
efficient approach was to pre-hybridize HEX-Rho with its 5’-biotinylated complement 
(BIO), then incubate overnight on MyOne C1 streptavidin magnetic beads (4 °C with 
rotation) that had been washed and pre-blocked with a 58-nt oligonucleotide (BLOCK) 
(Figure 5.2, band “BLOCK”). Pre-incubation with BLOCK served to block nonspecific 
binding sites on the streptavidin beads without interfering with the streptavidin-biotin 
interaction. Upon heating in Elution Buffer (see Methods), fluorescently labeled HEX 
was released (Figure 5.2, lane 7, bands HEX-Rho or BIO) along with a small amount of 
nonspecifically bound BLOCK (Figure 5.2, lane 7, band BLOCK). 
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Figure 5.2. Pulldown of 5’-hexynyl DNA clicked to rhodamine-B azide. A) reaction 
scheme. B) PAGE gel demonstrating pulldown. Top image is SYBR gold stain, which 
reveals all nucleic acids in gel. Bottom image is rhodamine fluorescence overlay, 
artificially colored magenta. Colors inverted for clarity. Lane 1: blocking DNA only. 
Lane 2: Rho-clicked hex DNA only. Lane 3: 5’-biotin complementary strand only. Lane 
4: pulldown supernatant. Lanes 5 and 6: washes 1 and 3, respectively. Lane 7: elution. 
Bands are labeled as follows: Blocking DNA (BLOCK). Rho-clicked hex DNA (HEX-
Rho) (lane 2) or 5’-biotin complementary strand (BIO) (lane 3). In the bottom gel, we 
include rhodamine fluorescence overlay, pre-SYBR gold stain. Magenta colors over 
bands in lanes 2, 4, and 7 reveal eluted rhodamine-clicked HEX. 
 
We next platinated a model cisplatin binding site, a synthetic DNA hairpin 
containing a single dGpG platinum(II) binding site (HP) using azaplatin (AzaPt, Wirth et 
al., 2015), a click-functionalized platinum(II) compound (Figure 5.1B). Platination was 
performed by incubating the DNA hairpin and azaplatin in a buffered solution overnight 
to allow aquation of the platinum species and coordination to the dGpG binding site 
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within HP. Unplatinated and platinated HP are separated by dPAGE wherein a lower 
band (Figure 5.3B, lane 1) migrates equivalent to an unplatinated HP control (not shown). 
Addition of azaplatin adds a +1 or +2 charge and a mass increase, resulting in a second 
band which migrates more slowly (Figure 5.3B, lane 1). Pt-HP clicks to a rhodamine-B 
azide in a Cu-dependent manner, and the clicked product further slows migration and 
results in an additional band shift (Figure 5.3B) present only in (+) CuSO4 lanes. The 
successful click reaction is also demonstrated by rhodamine-B fluorescence visible in the 
gel pre-staining (artificially colored magenta in Figure 5.3B, Rhodamine-B fluorescence, 
lanes 3, 5, 7). We determined that under our reaction conditions, 75 µM CuSO4 gives the 
greatest click conversion and minimal degradation of DNA (Figure 5.3B, lane 5). 
 85 
 
1 2 3 4 5 6 7 8
+-
50 µM
+-
75 µM
+-
100 µM
CuSO4
Rhodamine-B
fluorescence
SYBR Gold
stain
HP-AzaPt-Rho
HP-AzaPt
HP
G
G Pt N
H2
H2
N H
N
O
N3
G
G
G
G Pt N
H2
H2
N H
N
O
Pt
N
H2
H2
N
Cl
Cl H
N
O
N3
2 Cl-
+ Rho-B
Cu2+
Rho-B
A)
B)
HP HP-AzaPt HP-AzaPt-Rho
 
 
Figure 5.3. Rhoxamine-B alkyne clicked to azaplatin bound to DNA hairpin. A) reaction 
scheme. For simplicity rhodamine-B alkyne is shown as an orange star. B) PAGE gel 
demonstrating click reaction. Lanes 1 and 8: hairpin DNA treated with azaplatin (HP-
AzaPt). Lanes 2-7: click reactions (-) and (+) CuSO4 catalyst, as labeled. Click conditions 
are (final concentrations): 3 µM azaplatin-DNA, 13 uM rhodamine-B alkyne, 375 µM 
THPTA, 150 µM sodium ascorbate, 100 mM phosphate buffer, pH 7. Copper 
concentrations in each (+) CuSO4 reaction: 50 µM (lane 3), 75 µM (lane 5), 100 µM 
(lane 7). Top gel is SYBYR gold stain only, bottom is SYBYR gold plus rhodamine 
fluorescence overlay (pre-SYBR gold stain). Bands are labeled as follows: platinated 
hairpin clicked to rhodamine (HP-AzaPt-Rho). Platinated hairpin only (HP-AzaPt). 
Unplatinated hairpin (HP). 
 
Having optimized click conditions with rhodamine, we set out to click HP-AzaPt 
to HEX. We platinated HP with AzaPt as described, then reacted this complex with 
equimolar HEX for 2 hours at 37 °C. The resulting products were separated by dPAGE. 
The HEX-HP clicked DNA (Figure 5.4, band HP-AzaPt-HEX) migrates slower than 
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either unclicked complex (Figure 5.4, lane 5, compare A to B, C, and D) and is much 
more prevalent in (+) CuSO4 conditions (lane 5, as compared with lane 4). 
 
G
G Pt N
H2
H2
N H
N
O
N3 +
G
G Pt N
H2
H2
N H
N
O
HP-AzaPt
HEX
HP-AzaPt-HEX
A)
B)
1 2 3 4 5 6 7 8
A
B
C
D
HP-AzaPt-HEX
HEX
HP-AzaPt
HP
1 2 3 4 5
Cu2+
- +
CuSO4
 
Figure 5.4. Platinated Hairpin clicks to hexynyl-functionalized oligonucleotide HEX. A) 
reaction scheme. B) PAGE gel demonstrating successful click reaction. Lane 1: HP only. 
Lane 2: HP-AzPt. Lane 3: HP-AzPt + HEX click reaction (-) CuSO4. Lane 4: HP-AzPt + 
HEX click reaction (+) CuSO4. Lane 5: HEX only. Bands are labeled as follows: Click 
product (HP-AzaPt-HEX), unclicked hexynyl oligonucleotide (HEX), unclicked HP-
AzaPt (HP-AzaPt), unreacted HP (HP). 
 
We prepared more HP-AzaPt-HEX (Figure 5.5B, lane 5), and then incubated the 
reaction mixture with the 5’ biotinylated complement (BIO) (see Methods). This mixture 
was then incubated with washed and blocked streptavidin beads overnight at 4 °C with 
rotation. After washing (Figure 5.5B, lanes 7-9), samples were eluted from the beads by 
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heating to 95 °C for 5 minutes in Elution Buffer (see Methods), then placed on a magnet 
for 2 minutes to separate beads from eluant (Figure 5.5B, lane 10). Once again, reacting 
HP-AzaPt with HEX in the presence of 75 µM CuSO4 results in a visible click product 
band (Figure 5.5B, “HP-AzaPt-HEX”). This band is not visible in supernatant or any of 
the bead washes, suggesting successful capture of the complex hybridized to BIO by 
streptavidin. Upon eluting from the beads, the click product band is visible (Figure 5.5B, 
lane 10, “HP-AzaPt-HEX”) along with released BIO and HEX, suggesting these 
conditions have also captured and released unclicked HEX-BIO pairs which were 
enriched by the streptavidin beads.  
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Figure 5.5. DNA hybridization-based pulldown of platinated and clicked hairpin DNA. 
A) reaction scheme. Blocking treatment to magnetic beads not shown. B) PAGE gel 
showing pulldown of clicked HP-AzaPt-HEX. Lane 1: BLOCK only. Lane 2: BIO only. 
Lane 3: HEX only. Lane 4: HP-AzPt + HEX click reaction (-) CuSO4. Lane 5: HP-AzPt 
+ HEX click reaction (+) CuSO4. Lane 6: Supernatant remaining after overnight 
incubation of 5 with BLOCK-washed streptavidin beads. Lanes 7-9: washes 1, 3, 5 
respectively. Lane 10: Bead elution. Lane 11: BLOCK only. Lane 12: HP-AzaPt. Bands 
are labeled as follows: Blocking DNA (BLOCK), click product (HP-AzaPt-HEX), 5’-
biotin oligonucleotide (BIO), 5’hexynyl functionalized complementary oligonucleotide 
(HEX), unclicked platainated hairpin (HP-AzaPt), unplatinated hairpin (HP). 
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Conclusions 
Toward the goal of developing a DNA hybridization-based pulldown technique, 
we have successfully platinated a model DNA hairpin (HP) with a click-functionalized 
Pt(II) compound (Azaplatin), and clicked this compound to a 5’-hexynyl functionalized 
DNA oligonucleotide and captured it by biotin-streptavidin pulldown. This hybridization-
based pulldown technique shows great promise for isolating platinated oligonucleotides 
from complex solution while preserving the platinum-DNA bonds. DNA hybridization-
based methods are well-used for high-throughput sequencing target enrichment 
(Mamanova et al., 2010; Horn, 2012). Hybridization-based target capture is easy to use, 
highly specific, modular, and affordable, especially for large numbers of samples 
(Mamanova et al., 2010). Efforts are underway in our lab to platinate, fragment, and 
isolate genomic DNA, and we foresee this technique as a way of isolating those platinum 
sites intact for downstream sequencing approaches. 
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CONCLUDING REMARKS 
 
 
This work represents a significant step toward high-throughput mapping of Pt(II) 
adducts in cells treated with Pt(II) reagents. We have successfully mapped thousands of 
potential platination sites on hundreds of unique S. cerevisiae RNAs. Furthermore, we 
have demonstrated differential expression analysis from Platinum-seq datasets, a key step 
toward comprehensively understanding RNAs to which platinum reagents bind and the 
genetic response mounted against platinum reagent binding. This also allows us to assess 
relative abundance of different RNAs, improving models for platinum binding. Our work 
with the HDV ribozyme demonstrates great potential for using Pt(II) reagents for 
mapping important metal ion binding centers, which play key roles in coordinating RNA 
structure. Our pulldown methodology shows promise for enriching sample pools for 
platinated RNA pre-sequencing, decreasing experimental background noise and 
potentially allowing the discovery of low-copy number platinum bound nucleic acids. 
Future directions include using Platinum-seq to explore RNA binding in ribosome 
depleted samples, in order to sequence less abundant RNAs. We also plan to expand this 
approach toward looking at human cancer lines. Principles developed here for sequencing 
cisplatin binding sites are applicable to studying platinum lesions in genomic DNA, an 
important target that has not been thoroughly explored. 
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APPENDIX A 
Materials and Methods 
WT HDV ribozyme enzyme strand (ES) was produced by the Golden Lab 
(Purdue University, Lafayette, IN) using in-vitro transcription. Substrate strands (SS) 
were synthesized commercially and purchased from Dharmacon (GE Healthcare). DNA 
reverse transcriptase primers and controls were purchased from IDT. All RNA and DNA 
were 5’ end-labeled using T4 Polynucleotide Kinase (Thermo Scientific), following 
typical methods. Before labeling, the 5’ end phosphate on the HDV enzyme strand was 
removed using FastAP (Thermo Scientific), following manufacturer’s protocols. 
Sequences for each strand used can be found in the appendix A. 
 
13-mer substrate strand  
 Crosslinking  
Crosslinked species were formed by mixing 40 µM HDV enzyme strand (ES), 40 
µM substrate strand (SS, 13-mer,PS,dU1), and trace 32P ES or SS (as indicated) in 10 
mM pH 7 phosphate buffer (PB), and 100 mM NaNO3, then heating to 90 °C for 2 
minutes and slowly cooling to 20 °C over 20 minutes. After folding, samples were heated 
to 37 °C for 10 minutes, then Mg(NO3)2 was added to a final concentration of 30 mM, 
and cisplatin to 120 µM. Nitrate salts are used instead of halides in order to promote 
aquation of cisplatin. Samples were crosslinked for 0-6 at 37 °C, as indicated, then 
quenched in 3x volume formamide loading buffer and resolved on 8 M urea, 1x TBE, 
20% 29:1 bis:mono acrylamide gel.  
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Crosslinking kinetics  
20 µM ES and trace 32P SS (13-mer,PS,dU1) were mixed in 10 mM pH 7 PB, 
and 100 mM NaNO3, then folded by heating to 90 °C for 5 minutes and slowly cooling to 
25 °C over 20 minutes. After folding, samples were heated to 37 °C for 10 minutes, then 
Mg(NO3)2 and cisplatin were added to final concentrations of 30 mM and 60 µM, 
respectively, to initiate crosslinking. The reaction was allowed to proceed at 37 °C and 
sampled at times ranging from 0-1400 minutes, and crosslinking was quenched by 
addition of 3x volume of formamide loading buffer. Samples were resolved on 8 M urea, 
1x TBE, 20% 29:1 bis:mono acrylamide gel.  
  
Reverse transcriptase primer extension analysis  
40 µM ES and 40 µM SS (13-mer,PS,dU1) were mixed in 10 mM pH 7 PB, then 
folded by heating to XX for XX minutes and slowly cooling to 25 °C over 20 minutes. 
After folding, samples were heated to 37 °C for 10 minutes, then Mg(NO3)2 and cisplatin 
were added to final concentrations of 30 mM and 120 µM, respectively, to initiate 
crosslinking. The reaction was allowed to proceed at 37 °C for 6 hours then quenched via 
desalting (Sephadex G-25 column). Reverse transcription of crosslinked RNA was 
performed as described previously (Hostetter et al., 2012), using a 32P 5’-end labeled RT 
primer. RT products are resolved on an 8M urea, 1x TBE, 8% 19:1 mono:bis acrylamide 
sequencing gel. 
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11-mer Substrate Strand  
  
Crosslinking  
40 µM 32P 5’ end-labeled substrate strand ((11-mer,PS,dU1) or (11-
mer,PO,dU1), where noted) and 40 µM HDV enzyme strand were folded in the presence 
of 10 mM PB (pH 7), and 100 mM NaNO3 by heating to XX for XX minutes and slowly 
cooling to 25 °C over 20 minutes. After folding, samples were heated to 37 °C for 10 
minutes, and crosslinking was initiated by adding Mg(NO3)2 to a final concentration of 1 
mM and cisplatin to final concentrations ranging from 0-120 µM and allowed to react for 
6 hours at 37 °C. The reaction was quenched by the addition of 3x volume formamide 
loading buffer. Samples were resolved on 8 M urea, 1x TBE, 20% 29:1 bis:mono 
acrylamide gel.  
  
Crosslinking kinetics  
4 µM ES, 4 uM SS (11-mer,PS,dU1), and trace 32P SS(11-mer,PS,dU1) were 
mixed in 10 mM PB (pH 7), and 100 mM NaNO3,then folded by heating to XX for XX 
minutes and slowly cooling to 25 °C over 20 minutes. After folding, crosslinking was 
initiated by adding Mg(NO3)2 and cisplatin to a final concentration of 10 mM and 4 µM, 
respectively. Crosslinking proceeded at 37°C and the reaction was sampled and quenched 
in formamide loading buffer at times from 0-300 minutes. Samples were resolved on 8M 
urea, 1x TBE, 20% 29:1 bis:mono acrylamide gels.  
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Cleavage kinetics  
40 µM ES and Trace 32P SS (11-mer,PO) were mixed in 10 mM PB (pH 7) then 
folded by heating to XX for XX minutes and slowly cooling to 25 °C over 20 minutes. 
After folding, samples were heated to 37 °C for 10 minutes and Mg(NO3)2 was added to a 
concentration of 30 mM to initiate cleavage. Samples were taken from 0-600 minutes and 
quenched in 3x volume formamide loading buffer, then resolved on an 8M urea, 1x TBE, 
20% 29:1 bis:mono acrylamide gel. Kinetics are determined using SigmaPlot (Chapman 
and DeRose 2012).  
  
Alkali hydrolysis mapping  
Trace 32P 5’ end-labeled ES and 40 µM SS(11-mer,PS,dU1) were mixed in 10 
mM PB (pH 7) and 100 mM NaNO3, then folded by heating to XX for XX minutes and 
slowly cooling to 25 °C over 20 minutes. After folding, samples were heated to 37 °C for 
10 minutes and crosslinking was initiated by adding Mg(NO3)2 and either cisplatin or 2-
ADAP Pt to final concentrations of 10 mM and 40 µM, respectively. The reaction was 
allowed to proceed for 6 hours at 37 °C, then stopped by the addition of 3x volume of 
formamide loading buffer and the entire sample was run on a 15% 29:1 mono:bis 
acrylamide gel (8M urea, 1x TBE). After sufficient separation was achieved, products 
were resolved using autoradiography and crosslinked bands were excised and purified by 
crushing and soaking in 1 mL 100 mM acetic acid (pH adjusted to 3.4 using TEMED) at 
20 °C while rotating overnight. Eluted RNA was concentrated and purified using ethanol 
precipitation, followed by further desalting (Sephadex G-25 column) then thoroughly 
dried via speed-vac. Purified crosslinked complex is resuspended in water and 
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hydrolyzed by treatment with equal volume hydrolysis buffer (50 mM carbonate buffer, 
pH 9.5, 1 mM EDTA) at 90 °C for times ranging from 0-10 minutes. Hydrolysis was 
quenched using equal volume of 50 mM citrate buffer, pH 3.5 and hydrolysis fragments 
were resolved on a 15% 19:1 mono:bis acrylamide, 1xTBE, 8M urea sequencing gel. 
Reference ladders were generated using RNAse T1, following the manufacturer’s 
protocol (Thermo Scientific), to partially cleave 32P 5’ end-labeled ES and a thorough 
hydrolysis ladder was generated by hydrolyzing a small amount of 32P 5’ end-labeled ES 
completely for 18 minutes in hydrolysis buffer.  
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Supplementary Figures  
 
HDV Enzyme Strand (ES) 
5’-GGUCCGCAGCCUCCUCGCGGCGCAAGCUGGGCAACAUUCCGAAAGGUAAUGGCGAAUGCGGACC-
3’ 
 
Substrate Strands (SS) 
 
13-mer Substrates 
 Cleavable (13-mer,PO) 
 5’-CUUUUGGCUUGCA -3’ 
 Phosphorothioate-substituted (13-mer,PS,dU1) 
 5’-CUUUdU(PS)GGCUUGCA -3’ 
 Inhibited (13-mer,PO,dU1) 
 5’-CUUUdUGGCUUGCA -3’ 
 
11-mer Substrates 
 Cleavable (11-mer,PO) 
 5’-CCUGGCUUGCA -3’ 
 Phosphorothioate-substituted (11-mer,PS,dU1) 
 5’-CCdU(PS)GGCUUGCA -3’ 
 Inhibited (11-mer,PO,dU1) 
 5’-CCdUGGCUUGCA -3’ 
 
Figure A.1. Sequences used. HDV enzyme strand was synthesized and provided by the 
Golden Lab (Perdue University, Lafayette IN). Synthetic RNA was purchased from 
Dharmacon, synthetic DNA was purchased from IDT. 
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Figure A.2. Thiourea reversal of crosslinked ES-SS(11-mer,PS,dU1) complex. 32P 5’-
end labeled ES was crosslinked to SS as described in Methods, then treated with an equal 
volume of saturated thiourea at 37°C for times ranging from 0-18 hours. 
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Figure A.3. 11-mer substrate strand cleavage kinetics. A) Autoradiograph demonstrating 
cleavage of a 32P 5’-end-labeled SS (11-mer,PO). Catalytic activity of the HDV 
ribozyme against a cleavable substrate strand indicates proper folding of the enzyme-
substrate complex. A) Quantification of the image in A) demonstrates a rate of 0.39 ± 
0.04 min-1. This compares favorably to the rate of the native complex (0.34 ± 0.02 min-
1(Ananvoranich and Perreault, 1998)), suggesting this complex folds well.  
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Figure A.4. 11-mer substrate strand crosslink kinetics. A) Autoradiograph demonstrating 
crosslinking between folded HDV ribozyme and 32P 5’-end-labeled phosphorothioate SS 
(11-mer,PS,dU1). B) Quantification of A). Cisplatin crosslinks appear with an observed 
rate constant of kobs = .01 +/- 0.003 min-1, and a pseudo second-order rate constant 
calculated to be k2, calc = 42 +/- 13 M-1 s-1. k2, calc was estimated by dividing kobs by 
the concentration of cisplatin used (Chapman and DeRose, 2012).  
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Figure A.5. Alkali hydrolysis mapping full gels. A) (-) control is ES-PS11 mer folded and 
mock crosslinked with H2O. B) Cisplatin and C) 2-ADAP Pt are platinated with 40 uM 
final concentration of their respective platinum(II) compounds. All three samples were 
separated, purified, and crosslinked, and hydrolyzed identically.  
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Figure A.6. Distance from Pt(II) sites to phosphorothioate-substituted scissile phosphate 
stereoisomers. PS substrate strands are a racemic mixture of the Pro-Rp and Pro-Sp 
substituted phosphorothioate. Measurements from N7 of G25 (expected) and N7 of G28 
(observed) are estimated to the Pro-Rp A) and Pro-Sp B) position. These structures are 
obtained by modeling the nucleotides immediately surrounding the scissile phosphate in 
the hammerhead ribozyme (2OEU, Martick et al., 2008) into the crystal structure of the 
HDV ribozyme (3NKB), as described by Chen et al (2011).  
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APPENDIX B 
 
 
Materials and Methods 
 
The following synthetic DNA oligonucleotides were purchased from IDT: 
Mod-seq RT primer: 
AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCGGTGGTCGC/iSp1
8/CACTCA/iSp18/TTCAGACGTGTGCTCTTCCGATCTATTGATGGTGCCTACAG 
Mod-seq PCR FWD primer: 
 AATGATACGGCGACCACCGAGATCTACAC. 
Mod-seq Indexed PCR Rev Primer: 
CAAGCAGAAGACGGCATACGAGATxxxxxxGTGACTGGAGTTCAGACGTGTGC
TCTTCCG 
(where xxxxxx is a 6 nt Illumina Sequencing index.) 
 
Yeast preparation 
BY4741 yeast cells were grown from culture overnight at 30 °C in SD broth 
supplemented with 1x amino acids, then diluted to OD 0.2 in SD broth supplemented 
with 1x amino acids and either mock, cisplatin, or azaplatin at final concentrations of 100 
and 200 µM, in a final volume of 10 mL. Each sample was prepared in duplicate. 
Samples were grown at 37 °C for six hours while shaking, then spun at 4 °C, 4K RPM for 
10 minutes to pellet. 
 
RNA Extraction and fragmentation 
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After pelleting and decanting supernatant, remaining media was aspirated and 
cells were subject to lysis and RNA extraction using Qiagen’s RNEasy kit, following 
their mechanical lysis protocol. Extracted RNA was quantified using a nanodrop, 
genomic DNA was removed using TurboDNAse (Thermo Fischer), and RNA was 
cleaned up via phenol-chloroform extraction followed by ethanol precipitation in the 
presence of glycogen coprecipitant. 
Purified RNA was fragmented using RNA Fragmentation Reagents (Thermo 
Fisher) following the manufacturer’s protocol for 100 nt fragments. After fragmentation, 
samples were ethanol precipitated and sent for fragment analysis (UO GC3F Advanced 
Analytical Fragment Analyzer) to verify size distribution around 100 nt. 
 
Sequencing Preparation 
Samples were prepared for sequencing as described by Talkish et al. (2014) with 
some modifications. 3 µg of fragmented RNA was treated with T4 PNK (Thermo) in the 
absence of ATP to clean up 3’ ends. Samples were phenol-chloroform extracted and 
ethanol precipitated in the presence of glycogen, then re-suspended in 4 µL nuclease-free 
water and 1 µL of 0.5 µg/µL miRNA cloning linker (NEB). Re-suspended samples were 
heated at 80 °C for 2 minutes then placed on ice. 5 µL of T4 RNA ligation mixture (1 µL 
T4 RNA ligase buffer, 2 µL Peg8000, 1 µL SUPERase In (Thermo Fisher), 1 µL T4 
RNA Ligase, truncated KQ (NEB)) was added to each for a total of 10 µL. Ligation was 
allowed to proceed overnight at 16 °C. 
 Following ligation, samples were phenol-chloroform extracted followed by 
ethanol precipitation. Ethanol precipitated samples were re-dissolved in 11 µL nuclease 
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free water and 1 µL 2.5 µM Mod-seq RT primer (IDT DNA). Samples were heated to 80 
°C for 2 minutes and cooled on ice to anneal the RT primer. During this step, RT reaction 
mixture was prepared containing 4 µL 5x First Strand buffer (Thermo Fisher), 1 µL 10 
mM DNTP’s (AMRESCO), 1 µL 100 mM dTT (Thermo Fisher), and 1 µL SUPERase In 
(Thermo Fisher). After cooling, 7 µL RT reaction mixture was added to each sample. 
Reverse transcription was initiated by adding 1 µL SuperScript II reverse transcriptase 
(Thermo Fisher) then heating to 42 °C for 50 minutes. Reaction was stopped by heating 
to 70 °C for 15 minutes, then placed on ice. RNA template was destroyed by adding 2 µL 
1 M NaOH and heating to 98 °C for 20 minutes. 
 Samples were ethanol precipitated to remove NaOH. RT products were run out on 
an 8% 19:1 mono:bis acrylamide gel containing 8M urea, 1xTBE. 15 µL nuclease free 
water and 5 µL loading buffer was added to each sample, then samples were heated to 80 
°C for 3 minutes to re-dissolve, then immediately placed on ice. Gel lanes were flanked 
with Low MW DNA Ladder (NEB) to use as size markers for excising bands. 
 The acrylamide gel was run at 170v for approximately 2 hours, until the 
bromophenol blue band was approximately 1 cm from bottom. Bands were stained with 
SYBR Gold (Thermo Fisher) and visualized using blue light transillumination. Bands 
between 150 and 300 nt were excised from each lane and pulverized, 1 mL of 300 mM 
sodium acetate was added to each pulverized gel, and samples were rotated for 36 hours 
at 4 °C to allow RT products to diffuse into solution. 
 Pulverized gel pieces were filtered from supernatant using an empty spin column 
and samples were placed in a speed vacuum until volume was below 300 µL then ethanol 
precipitated in the presence of glycogen. 
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 After ethanol precipitation, samples were treated with T4 PNK (Thermo Fisher) to 
phosphorylate their 5’ ends, in preparation for circularization. After phosphorylation, 
samples were phenol chloroform extracted and ethanol precipitated. 
 To generate templates suitable for PCR amplification, samples were circularized 
using Circligase (Epicentre). Samples were resuspended in 15 µL nuclease free water, 
then 7.5 µL was added to 2 µL of Circligase reaction mixture (1 µL 10x Circligase 
buffer, 0.5 µL 1 mM ATP, 0.5 µL 50 mM MnCl) in a new PCR tube. 0.5 µL of 
Circligase was added, and samples were incubated at 60 °C for 2 hours, the reaction 
stopped by heating to 80 °C for 10 minutes, and samples were frozen until ready for use. 
 1 µL of circularized samples were amplified using Phusion Polymerase (Thermo 
Fisher) for 16 cycles using Mod-seq PCR FWD primer and one of ten balanced Mod-seq 
Indexed PCR Rev Primers. Reverse primers contain a unique 6 nt indexing region so 
each sample can be uniquely identified from the rest after pooling for sequencing. 
Together, these two primers build in necessary Illumina adapters, sequencing tags, and 
indexing tags. After PCR, samples were cleaned up using MagBind DNA extraction 
beads following the manufacturer’s instructions (Omega Bio-tek), nanodropped, and 
analyzed using a fragment analyzer (Advanced Analytical). 
 
Illumina Sequencing 
Samples were pooled to equivalent concentrations and submitted to the University 
of Oregon’s Genomics and Cell Characterization Core Facility (GC3F) for Illumina 
Sequencing. Samples were sequenced on a NextSeq 500, 75 nt single-end read. 
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Approximately 58 million reads were returned across 10 samples, ranging from 3.8-7.3 
million reads per sample with a median of 5.7 million reads per sample. 
 
Reverse transcription primer extension analysis 
Yeast was grown as described and treated with either mock or 200 µM cisplatin 
for six hours. RNA was extracted as described and reverse transcription was performed 
using Superscript II (Thermo Fisher) following manufacturer’s instructions, using 32P-
labeled primers. The following primers were used for extension: 
CTCTTCCAGCCATAAGACCCC, which anneals 22 nt downstream of C1711 and 
CACCGGAGCCAGCAAAGG, which anneals 50 nt downstream of C1711. Dideoxy 
sequencing ladders were generated by adding 1 µL of 10 mM ddA, ddT, ddC, or ddG in 
their respective reactions. Samples were run on an 8% 19:1 mono:bis acrylamide gel. 
 
Data Processing 
Sequencing adapters were trimmed using CutAdapt (Martin et al., 2011), and 
trimmed files were aligned to the Saccharomyces cerevisiae genome using Bowtie 
(bowtie -v 0 -a --best --strata --chunkmbs 500 -p 16 -t –S) (v. 1.1.2, Langmead et al., 
2009), constrained to allow either 0 or 1 mismatch in alignment. Aligned reads were 
analyzed for differential expression using the DESEQ2 R package to ensure correct 
matching of control treatments. Alignment files were fed into the Mod-seq pipeline 
(Talkish et al., 2014), bypassing their trim and align steps, to generate predicted 
platination locations based on the frequency of RT termination 5’ to a given stop site. 
Stops were considered if they met a minimum threshold of 1.5-fold enrichment over 
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background. The resulting data was parsed in R and plotted using the ggplot2 R package, 
and three-dimensional images were created in PyMol by noting our cisplatin stop sites on 
PDB 4V7R. All R scripts will be available online. 
 
Reverse transcription primer extension analysis 
Yeast was grown, treated with 0 or 200 µM cisplatin, and RNA was extracted as 
described above. RT primers corresponding with regions 1733-1753 and 1761-1779 of 
the yeast 25S rRNA were 5’end labeled with 32P using PNK (Thermo Fisher). After 
extraction, 3 µg of purified RNA (+ or – cisplatin) was reverse transcribed using 
Superscript II and one of the two radiolabeled primers, following manufacturer’s protocol 
(20 µL). dideoxy sequencing ladders were generated by reverse transcribing 3 µg of 
control RNA in the presence of 1 µL 1 µM ddA, ddT, ddC, or ddG (Affymetrix). Post-
RT, samples were cleaned up as described above, then run on a 20 x 40 cm sequencing 
gel (8 M urea, 1x TBE, 8% 19:1 mono:bis) at 30W for 2 hours. Gels were dried and 
exposed on a phosphorimager. Gel images were imported into ImageJ and contrast 
adjusted, then plots of line intensity were taken down each lane. Stop site peaks were 
picked out of control vs background and used to generate a line plot for overlay with Pt-
seq data. 
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Supplementary Figures 
 
 
Figure B.1. Azaplatin stop sites on the yeast 25S rRNA. 100 µM, 200 µM and all 
matching stops. 
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Figure B.2. Complete sequencing gel from Figure 3.9A 
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Figure B.3. Circligase preferentially ligates A and T residues in the 3’ position. Use of 
Circligase to generate final templates for sequencing library preparation induces a strong 
bias toward A and T residues on the 3’ end. This effect is less apparent at 200 µM 
cisplatin treatment. 
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Figure B.4. Plot of fold-enrichment for each biological replicate by position compared 
against the same control. All stops greater than 1.5 fold-enriched over control are 
considered. Data was fit to a linear model to find R2 values in order to assess correlation. 
A) 100 µM cisplatin (R2 =0 .07). B) 200 µM cisplatin (R2 =0 .42). C) 100 µM azaplatin 
(R2 =0 .80). D) 200 µM azaplatin (R2 =0 .85). Data points at 0 on the X and Y axes are 
stops present in one replicate but not the other. Gaps exhibited between these data points 
and the main data cluster are due to our chosen 1.5-fold minimum enrichment threshold.  
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Figure B.5. Plot of fold-enrichment for each biological replicate by position compared 
against the same control. Only shared stops greater than 1.5 fold-enriched over control 
considered. A) 100 µM cisplatin (R2 =0 .90). B) 200 µM cisplatin (R2 =0 .66). C) 100 
µM azaplatin (R2 =0 .89). D) 200 µM azaplatin (R2 =0 .92). 
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Figure B.6 – Plot of ln-transformed fold-enrichment for each biological replicate by 
position compared against the same control (data from figure B.5) demonstrate 
reproducible correlation between stop instensity and position. Only shared stops greater 
than 1.5-fold enriched over control considered. A) 100 µM cisplatin. B) 200 µM 
cisplatin. C) 100 µM azaplatin. D) 200 µM azaplatin. 
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Table B.1. Pt-seq stops for positions 1710-1720 on the 25S rRNA by treatment and 
replicate. Values presented are fold-enrichment over conrol (control replicate 2 for each 
experiment). 
 
rep 1 rep 2 rep 1 rep 2 rep 1 rep 2 rep 1 rep 2
1700 - - - - - - - -
1701 - - - - - - - -
1702 - - - - - - - -
1703 - - - - - - 1.8 1.6
1704 - - - - - - - -
1705 1.7 - - - 1.8 1.7 2.5 2.6
1706 - - - - 1.5 1.8 2.1 -
1707 2.4 - - - 2.0 2.4 4.0 3.1
1708 1.9 - - - - 1.5 2.1 -
1709 1.5 - - - - - - -
1710 - - - - - - - -
1711 14.2 13.6 15.8 26.6 12.3 14.1 13.5 13.8
1712 - - 2.6 - - - - -
1713 - - - - - - - 1.8
1714 1.7 - - - - - - -
1715 1.6 - 2.5 2.8 - - 1.6 -
1716 1.7 - 1.9 - - - - -
1717 - - - - - - 2.1 2.6
1718 - - - - 1.5 - 1.5 -
1719 - - - - - - - -
1720 - - - - - - - -
200 µM azaplatin100 µM azaplatin200 µM cisplatin100 µM cisplatinposition 
on gene
 
 
 
 113 
 
Table B.2. Pt-seq stops for positions 780-839 on the 25S rRNA by treatment and 
replicate. Values presented are fold-enrichment over conrol (control replicate 2 for each 
experiment). 
 
rep 1 rep 2 rep 1 rep 2 rep 1 rep 2 rep 1 rep 2
780 - - - - - - - -
781 1.6 - - - - - - -
782 1.8 - - - 2.8 1.5 3.1 2.3
783 - - - - - - - -
784 1.8 - - - - - 1.7 -
785 - - - - - - - -
786 - - - - - - - -
787 1.9 - - - - - - -
788 - - - - 2.3 - 1.6 -
789 - - - - - - - -
790 - - - - - 1.8 1.9 1.5
791 - - - - - - - -
792 - - - - - - - -
793 - - - - - - - -
794 - - - - - - - -
795 - - - - - - - -
796 - - - - - - - -
797 - - 2.9 - - - 2.2 -
798 - - - - - - 9.4 -
799 - - - - - - - -
800 - - - - - - - -
801 1.8 - - - - - - -
802 2.0 - - - - - - -
803 4.1 - - - - - - -
804 - - - - 5.1 3.3 3.3 -
805 - - 5.9 4.5 11.0 14.6 11.3 8.8
806 3.5 - 2.4 2.3 3.6 4.7 3.8 3.7
807 3.7 - 61.1 39.5 91.8 126.1 114.7 114.1
808 - - 5.3 - 23.8 22.4 27.0 22.1
809 - - - - - - - -
810 - - - - - - - -
811 - - 2.7 2.3 1.9 2.4 2.0 1.9
812 - - - - - - - -
813 - - - - - - - -
814 - - 2.0 - - - - 1.6
815 - - - - - - - -
816 - - - - - - - -
817 - - 2.0 - 1.9 1.8 3.0 3.0
818 - - - 1.7 2.1 2.0 2.2 2.0
819 - - - 1.5 - - 1.5 -
820 - - - - - - 1.6 -
821 - - - - - - 1.5 -
822 - - - - - - - -
823 - - - - - - - -
824 - - 1.6 - - - - -
825 - - 1.6 - - 1.6 - 1.7
826 - - - - - - 1.6 1.7
827 - - - - - - - -
828 1.6 - 1.8 2.2 1.5 - 1.7 -
829 - - 2.1 2.1 2.6 2.0 2.9 2.0
830 - - 3.4 - 2.8 - 3.4 2.9
831 - - - - - - 1.8 -
832 - - - - - - - -
833 - - - - - - - -
834 - - - - 2.8 2.2 3.9 4.1
835 - - - - - - 1.6 -
836 - - - - 2.0 2.1 2.2 2.3
837 - - - - 1.5 1.6 1.7 2.1
838 - - - - - - 1.6 -
839 - - - - 1.6 1.6 2.3 -
100 µM azaplatin 200 µM azaplatin100 µM cisplatin 200 µM cisplatinposition 
on gene
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Table B.3. Counts of stops observed on all S. cerevisiae RNA at 100 µM cisplatin  
GeneName Stops GeneName Stops GeneName Stops GeneName Stops
15S_rRNA 23 tD(GUC)J2 1 tG(GCC)D1 1 YDR261C-D 1
21S_rRNA 16 tD(GUC)J3 1 tG(GCC)D2 1 YDR316W-B 1
RDN18-1 74 tD(GUC)J4 1 tG(GCC)E 1 YDR365W-B 1
RDN18-2 74 tD(GUC)K 1 tG(GCC)F1 1 YER138C 1
RDN25-1 141 tD(GUC)L1 1 tG(GCC)F2 1 YER160C 1
RDN25-2 141 tD(GUC)L2 1 tG(GCC)G1 1 YGR038C-B 1
RDN37-1 214 tD(GUC)M 1 tG(GCC)G2 1 YGR161C-D 1
RDN37-2 214 tD(GUC)N 1 tG(GCC)J1 1 YHR214C-B 1
RDN5-1 3 tD(GUC)O 1 tG(GCC)J2 1 YJR027W 1
RDN5-2 2 tE(CUC)D 1 tG(GCC)M 1 YJR029W 1
RDN5-3 2 tE(CUC)I 1 tG(GCC)O1 1 YLR035C-A 1
RDN5-4 2 tE(UUC)B 1 tG(GCC)O2 1 YLR154C-G 4
RDN5-5 2 tE(UUC)C 1 tG(GCC)P1 1 YLR157C-B 1
RDN5-6 3 tE(UUC)E1 1 tG(GCC)P2 1 YML039W 1
RDN58-1 1 tE(UUC)E2 1 tL(UAA)B1 1 YML045W 1
RDN58-2 1 tE(UUC)E3 1 tL(UAA)B2 1 YMR045C 1
SCR1 13 tE(UUC)G1 1 tL(UAA)D 1 YMR050C 1
snR17a 1 tE(UUC)G2 1 tL(UAA)J 1 YNL054W-B 1
snR56 1 tE(UUC)G3 1 tL(UAA)K 1 YNL284C-B 1
snR9 1 tE(UUC)I 1 tL(UAA)L 1 YOL103W-B 1
tD(GUC)B 1 tE(UUC)J 1 tL(UAA)N 1 YOR142W-B 1
tD(GUC)D 1 tE(UUC)K 1 YAR009C 1 YPL257W-B 1
tD(GUC)G1 1 tE(UUC)L 1 YBL005W-B 1 YPR080W 1
tD(GUC)G2 1 tE(UUC)M 2 YBR012W-B 1 YPR137C-B 1
tD(GUC)I1 1 tE(UUC)P 1 YBR118W 1 YPR158W-B 1
tD(GUC)I2 1 tG(GCC)B 1 YDR098C-B 1
tD(GUC)J1 1 tG(GCC)C 1 YDR210C-D 1
100 µM Cisplatin
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Table B.4. Counts of stops observed on all S. cerevisiae RNA at 200 µM cisplatin  
GeneName Stops GeneName Stops GeneName Stops GeneName Stops
15S_rRNA 16 tA(UGC)L 1 tG(GCC)P1 1 YJR028W 2
21S_rRNA 24 tA(UGC)O 1 tG(GCC)P2 1 YJR029W 2
LSR1 9 tE(CUC)D 1 YAR010C 2 YLR154C-G 7
RDN18-1 171 tE(CUC)I 1 YBR012W-A 2 YLR157C-A 2
RDN18-2 171 tE(UUC)B 1 YBR012W-B 2 YLR157C-B 2
RDN25-1 304 tE(UUC)C 1 YDR098C-A 2 YLR227W-A 2
RDN25-2 304 tE(UUC)E1 1 YDR098C-B 2 YLR227W-B 2
RDN37-1 522 tE(UUC)E2 1 YDR210C-C 2 YLR256W-A 2
RDN37-2 522 tE(UUC)E3 1 YDR210C-D 2 YML039W 2
RDN5-1 4 tE(UUC)G1 1 YDR261C-C 2 YML040W 2
RDN5-2 2 tE(UUC)G2 1 YDR261C-D 2 YML045W 2
RDN5-3 2 tE(UUC)G3 1 YDR278C 4 YML045W-A 2
RDN5-4 2 tE(UUC)I 1 YDR316W-A 2 YMR050C 2
RDN5-5 2 tE(UUC)J 1 YDR316W-B 2 YMR051C 2
RDN5-6 4 tE(UUC)K 1 YDR365W-A 2 YNL054W-A 1
RDN58-1 3 tE(UUC)L 1 YDR365W-B 2 YNL054W-B 1
RDN58-2 3 tE(UUC)M 1 YER137C-A 2 YOL103W-A 2
SCR1 16 tE(UUC)P 1 YER138C 2 YOL103W-B 2
snR10 1 tG(GCC)B 1 YER159C-A 2 YOR142W-A 2
snR128 5 tG(GCC)C 1 YER160C 2 YOR142W-B 2
snR13 1 tG(GCC)D1 1 YGL008C 1 YPL257W-A 2
snR19 2 tG(GCC)D2 1 YGR027W-A 2 YPL257W-B 2
snR3 2 tG(GCC)E 1 YGR027W-B 2 YPR137C-A 2
snR30 3 tG(GCC)F1 1 YGR038C-A 2 YPR137C-B 2
snR32 1 tG(GCC)F2 1 YGR038C-B 2 YPR158C-C 2
snR49 1 tG(GCC)G1 1 YGR161C-C 2 YPR158C-D 2
snR7-L 3 tG(GCC)G2 1 YGR161C-D 2 YPR158W-A 2
snR7-S 3 tG(GCC)J1 1 YGR192C 1 YPR158W-B 2
snR9 3 tG(GCC)J2 1 YHR214C-B 2
tA(UGC)A 1 tG(GCC)M 1 YHR214C-C 2
tA(UGC)E 1 tG(GCC)O1 1 YJR026W 2
tA(UGC)G 1 tG(GCC)O2 1 YJR027W 2
200 µM Cisplatin
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Table B.5. Counts of stops observed on all S. cerevisiae RNA at 100 µM azaplatin  
GeneName Stops GeneName Stops GeneName Stops GeneName Stops
15S_rRNA 104 snR5 1 tE(UUC)J 6 YHR214C-C 2
21S_rRNA 89 snR56 2 tE(UUC)K 6 YJR026W 2
LSR1 31 snR6 6 tE(UUC)L 6 YJR027W 12
NME1 1 snR7-L 3 tE(UUC)M 6 YJR028W 2
Q0055 2 snR7-S 5 tE(UUC)P 6 YJR029W 10
Q0250 1 snR70 1 tG(CCC)D 2 YLR035C-A 3
RDN18-1 465 snR72 1 tG(UCC)G 1 YLR044C 1
RDN18-2 465 snR73 1 tG(UCC)N 1 YLR110C 5
RDN25-1 835 snR77 1 tG(UCC)O 1 YLR154C-G 28
RDN25-2 835 snR8 1 tR(CCG)L 1 YLR157C-A 2
RDN37-1 2155 snR81 1 tS(UGA)E 1 YLR157C-B 13
RDN37-2 2155 snR9 9 tS(UGA)I 1 YLR227W-A 2
RDN5-1 24 tA(UGC)A 2 tS(UGA)P 1 YLR227W-B 7
RDN5-2 25 tA(UGC)E 2 YAR009C 5 YLR256W-A 2
RDN5-3 25 tA(UGC)G 2 YAR010C 3 YML039W 13
RDN5-4 25 tA(UGC)L 2 YBL005W-B 3 YML040W 2
RDN5-5 25 tA(UGC)O 2 YBR012W-A 2 YML045W 9
RDN5-6 24 tD(GUC)B 5 YBR012W-B 5 YML045W-A 2
RDN58-1 43 tD(GUC)D 5 YDR098C-A 2 YMR045C 5
RDN58-2 43 tD(GUC)G1 5 YDR098C-B 11 YMR050C 8
RPR1 2 tD(GUC)G2 5 YDR210C-C 2 YMR051C 2
SCR1 69 tD(GUC)I1 5 YDR210C-D 6 YNL054W-A 2
snR10 1 tD(GUC)I2 5 YDR261C-C 2 YNL054W-B 8
snR11 1 tD(GUC)J1 5 YDR261C-D 12 YNL284C-A 1
snR128 6 tD(GUC)J2 5 YDR278C 6 YNL284C-B 5
snR13 1 tD(GUC)J3 5 YDR316W-A 2 YOL103W-A 2
snR14 4 tD(GUC)J4 5 YDR316W-B 10 YOL103W-B 12
snR17a 10 tD(GUC)K 5 YDR365W-A 2 YOR142W-A 2
snR17b 2 tD(GUC)L1 5 YDR365W-B 13 YOR142W-B 9
snR189 1 tD(GUC)L2 5 YEL021W 1 YPL257W-A 2
snR19 8 tD(GUC)M 5 YER137C-A 2 YPL257W-B 15
snR190 3 tD(GUC)N 5 YER138C 13 YPR137C-A 3
snR24 1 tD(GUC)O 5 YER159C-A 2 YPR137C-B 12
snR3 5 tE(CUC)D 5 YER160C 7 YPR158C-C 2
snR30 4 tE(CUC)I 5 YGL008C 3 YPR158C-D 7
snR31 1 tE(UUC)B 6 YGL088W 1 YPR158W-A 2
snR32 2 tE(UUC)C 6 YGR027W-A 3 YPR158W-B 9
snR34 1 tE(UUC)E1 6 YGR027W-B 12
snR37 10 tE(UUC)E2 6 YGR038C-A 2
snR40 1 tE(UUC)E3 6 YGR038C-B 14
snR43 3 tE(UUC)G1 6 YGR161C-C 2
snR44 3 tE(UUC)G2 6 YGR161C-D 7
snR47 2 tE(UUC)G3 6 YGR192C 2
snR48 1 tE(UUC)I 6 YHR214C-B 7
100 µM Azaplatin
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Table B.6. Counts of stops observed on all S. cerevisiae RNA at 200 µM azaplatin  
GeneName Stops GeneName Stops GeneName Stops GeneName Stops
15S_rRNA 171 snR70 1 tG(GCC)O1 4 YER137C-A 4
21S_rRNA 213 snR8 1 tG(GCC)O2 4 YER138C 15
LSR1 47 snR86 1 tG(GCC)P1 4 YER159C-A 2
Q0045 1 snR9 8 tG(GCC)P2 4 YER160C 7
Q0050 6 tA(UGC)A 2 tG(UCC)G 2 YGL008C 2
Q0055 5 tA(UGC)E 2 tG(UCC)N 2 YGL088W 3
Q0070 1 tA(UGC)G 2 tG(UCC)O 2 YGR027W-A 3
Q0110 2 tA(UGC)L 2 tG(UCC)Q 1 YGR027W-B 9
Q0115 1 tA(UGC)O 2 tH(GUG)E1 1 YGR038C-A 2
Q0130 7 tD(GUC)B 12 tH(GUG)E2 1 YGR038C-B 9
Q0275 1 tD(GUC)D 12 tH(GUG)G1 1 YGR161C-C 2
RDN18-1 579 tD(GUC)G1 12 tH(GUG)G2 1 YGR161C-D 7
RDN18-2 579 tD(GUC)G2 12 tH(GUG)H 1 YGR192C 5
RDN25-1 1188 tD(GUC)I1 12 tH(GUG)K 1 YHR174W 4
RDN25-2 1188 tD(GUC)I2 12 tH(GUG)M 1 YHR214C-B 6
RDN37-1 1839 tD(GUC)J1 12 tI(UAU)D 3 YHR214C-C 1
RDN37-2 1839 tD(GUC)J2 12 tI(UAU)L 3 YJR026W 4
RDN5-1 20 tD(GUC)J3 12 tL(CAA)A 1 YJR027W 14
RDN5-2 16 tD(GUC)J4 12 tL(CAA)C 2 YJR028W 2
RDN5-3 16 tD(GUC)K 12 tL(CAA)D 1 YJR029W 13
RDN5-4 16 tD(GUC)L1 12 tL(CAA)G1 2 YKL060C 4
RDN5-5 16 tD(GUC)L2 12 tL(CAA)G2 2 YLR035C-A 6
RDN5-6 20 tD(GUC)M 12 tL(CAA)G3 2 YLR044C 1
RDN58-1 51 tD(GUC)N 10 tL(CAA)K 2 YLR110C 9
RDN58-2 51 tD(GUC)O 12 tL(CAA)L 1 YLR157C-A 4
SCR1 70 tD(GUC)Q 1 tL(CAA)M 2 YLR157C-B 14
snR10 3 tE(CUC)D 4 tL(CAA)N 2 YLR227W-A 4
snR11 2 tE(CUC)I 4 tL(GAG)G 1 YLR227W-B 9
snR128 2 tE(UUC)B 11 tQ(UUG)B 2 YLR256W-A 4
snR13 1 tE(UUC)C 11 tV(CAC)D 2 YML039W 15
snR14 3 tE(UUC)E1 11 tV(CAC)H 2 YML040W 4
snR17a 9 tE(UUC)E2 11 tW(CCA)G1 2 YML045W 11
snR17b 2 tE(UUC)E3 11 tW(CCA)G2 2 YML045W-A 1
snR19 7 tE(UUC)G1 11 tW(CCA)J 2 YML123C 6
snR190 5 tE(UUC)G2 11 tW(CCA)K 2 YMR045C 4
snR191 1 tE(UUC)G3 11 tW(CCA)M 2 YMR050C 12
snR24 1 tE(UUC)I 11 tW(CCA)P 2 YMR051C 2
snR3 8 tE(UUC)J 11 YAL038W 3 YNL054W-A 2
snR30 22 tE(UUC)K 11 YAR009C 7 YNL054W-B 7
snR32 2 tE(UUC)L 11 YAR010C 2 YNL284C-A 2
snR34 3 tE(UUC)M 8 YBL005W-B 5 YNL284C-B 8
snR35 1 tE(UUC)P 11 YBR012W-A 2 YOL013W-A 1
snR37 12 tE(UUC)Q 3 YBR012W-B 7 YOL103W-A 3
snR39 1 tG(CCC)D 4 YBR118W 3 YOL103W-B 15
snR40 1 tG(CCC)O 1 YCR012W 1 YOL154W 1
snR42 1 tG(GCC)B 4 YDR098C-A 2 YOR142W-A 2
snR43 2 tG(GCC)C 4 YDR098C-B 9 YOR142W-B 10
snR44 1 tG(GCC)D1 4 YDR210C-C 2 YPL257W-A 4
snR45 1 tG(GCC)D2 4 YDR210C-D 9 YPL257W-B 14
snR47 4 tG(GCC)E 4 YDR261C-C 3 YPR080W 4
snR48 1 tG(GCC)F1 4 YDR261C-D 11 YPR137C-A 2
snR49 1 tG(GCC)F2 4 YDR278C 8 YPR137C-B 11
snR5 2 tG(GCC)G1 4 YDR316W-A 2 YPR158C-C 4
snR56 1 tG(GCC)G2 4 YDR316W-B 9 YPR158C-D 11
snR6 9 tG(GCC)J1 4 YDR365W-A 4 YPR158W-A 2
snR7-L 8 tG(GCC)J2 4 YDR365W-B 11 YPR158W-B 10
snR7-S 6 tG(GCC)M 4 YEL021W 8
200 µM Azaplatin
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APPENDIX C 
 
Methods 
Yeast BY4741 cells were treated with either 0, 100, or 200 µM cisplatin or 
azaplatin and sequencing libraries prepared as in Plakos and DeRose (2016). Reads were 
aligned to the yeast genome with up to one allowed mismatch using Bowtie (bowtie -v 3 -
a --best --strata --chunkmbs 500 -p 16 -t –S) (v1.1.2, Langmead et al., 2009), then 
alignments within genome features counted using HTSeq-count (Anders et al., 2005). 
This data were imported into R and differential expression analysis performed with the 
DESEQ2 R package (Love et al., 2014). Genes with a padj of >0.1 were considered for 
further analysis. Differential expression results were plotted with R and Excel. Gene 
names were translated from SGD Gene ID to human homologs, where available, using 
SGD’s YeastMine (Cherry et al., 2012). KEGG pathway analysis and GO-term analysis 
were performed using the gage R package (Luo et al., 2009). KEGG and GO data was 
sourced as in Supplementary Table 1. 
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Supplementary Information 
Table C.1. KEGG and GO analysis annotation and reference information. Data printed 
from gage (Luo et al., 2009) 
 
OrgDb object: 
DBSCHEMAVERSION: 2.1 
Db type: OrgDb 
Supporting package: AnnotationDbi 
DBSCHEMA: YEAST_DB 
ORGANISM: Saccharomyces cerevisiae 
SPECIES: Yeast 
YGSOURCENAME: Yeast Genome 
YGSOURCEURL: http://downloads.yeastgenome.org/ 
YGSOURCEDATE: 12-Mar-2016 
CENTRALID: ORF 
TAXID: 559292 
KEGGSOURCENAME: KEGG GENOME 
KEGGSOURCEURL: ftp://ftp.genome.jp/pub/kegg/genomes 
KEGGSOURCEDATE: 2011-Mar15 
GOSOURCENAME: Gene Ontology 
OSOURCEURL: ftp://ftp.geneontology.org/pub/go/godatabase/archive/latest-lite/ 
GOSOURCEDATE: 20160305 
EGSOURCEDATE: 2016-Mar14 
EGSOURCENAME: Entrez Gene 
EGSOURCEURL: ftp://ftp.ncbi.nlm.nih.gov/gene/DATA 
ENSOURCEDATE: 2016-Mar9 
ENSOURCENAME: Ensembl 
ENSOURCEURL: ftp://ftp.ensembl.org/pub/current_fasta 
UPSOURCENAME: Uniprot 
UPSOURCEURL: http://www.UniProt.org/ 
UPSOURCEDATE: Wed Mar 23 16:02:02 2016 
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Figure C.1. Plots of natural-log transformed raw counts of alignments on all genes except 
rRNA and tRNA genes for A) Controls. B) 100 µM cisplatin treatment. C) 200 µM 
cisplatin treatment. D) 100 µM azaplatin treatment. E) 200 µM azaplatin treatment. Data 
is strongly linear for all samples (r-squared >0.9, not shown). 
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Figure C.2. MA plots of A) 100 µM cisplatin vs. control. B) 200 µM cisplatin vs. control. 
C) 100 µM azaplatin vs control. D) 200 µM azaplatin vs control. Points plotted are 
representative of genes with nonzero read coverage. Gray points exhibit adjusted p-values 
greater than 0.1, red points less than 0.1. 
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Table C.2. List of genes significantly differentially expressed under each treatment 
condition. SGD ID, log2fold enrichment, and padj are given for each. 
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Table C.2. (continued) 
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Table C.2. (continued) 
 125 
 
 
APPENDIX D 
Materials and Methods 
Oligonucleotides used were purchased from IDT and are as follows: 
5’ hexynyl functionalized oligonucleotide (HEX): 
5’-/5Hexynyl/TTTTTTTCTGTAGGCACCATCAAT-3’ 
5’ Biotinylated hexynyl complement (BIO): 
5’-/5Biosg/TTTTTTTTTATTGATGGTGCCTACAG-3’ 
Nonspecific blocking oligonucleotide (BLOCK): 
5’-
CAAGCAGAAGACGGCATACGAGATGTCATGTACTGGAGTTCAGACGTGTGCT
CTTCCG-3’ 
DNA Hairpin containing a preferred Pt(II) binding site (HP): 
5’-TATGGTATTTTTATACCATA -3’ 
 
Oligonucleotides were suspended in nuclease free H2O to a final concentration of 
1 mM, aliquoted and stored at -30 °C, then diluted to working concentrations 
immediately before use. 
 
Rhodamine-B Azide and alkyne 
Rhodamine-B azide and rhodamine-B alkyne were prepared in house (Wirth et 
al., 2015).  
 
Preparation of MyOne C1 magnetic beads 
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10 µL MyOne strepatividin C1 beads were washed and prepared according to 
manufacturer’s instructions (Thermo Fisher). Prior to biotin binding, beads were treated 
with 50 µM BLOCK for 20 minutes, rotating at room temperature. Beads were drawn 
from solution using a magnet and rinsed three times with 40 µL Nitrate Bind and Wash 
buffer (10 mM Tris-HCl (pH 7.5), 1 mM EDTA, 2 M NaNO3) by aspirating the beads 
using a micropipette and returning the tube to the magnet for two minutes to remove 
beads from solution. 
 
Binding to streptavidin beads 
Simultaneously, 100 pmol of BIO was annealed to 100 pmol of 5’ HEX clicked to 
Rho-B-azide in 40 µL Nitrate Bind and Wash buffer (10 mM Tris-HCl (pH 7.5), 1 mM 
EDTA, 2 M NaNO3) by heating to 90 °C for five minutes, then cooled to room 
temperature for 20 minutes. This hybridized solution was applied to the washed and 
blocked beads and incubated at 4 °C overnight with rotation. 
 
Elution of captured oligonucleotides 
After incubation, DNA-bound beads were washed six times with 40 µL of 
decreasing concentrations of NaNO3 in 5 mM tris-HCl, 0.5 mM EDTA (from 1 M 
NaNO3 to 100 µM NaNO3 in six increments). Each wash step was left on the magnet for 
two minutes to remove beads from solution, then supernatant was removed and beads re-
suspended in the next wash buffer. Wash supernatants were saved for later analysis. 
After completing the wash steps, DNA was re-suspended in 20 µL Elution buffer 
(0.15 M NaCl, 0.015 M sodium citrate, pH 7.0) and eluted from beads by heating to 95 
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°C for 5 minutes, then placed on a magnet to extract supernatant. Samples were ethanol 
precipitated and visualized on a 15% 19:1 mono:bis acrylamide gel using UV 
transillumination. 
 
Platination of hairpin DNA 
HP-AzaPt was prepared as follows: 40 µM in vitro synthetic hairpin DNA was 
added to 10 mM phosphate buffer, 100 mM NaNO3 (final concentration), then denatured 
by heating to 90 °C for 5 minutes and slow cooled to 4 °C. Samples were warmed to 
room temperature then Mg(NO3)2 and azaplatin (Figure 1) were added to final 
concentrations of 1 mM and 120 µM, respectively, then incubated overnight at room 
temperature with rotation to allow azaplatin to react with hairpin DNA (Wirth et al., 
2015). 
 
Click reactions 
Bulk solution of HEX-Rho was prepared for pulldown optimization as follows: 
HEX was added to a solution containing 100 mM phosphate buffer, pH 7 and premixed 
150 µM CuSO4, 1.5 mM THPTA. Rhodamine-B azide was added to a final concentration 
of 200 µM, and sodium ascorbate was added to a final concentration of 150 µM to 
initiate the click reaction. Reaction was allowed to proceed for two hours at room 
temperature, with rotation, away from light. Reaction was quenched by running sample 
through a sephadex G-25 column. 
Experimental click reactions were performed as follows: HP-AzaPt was prepared 
as described, then added to a final concentration of 3 µM to a solution containing (final 
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concentrations): Alkyne constituent (either HEX or rhodamine-B alkyne) 13 µM; 100 
µM phosphate buffer, pH 7; 75 µM CuSO4 premixed with 375 µM THPTA. Sodium 
ascorbate was added to a final concentration of 150 µM to initiate the click reaction. The 
reaction was allowed to proceed for 2 hours at 37 °C with rotation, then quenched by 
running samples through sephadex G-25 columns. Bead pulldown was performed as 
described for all clicked samples. Samples were visualized on a 20% 19:1 mono:bis 
acrylamide gel and stained with SYBR gold (Thermo Fisher). 
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